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DUOX1 Dual oxidase 1
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protein 1
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IER3-DDR1 Immediate early response 3-Discoidin Domain receptor tyrosine ki-
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The human eye
Our vision is mediated by a complex process involving our eyes and the visual cortex 
of the brain. When light initially enters our eyes through the cornea, pupil and lens it 
is focused on the retina located in the back of the eye. The human retina is comprised 
of various specialized neuronal layers containing different types of cells. Light is 
converted into a biochemical signal by the photoreceptor cells through an elaborate 
process called the phototransduction cascade. The synapses of multiple photoreceptor 
cells are connected to one bipolar cell, and also have a connection with the horizontal 
cells, which provide lateral interaction. The signal of multiple bipolar cells in turn is 
transferred to the ganglion cells, which are laterally interconnected with amacrine 
cells. The axons on the ganglion cells make up the optic nerve, which sends the signal 
to the visual cortex in the brain, where it is interpreted and the image is perceived 
(Figure 1).1,2 
There are two different types of photoreceptors cells in the retina: the rods and the 
cones. The rods are mainly active during dim light conditions and mediate our black, 
white, and contrast vision, while the cones are important for color and high resolution 
vision. Rods are mainly present in the peripheral retina, whereas cones are more 
abundant in the macula, the central part of the retina which is responsible for central 
and sharp vision.1,2 To maintain proper functioning of the visual process the retinal 
pigment epithelial (RPE) cells located beneath the neuronal layers and the choroidal 
blood flow beneath the RPE are of great importance.4,5
The retinal pigment epithelium (RPE)
The RPE cells encapsulate the outer segments of the photoreceptors and are connected 
to each other through tight-junctions (Figure 4A). Functions of the RPE cells, among 
others, include providing nutrients to the photoreceptor cells, preventing photo-
 
Figure 1: Schematic representation of the visual process. Light enters the eye through the lens and passes 
through the eye to fall on the retina (1). In the retina the light signal is received by two types of photoreceptors, 
the rods and cones (2) and is converted to a biochemical signal. The signals of multiple photoreceptors is passed 
on to a single bipolar cell, multiple bipolar cells in turn transfer their signal to a ganglion cell. (3) The axons 
of the ganglion cells make up the optic nerve (4) and pass on the signal to the visual cortex of the brain (5).3
oxidation, recycling waste products of the visual cycle and performing phagocytosis 
of the photoreceptor outer segment discs.4 Together with the Bruch’s membrane (BM) 
the RPE cells form the outer blood-retina barrier. This barrier effectively controls 
the transport of water, ions and nutrients from the neuroretina to the underlying 
choroidal structure and vice versa.4,6,7 Waste products from the photoreceptors are 
transported through the subretinal space, to the RPE cells. Here the products move 
from the apical- to the basolateral side, pass through the Bruch’s membrane (BM) 
and are taken up by the choriocapillaris, a fine network of permeable blood vessels 
that allow rapid product exchange. The choriocapillaris transports the waste products 
towards more distal parts of the choroid, where blood vessels are larger and no longer 
permeable, eventually releasing the waste products in the blood stream.5 Nutrients 
and oxygen on the other hand follow the reversed route, and are transported from 
the choroid through the BM and RPE to the photoreceptor cells.
Due to the large metabolic turnover of the photoreceptor cells, a large volume of 
water is produced and released in the subretinal space. Elimination of the water from 
the retina is mediated by the RPE cells through a tightly controlled ion-balance, and 
generates an adhesion force between the RPE and retina.4 The transport of chloride 
(Cl-) ions mainly drives the apical to basolateral water transport in the RPE, which 
is estimated to be 1.4-11 µL/cm2/h.4 Multiple ion channels, ion exchangers and 
cotransporters are involved in this process (Figure 2).4,6 Additionally, aquaporin 1 
molecules, which are known to transport water, are found on both the apical and 
basolateral side of the RPE, providing additional water efflux.4 
Figure 2: Summary of the mechanisms for transepithelial transport adapted from Reichart and Strauss 2014.6 
Transepithelial transport of water and Cl-: A gradient for Na+ into the cell is provided by the activity of the apical 
Na+/K+-ATPase and inward rectifier K+ channel Kir7.1. The gradient is used to transport Cl- into the cell via the 
activity of the Na+/K+/2Cl- cotransporter, leading to an intracellular Cl- concentration of 40-60 mM. Cl- leaves 
the cell across the basolateral membrane via different types of Cl channels, osmotically driving water through 
aquaporins across the epithelium. AQP1: Aquaporin 1; best-1: Bestrofin 1; ClC-2: Cl channel-2 of the ClC 
family; CFTR: cystic fibrosis transmembrane conductance regulatorl; Kir7.1: inward rectifier K+ channel.
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Figure 3: Clinical features of acute and chronic CSC. Multimodal imaging of the left eye of a 41-year-old 
male patient (A-F) with acute central serous chorioretinopathy (aCSC) and the right eye of a 40 year-old male 
patient (G-L) with chronic CSC (cCSC). B) Fluorescein angiography (FA) revealed a single “hot spot” of leakage 
and no atrophic retinal pigment epithelium (RPE) changes in the aCSC patient. C) On mid-phase indocyanine 
green angiography (ICGA) a small hyperfluorescent lesion was observed at the location of the “hot spot” on 
FA. D) Fundus autofluorescence (FAF) imaging showed granular hyper-autofluorescent changes at the site 
of the serous neuroretinal detachment. E) Optical coherence tomography (OCT) scan at first presentation 
revealed a subretinal serous fluid (SRF) accumulation , F) which resolved after four weeks. H) FA imaging in 
the cCSC patient revealed a large area of atrophic RPE changes and multiple leakage spots. I) ICGA imaging 
in this patient revealed diffuse choroidal hyperpermeability which was slightly larger than the area of leakage 
visible on FA. J) FAF imaging showed a mixture of intense areas of hyper-autofluorescence together with gran-
ular hypo-autofluorescent changes. K) At diagnosis, foveal SRF and a small RPE detachment were observed 
on the OCT scan of the cCSC patient, L) which both resolved within three weeks after treatment with half-dose 
photodynamic therapy. Image from chapter 2.4 of this thesis. 
Central serous chorioretinopathy
One of the main defining features of central serous chorioretinopathy (CSC) is the 
accumulation of serous fluid underneath the retina (Figure 3E/K and Figure 4B). This 
subretinal fluid disrupts the interaction between the photoreceptor cells and the 
retinal pigment epithelium (RPE) leading to visual complaints such as blurred vision, 
metamorphopsia and loss of visual acuity when the subretinal fluid is present in the 
central part of the retina.8-10 The diagnosis of CSC is determined using combined 
information from different imaging modalities such as fundus photography, optical 
coherence tomography (OCT), fluorescein angiography (FA) and indocyanine green 
angiography (ICGA) (Figure 3).
Two forms of CSC can be distinguished: acute and chronic CSC. One of the 
discriminating factors between the two subtypes is the duration of complaints; 
where acute CSC (aCSC) usually spontaneously resolves within 3-6 months with 
minimal visual acuity loss, chronic CSC (cCSC) is characterized by prolonged fluid 
accumulation.8,11 The subtypes can be further distinguished by the number of retinal 
abnormalities; patients with acute CSC usually present with only a single focal leakage 
spot on FA (Figure 3B), whereas chronic CSC is characterized by more widespread 
RPE alterations or atrophy, more numerous RPE detachments and leakage points 
(Figure 3H) and in general a poorer visual prognosis.8,11 Besides RPE alterations, 
increased permeability of the choroid and an overall thickening of the choroid can 
also be observed in CSC.8,9,12 It is still unclear if acute and chronic CSC represent two 
distinct entities or whether they belong to a spectrum within the same disease. 
The mechanism behind the occurrence of CSC is currently unknown. It has been 
hypothesized that increased pressure from the (thickened) choroid in combination 
with a dysfunctional pump-function of the RPE underlie the subretinal fluid 
accumulation.8,9 However, there is no consensus how both the thickened choroid and 
RPE dysfunction itself occur. Several clinical risk factors for CSC have been described, 
the most predominantly being (perceived) stress and the use of corticosteroids.10
Other risk factors include pregnancy, Helicobacter pylori infection, type-A personality, 
hypertension and Cushing’s disease.8,13 A large meta-analysis of 17 studies on CSC 
risk factors was performed by Liu et al, providing an overview of the odds ratios 
associated with the different risk factors for CSC (Table 1).13 
Patients with CSC usually present with their first symptoms between 40-55 years 
of age, when they are still professionally active and visual complaints cause major 
consequences for their day-to-day life.8 A skewed disease incidence in men compared 
to women is observed (9.9 cases per 100,000 men, 1.7 per 100,000 women).30 
Therefore, it has been suggested that the stress axis, or other hormonal imbalances 
may underlie the disease.8,31 So far, one animal study demonstrated that features of 
CSC, namely a thickened choroid and increased leakage, could be modeled in rats 
after injection of a high dose of the mineralocorticoid aldosterone.32 This animal work 
was translated into humans by testing mineralocorticoid receptor (MR) antagonists as 
a potential treatment for CSC. 
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Table 1. Overview of reported risk factors for CSC from Liu et al. 201613
Risk factor
Meta-analysis
P-value
Meta-analysis 
OR (95% CI) 
Studies included in 
meta-analysis
Coronary heart disease NS 1.31 (0.94-1.82) 14-16
Hypertension 0.0002 1.70 (1.28-2.25) 14-21
Helicobacter pylori infection <0.0001 3.12 (1.81-5.40) 22-24
Steroid usage 0.0002 4.29 (2.01-9.15) 14-17,19,21,25,26
Sleeping disturbance 0.002 1.90 (1.28-1.83) 18-20
Autoimmune disease 0.0001 3.44 (1.90-6.26) 17,21,25
Psychopharmacologic medica-
tion use
0.0001 2.69 (1.63-4.45) 15-17
Type-A behavior 0.03 2.53 (1.08-5.96) 21,27,28
Gastroesophageal reflux 
disease
<0.05 3.29 (1.04-10.34) 17
Peptic Ulcer <0.05 1.56 (1.30-1.88) 14,22
Organ transplantation NS 6.30 (0.85-46.94) 17,19
Urbanization level <0.05 0.86 (0.76-0.98) 14,19
Antihistamines <0.05 2.93 (1.62-5.31) 17,29
Smoking NS 1.16 (0.81-1.67) 17,29
CI: Confidence Interval; NS: Not significant; OR: Odds Ratio
Although some cases of CSC spontaneously resolve, treatment of the disease is 
warranted in most cases of cCSC. Currently, treatment options for CSC are limited, but 
most commonly used treatments are either micropulse laser or photodynamic therapy 
(PDT). For PDT, verteporfin is administered intravenously and a laser beam is used to 
activate the substance when it enters the choroid.33 In micropulse laser treatment the 
RPE cells are targeted, and subjected to ultrashort laser pulses.34 Although it has been 
postulated that PDT reduces choroidal congestion and micropulse laser stimulates 
RPE pumping function, the exact biological mechanism of action of both techniques 
is not known.8,33,35 Recent studies indicate a better disease outcome while using half-
dose PDT compared to high-density subthreshold micropulse laser.36,37 Additionally, 
several reports have discussed the effectiveness of MR antagonists in CSC,38-40 but 
to date no randomized controlled clinical trial has been performed to properly assess 
superiority over other treatments in CSC.
Familial CSC - The basis of a genetic component for CSC
For CSC, reports about familial CSC occurrence go back many decades with the first 
report published in 1960 and the latest, to date, published in 2017.41,42 These studies 
have led to the first hints on a genetic component for CSC and form the basis for the 
work presented in this thesis.
In 1960, an interesting case was presented in literature about a monozygotic twin 
pair that almost simultaneously presented with CSC.41 The two twin brothers, 36 
years of age, visited an ophthalmologist within 9 months from each other, presenting 
with unilateral CSC. They were treated with rest, vasodilator drugs and anti-allergics 
and vision improved in both instances to normal in one brother (10/10) and almost 
normal in the other (8/10). Even though the brothers had experienced hardship 
during World War II, they were described as ‘happy and cheerful men’. The author 
was not able to pin-point a specific current stressor in their lives, nor any commonality 
in their exposure to environmental circumstances that might trigger the disease. The 
author suggested that this particular case supports a theory in which constitutional 
hereditary factors may play a role in CSC.41
Eight years after this initial report of two twin brothers, the first parent-child 
relationship was presented. In 1968, Haik et al described the case of a 30-year old 
housewife from Costa Rica, who had moved to the United States with her husband, 
presenting with CSC.43 According to the report she had experienced “unaccustomed 
stresses from loneliness, household duties, and long hours of study to learn English” 
before waking up one day with a dark spot in the vision of her left eye. Treatment with 
a vasodilator, tranquilizer and corticosteroids led to disappearance of most of the 
fluid after four weeks, while vision returned to normal after six weeks. Interestingly, 
nine days after initial onset of CSC in the patient, her mother also presented in the 
clinic with complaints of a dark spot in her left eye. The mother was described as 
being “unduly concerned about illnesses within her family” and she had also suffered 
a recent loss of uninsured property in Costa Rica around the same time.43 The course 
of disease followed a similar pattern as that of her daughter, and after eight weeks 
both the fundus and visual acuity returned to normal. 
Figure 4: Graphical representation of the retinal anatomy in a normal and an eye affected with CSC. A) Normal 
retina, indicated are the various different cell layers involved in the visual process. B) Retina affected with 
CSC, fluid accumulation is present between the photoreceptor layer and RPE cells, leading to disruption of 
their interaction. BM: Bruch’s membrane. RPE: Retinal Pigment Epithelium. Original figure courtesy of Maartje 
Geerlings, PhD.
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During the following years scattered reports of familial occurrence emerged in 
literature, but in 1996, the first series of eleven families presenting with CSC were 
described. In each family, two to four family members were affected with CSC.44 Most 
of these families contained affected siblings, but one family showed CSC in a mother 
and her son. Of note, in most of these patients both eyes were affected in contrast to 
the earlier reports where only one eye was affected. Moreover, the mean age of the 
patients was 44.9 years, which is in the range of the demography of cCSC patients, 
whereas the patients in the initial reports were quite young, suggesting that they may 
represent acute cases.44 
After this collection of eleven families was described, a few additional families were 
reported in literature,45-48 but the next major collection of families was described more 
than 20 years later in 2017.42 This study expanded on the families described in the 
1996 publication of Oosterhuis et al, and now included a total of 23 families with 103 
subjects.42 Of particular interest in this work was the long-term follow up of subjects 
that had been enrolled in the initial study, demonstrating that 24% of subjects that 
were previously unaffected showed (sub)clinical signs of CSC after 20 years.42 These 
results suggest that familial occurrence is a strong risk factor of developing the 
disease, underscoring the possible involvement of genetic factors.
Although these observations of familial CSC occurrence do not completely rule out 
other attributing factors, such as simultaneous exposure to environment triggers or 
circumstances that are a consequence of nurture rather than nature, they do suggest 
that a genetic predisposition or susceptibility to such environmental factors can be 
passed on through the generations, leading to a higher chance of CSC development 
in family members. 
A brief history of human genetics
In 1866, Mendel discovered that “traits” are transmitted to offspring in certain 
reproducible patterns,49 a discovery that can be seen as the start of the modern 
genetics era. However, only after the observation in 1902 that chromosomes were 
the carriers of these “traits” or also called genes,50,51 and the discovery in 1911 that 
certain genes are located on specific chromosomes,52 advancements in the genetics 
field really took flight. In rapid succession, the DNA double helix was discovered to 
be the carrier of genetic information, RNA was identified to be transcribed from DNA 
and proteins from RNA, establishing the central dogma of molecular biology.53 
Inheritance patterns
Genetic diseases can be divided in several categories based on the contribution of 
the genetic component to the disease. Mendelian diseases are single gene disorders 
that can be inherited through different inheritance patterns. In a dominant disease, 
a single (rare) variant in a gene (Box 1) causes the disease, and subsequently the 
disease is transmitted from generation to generation.49,54 Recessive disorders are 
caused by the inheritance of two disease-causing variants in a single gene from 
each parent, only leading to disease when both gene-copies are affected. In addition 
more complex inheritance patterns may occur, including sex-linked inheritance 
patterns, which are caused by disease-causing variants on the X- or Y-chromosomes, 
incomplete penetrance in which individuals that carry a disease-causing variant remain 
unaffected, and digenic disorders, in which disease-causing variants in two genes 
underlie the disease.54 However, the common consensus is that disorders following 
these inheritance patterns are caused by (rare) variants that often have a large effect 
on protein function, and are absent or very rare in non-affected individuals. 
On the contrary, in complex diseases, such as age-related macular degeneration (AMD), 
the combined effect of multiple genetic variants (that are generally common in the 
population) and environmental risk factors determines the disease susceptibility.55,56 
In complex diseases, the effect size of common variants on disease is represented by 
the odds ratios (ORs). These allelic ORs are calculated by comparing the allele (Box 
1) frequency of a variant between patients and an unaffected control population. A 
higher allele frequency of the variant in the patient population compared to healthy 
individuals indicates that the variant increases risk for disease (OR>1), whereas the 
opposite applies when a variant is more common in healthy individuals (OR<1) and is 
thus protective for the disease.
For complex diseases, a concurrence of circumstances might cause disease such 
as variations in one or multiple genes or pathways, influenced by one or more 
environment triggers.55,56 These multiple layers of complexity make it challenging 
to study the genetic origin of complex diseases. By comparing genetic data of large 
cohorts of affected and unaffected individuals, genetic association studies aim to find 
Box 1: Commonly used genetic terminology
Allele: Variation of a gene which can span one or multiple consecutive nucleotides. The most common 
occurrence of the variation is referred to as the major allele, whereas the less occurring change is indica-
ted as the minor allele. 
expression Quantitative Trait Loci (eQTLs): A locus or SNP that directly influences the expression of a close 
by (cis-eQTL) or distal (trans-eQTL) gene. Due to different activation of transcription factors and regulato-
ry elements eQTLs are often tissue-specific.
Gene: Region of the genome that is translated into a functional protein. Genes consist of coding regions 
(exons), non-coding regions (introns), and untranslated regions (UTRs). After transcription, intronic regions 
are spliced out and the exonic regions are translated into amino-acids forming the functional protein. 
Haplotype (block): A stretch of DNA containing multiple alleles inherited together due to the process of 
recombination and presence of linkage disequilibrium in the genome. 
Imputation: The prediction of alleles on the same haplotype block based on the information of alleles 
that have been genotyped. This method can be used to greatly increase the amount of variants in a study. 
Linkage disequilibrium (LD): The non-random distribution of alleles at a locus, indicating that in a popu-
lation certain alleles are not independently inherited, but co-occur more often than expected by chance. 
This gives rise to the occurrence of haplotype blocks. The amount of LD between variants is expressed as 
a R2 value from 0=no linkage to 1=perfect linkage.
Locus: Location of a gene on the genome. 
Recombination: Merging and shuffling of chromosomal parts during cell division when the chromosomes 
are paired. During meiosis maternal and paternal chromosomes can be mixed leading to the formation 
of new haplotypes. The amount of recombination varies between regions of the genome.
Single-Nucleotide Polymorphism (SNP): A variation in the DNA that spans only one nucleotide and has a 
frequency of >1% in the population. 
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variants that occur at different frequencies in patients compared to controls, and may 
contribute to the disease.57 
Modern genotyping methods
Initially, the only way to observe genetic abnormalities was by karyotyping, which 
uses microscopy and chromosomal staining to identify relatively large chromosomal 
abnormalities.58,59 Later, linkage analysis was used in families to pinpoint the 
approximate location of disease specific mutations. This technique uses SNP 
information to identify haplotype blocks segregating with the disease due to linkage 
disequilibrium (Box 1).60 Later, after the development of Sanger sequencing,61 these 
locations could be sequenced to identify disease-causing genetic variants at the 
level of single nucleotides. A rapid growth of research into the genetics of diseases 
followed, identifying an ever growing list of causal genes in for example Huntington’s 
disease (1983), color blindness (1986), cystic fibrosis (1989), breast cancer (1994) and 
many others.62-66
Currently, sequencing and genotyping techniques are evolving to cheaper and high-
throughput approaches, allowing us to delve deeper into the genetic origins of 
disease. Depending on the study design, various methods can be used to determine 
genetic variation. In a classic candidate variant/gene approach, a specific single 
nucleotide variant (SNP) or gene is selected and genotyped, and its association to 
a disease is tested. SNPs can be genotyped with various methods including uniplex 
genotyping assays targeting one particular variant, or multiplex genotyping chips or 
arrays targeting hundreds of thousands of genetic variants simultaneously.67,68 The 
entire coding regions of genes can be sequenced with Sanger sequencing, but the 
field is shifting to faster and scalable new techniques, for example molecular inversion 
probes (MIPs) combined with next-generation sequencing.69,70 The candidate gene/
variant-approach can be very effective when variants are known or suspected to be 
involved in disease. However, problems with scalability occur when a large number of 
variants or genes needs to be tested, or when there is no prior knowledge about the 
genetic loci involved in the disease.71
Therefore, genome-wide unbiased approaches can be used in order to test many 
variants and genes at the same time and to find new loci in the genome that are 
associated to disease.57 Hundreds of thousands of genetic variants spread throughout 
the genome can be genotyped using commercially available chips or arrays.67 Data 
of these (mostly) common variants can be imputed with reference panels, in which 
non-genotyped variants are predicted based on known inheritance patterns present 
in the genome (linkage disequilibrium, Box 1), increasing the data sets to millions 
of variants.72 In a genome-wide association study (GWAS) the frequency of these 
(mostly) common variants are compared between affected and unaffected individuals, 
and regions of the genome can be identified that increase susceptibility to disease.57 
As an example, the GWAS method has been very successful in identifying over 52 
independent variants at 34 genomic loci associated with AMD.73 
Alternatively, all the coding regions of the genome (the exome) or the entire genome 
of an individual can be sequenced and the frequencies of both rare and common 
variants can be compared to healthy individuals. However, as on average every 
individual carries 4.1-5 million variations compared to the reference genome, of 
which ~149-182 sites are protein-truncating and 10,000-12,000 variants alter an 
amino-acid,74 the large datasets generated by such techniques provide a challenge 
to determine causality. Another challenge when using exome or genome sequencing 
is that due to the low frequencies of most rare variants, large cohorts are necessary 
to obtain sufficient statistical power to prove that a rare variant is associated with a 
disease. To overcome this hurdle, the cumulative effect of multiple variants in one 
gene can be determined using gene-based tests, or the combined effect of variants in 
multiple genes can be analyzed using pathway enrichment analyses.75,76 
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Aims and outline of this thesis
Currently, the etiology of CSC is unknown and treatment options are limited. Studying 
the genetic architecture of a disease has the potential to uncover novel insights on 
the disease pathogenesis and to work towards therapies targeting the biological 
mechanisms underlying the disease. This approach has been followed for several 
other multifactorial eye diseases such as AMD, glaucoma and myopia.77 In particular 
for AMD the genetic architecture of the disease has been thoroughly investigated 
over the past 15 years, yielding significant insights into the molecular mechanisms of 
AMD development. 
The aim of this doctoral thesis is to investigate the genetic components contributing 
to cCSC development in order to increase our knowledge of the disease etiology and 
on the long-term to improve treatment options for patients affected with cCSC. 
In Chapter 1, an introduction is given about the eye and the disease characteristics 
of aCSC and cCSC. The first familial studies on CSC are described, which provided 
the initial hypothesis that a genetic component may underlie CSC. A brief history 
of genetics is supplied along with the most commonly used techniques in genetic 
studies. 
Section 2 of this thesis describes various candidate studies performed for CSC. 
In Chapter 2.1, previously associated AMD SNPs as well as variants in the complement 
factor H (CFH) gene are investigated in a cohort of cCSC patients. Frequencies of 
these genetic variants are compared between cCSC patients, healthy controls and 
AMD patients, and haplotypes of the CFH gene are constructed.
Chapter 2.2 investigates the involvement of copy number variations of the C4 
gene in cCSC. The protein encoded by this gene (C4) plays an important role in the 
complement system, and has also been shown to increase cortisol response, making 
it an interesting candidate gene for cCSC. 
Functional variants in the glucocorticoid receptor gene (NR3C1) and mineralocorticoid 
receptor (NR3C2) are investigated in cCSC patients in Chapter 2.3. Additionally, 
haplotypes of both genes are constructed.
In Chapter 2.4 all variants that were previously associated with cCSC are investigated 
in patients with aCSC. Additionally, minor allele frequencies of the selected variants 
were compared between cCSC and aCSC patients.
In order to identify new loci in the genome implicated in cCSC Section 3 focuses on 
unbiased case-control studies for cCSC.  
Chapter 3.1 describes the first GWAS study conducted on a large cohort of cCSC 
patients and population controls. Genetic variants throughout the genome are 
compared between these groups and information from eQTL databases is used to 
predict gene expression levels in cCSC patients and controls to identify genes that 
might be differentially expressed in cCSC patients. 
An exome sequencing study on cCSC patients is conducted in Chapter 3.2. In order 
to find new genes implicated in the disease, multiple variants in the same gene 
are grouped to perform gene-burden analyses. In addition, males and females are 
analyzed separately to identify genetic associations that are sex-specific. 
Section 4 focuses on familial cases of CSC.   
In Chapter 4.1, the disease characteristics of familial CSC patients and their family 
members are described. A number of families described in a previous study are 
investigated again to provide long-term follow-up, and more families are included 
compared to the previous study. 
Multiple families included in Chapter 4.1 are investigated on a genetic level in Chapter 
4.2. Rare variant segregation analysis is performed for the families, and gene-based 
analyses of rare variants are also provided.
Chapter 5 investigates levels of 17 steroid hormones in cCSC patients with an active 
episode of fluid accumulation compared to health controls. 
Chapter 6 summarizes the primary findings of this thesis, and provides an overview 
of all genetic studies performed on cCSC to date. The current knowledge on the 
genetics of CSC is placed into current literature and future perspectives and follow-
up studies are discussed.
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Abstract
Purpose: In this study, single nucleotide polymorphisms (SNPs) at 19 loci, previously 
associated with age- related macular degeneration (AMD), were systematically 
tested for association in patients with chronic central serous chorioretinopathy 
(cCSC). In addition, we evaluated the effect of detailed phenotyping on these genetic 
associations.
Design: Case-control study.
Participants: We included 292 cCSC patients, 1147 AMD patients, and 1311 control 
individuals.
Methods: We genotyped SNPs at 19 AMD-associated loci and 6 additional SNPs 
at the complement factor H (CFH) locus. Phenotyping of all patients was based on 
fundoscopy, spectral-domain optical coherence tomography, fluorescein angiography 
(FA), and indocyanine green angiography.
Main Outcome Measures: We measured the allele frequencies of 25 AMD-associated 
SNPs and CFH haplotype frequencies in patients with cCSC and the effect of 
phenotypic subdivision of cCSC on genetic associations.
Results: One SNP in ARMS2 (rs10490924) was significant after Bonferroni correction 
(Punadjusted = 0.002; odds ratio [OR] = 0.64). The SNPs at 3 other AMD loci (CFH, 
TNFRSF10A, ADAMTS9) showed a trend toward association with typical cCSC. 
Further analysis of the CFH locus identified 2 SNPs that significantly conferred 
increased risk for cCSC and 1 that was protective. The CFH-H3 haplotype was also 
found to be protective (P=0.01; OR=0.54). Using multimodal imaging, 197 patients 
were classified as having typical cCSC, 52 patients had unilateral abnormalities on FA 
that were otherwise typical of cCSC, and 43 patients had a clinical picture that could 
be compatible with cCSC, but with features that could also indicate other macular 
diseases. Significant differences of the minor allele frequencies of the tested SNPs 
were observed between these 3 phenotypic subgroups.
Conclusions: Chronic CSC is associated with genetic variants in ARMS2 and CFH, 
indicating a genetic and pathophysiologic overlap between cCSC and AMD. 
Intriguingly, alleles in ARMS2 and CFH that confer risk of AMD may be protective for 
cCSC, and alleles in CFH that are protective for AMD confer risk for cCSC. Significant 
differences in allele frequencies were found among the phenotypic subgroups for 
several SNPs, illustrating the importance of correct clinical classification. 
Introduction
Central serous chorioretinopathy (CSC) is among the most common forms of macular 
disease in the Western world.1,2 It is characterized by a serous detachment of the 
neuroretina from the underlying retinal pigment epithelium (RPE) in the macula due 
to fluid leakage through a dysfunctional RPE. Clinical evidence from multimodal 
imaging, such as choroidal congestion and thickening and hyperpermeability of the 
choroid, implies an important role for choroidal abnormalities as an underlying 
cause for RPE dysfunction and subretinal fluid leakage in CSC.1-3 
Two main subtypes of CSC can be distinguished. Patients with acute CSC present 
with sudden and marked central vision loss. Acute CSC is characterized by a focal 
leakage spot on fluorescein angiography (FA), beneath a macular neurosensory retinal 
detachment.1-9 This so-called hot spot indicates leakage at the level of the RPE.1,4,10 
The acute form of CSC generally has a favorable prognosis because the accumulated 
subretinal fluid often subsides spontaneously within 2 to 3 months, with (near-)
normal recovery of vision (Figure 1A-C).1 In contrast, chronic CSC (cCSC) is typically not 
self-limiting and subretinal fluid remains present for >3 months.2,4,10
Patients have more diffuse multifocal leakage on FA and indocyanine green 
angiography (ICGA), as well as often irregularly distributed widespread RPE changes 
associated with various degrees of low-grade leakage (Figure 1D-F).1-10 Because 
of persistent serous neuroretinal detachments with progressive and irreversible 
photoreceptor damage, cCSC has a poorer visual prognosis than acute CSC.2,6,11,12
Although the etiology of CSC is largely obscure, clinical observations point toward 
an association with the use of corticosteroids, hypercortisolism, stress, and type A 
personality.1,10,13 The incidence of CSC is approximately 6 times higher in men than in 
women,1 although this male-to-female proportion seems to be less pronounced in cCSC 
and steroid-related CSC. 
Figure 1: Examples of fluorescein angiography (FA), indocyanine green (ICG) angiography, and spectral-domain 
optical coherence tomography (SD OCT) in acute and chronic central serous chorioretinopathy (CSC). A+C, 
The left eye of a patient with classical acute CSC, showing a small focal leak in the early phase of FA and a 
typical smokestack fluorescein leak on late-phase FA (A, B); the corresponding SD OCT image showed a large 
central subretinal fluid (SRF) accumulation associated with a focal, shallow retinal pigment epithelial (RPE) 
detachment (C). De F, The right eye of a patient with chronic CSC with more widespread leakage on FA (D) and 
diffuse hyperfluorescent areas on ICG angiography (E), as well as SRF and multiple RPE detachments on SD 
OCT (F).
A
C
B D E
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Interracial differences in the prevalence of cCSC and the familial occurrence of cCSC 
suggest strong genetic involvement.2,14-16 However, only a limited number of possible 
genetic associations have been reported so far.17,18 Certain phenotypic features of 
cCSC, such as serous RPE detachments, neurosensory retinal detachment, and 
patchy atrophy of the RPE, are also observed in other macular diseases, such as 
age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy.19 
This phenotypic overlap suggests that a genetic overlap may also exist; AMD is known 
to be a multifactorial and genetically complex disorder, and 19 genetic loci have been 
associated with the disease.20-22
To assess the degree of phenotypic and genotypic overlap between cCSC and AMD, 
this study used a combination of detailed phenotyping based on multimodal imaging 
and systematic analyses of single nucleotide polymorphisms (SNPs) at the 19 
known AMD-associated loci in cCSC patients. Furthermore, a detailed analysis of 
complement factor H (CFH) haplotypes in cCSC patients was performed. Finally, the 
effect of phenotypic differentiation on these genetic associations was evaluated.
Methods
In this study, we included 292 patients with cCSC who visited the outpatient clinic 
of the Department of Ophthalmology at the Radboud University Medical Center, 
Nijmegen, the Netherlands (Table 1). The diagnosis of cCSC and phenotyping 
with multimodal imaging was based on an extensive ophthalmologic examination, 
including fundoscopy, spectral-domain optical coherence tomography (SD-OCT), 
FA, and ICG angiography. The definition of cCSC used in this study was based on 
the currently available literature, taking the following characteristics into account 
(all had to be present): serous subretinal fluid on OCT, 2:1 areas of multifocal diffuse 
leakage on FA, and corresponding hyperfluorescence on ICG angiography in 2:1 
eye.1-10 Patients suffering from acute CSC as recognized by a focal leakage spot or a 
smokestack pattern on FA, and patients with a disease period of <3 months, were 
excluded.1-10 A total of 1311 control subjects were recruited from the blood bank 
of the Radboud University Medical Center, Nijmegen, the Netherlands (n = 177), 
and the European Genetic Database (EUGENDA, www.eugenda.org; n = 1134). For 
control subjects recruited from EUGENDA, ophthalmologic grading was performed 
excluding signs of AMD. In addition, 1147 AMD patients from the EUGENDA 
(www.eugenda.org) were used to calculate the minor allele frequencies of SNPs 
at AMD-associated loci (Table 1). The diagnosis of AMD was defined as described 
previously.23 Informed consent for the use of DNA for genetic studies was obtained 
from all subjects. The study adhered to the tenets of the Declaration of Helsinki. 
Institutional review board/ethics committee approval was obtained.
Single Nucleotide Polymorphism Genotyping
Genomic DNA was extracted from peripheral blood samples using standard 
procedures. Nineteen SNPs at loci previously associated with AMD [(rs10490924 
(ARMS2), rs12144939 (CFH), rs429608 (C2-CFB), rs2230199 (C3), rs9621532 (TIMP3), 
rs4420638 (APOE), rs3764261 (CETP), rs943080 (VEGFA), rs13278062 (TNFRSF10A), 
rs493258 (LIPC), rs10033900 (CFI), rs3812111 (COL10A1), rs13081855 (COL8A1-
FILIP1L), rs3130783 (IER3-DDR1), rs8135665 (SLC16A8), rs334353 (TGFBR1), 
Table 1. Demographics of the Study Population
Characteristic Subgroup 1 Subgroup 2 Subgroup 3 Controls AMD
No. of subjects 197 52 43 1311 1147
Sex (male/female) 154/43 38/14 26/17 629/682 448/699
Mean age ± SD (yrs) 53±10 55±12 57±13 66±12 76±9
Age range (yrs) 29-74 32-78 30-78 19-97 55-101
AMD=age-related macular degeneration; SD=standard deviation.
rs8017304 (RAD51B), rs6795735 (ADAMTS9), and rs9542236 (B3GALTL)] were 
genotyped in 292 cCSC patients and 1311 controls by outsourcing to the genotyping 
service of LGC Genomics (LGC Limited, Fordham, UK).20-22 Genotyping of 6 CFH 
SNPs (rs1061170, rs3753394, rs800292,rs2284664, rs1329428, rs1065489) was 
performed with KASP genotyping assays (LGC Genomics) in 292 cCSC patients 
and 881 controls. The SNP-specific KASP primer mix and KASP master mix were 
added to 10 ng of DNA according to the manufacturer’s instructions. Polymerase 
chain reaction amplification was performed (Veriti 384 thermal cycler; Applied 
Biosystems, Foster City, CA). Fluorescent FAM and HEX signals were read out with 
the 7900HT Fast Real-Time Polymerase Chain Reaction System (Applied Biosystems) 
and converted to genotype information with the SDS program (version 2.3; Applied 
Biosystems).
Statistical Analysis
Differences in allele frequencies were calculated using the Fisher exact test (2 sided 
for the 19 AMD loci and 1-sided for CFH SNPs, based on previous reports), and a 
Bonferroni correction was performed. The individual tests for the 19 AMD loci were 
considered significant at P < 0.0026, corrected for 19 tests. The significance threshold 
for the 6 CFH variants was set at P < 0.0083, correcting for 6 tests. Haplotypes were 
generated with R (version 3.0.2) and R Studio (version 0.98.501), using the haplo.stats 
package (version 1.6.8). For each SNP, information for both alleles was inserted into 
R and the haplo.cc command was used to determine associations between haplotype 
frequencies and cCSC. The most frequent haplotypes (frequency in controls >5%) 
were named H1 to H5 according to Hageman et al.24 Haplotypes were considered 
to be significantly associated to CSC if P < 0.01, correcting for 5 tests. Minor allele 
frequencies of significantly associated SNPs were compared between subgroups of CSC 
using a Fisher’s exact test and were considered significant if P < 0.0125, correcting for 
4 tests.
Results
Phenotyping and Classification of Chronic Central Serous Chorioretinopathy 
Patients
All cCSC patients were classified into 3 subgroups based on their phenotypic 
characteristics on multimodal imaging. Patients in phenotypic subgroup 1 (n=197) 
showed the most typical clinical picture of cCSC. This typical picture was defined 
as the presence of chronic serous subretinal fluid in ≥1 eye on SD OCT, bilateral 
irregular RPE window defects on FA with ≥1 “hot spot” of leakage in the affected 
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Figure 2: Examples of fluorescein angiography (FA; of right eyes [REs] in column I and left eyes [LEs] in column 
III), indocyanine green (ICG) angiography (REs in column II and LEs in column IV), and spectral-domain optical 
coherence tomography (SD OCT; of REs in upper images of column V and LEs in lower images of column V) 
imaging of each phenotypic subgroup. A, B, The REs and LEs of 2 patients representing subgroup 1, demonstrat-
ing diffuse areas of leakage on FA and ICG angiography (A/I-II, B/III-IV) and subretinal fluid (SRF) beneath the 
fovea (A/V [upper image], B/V [lower image]), illustrating typical active chronic central serous chorioretinopathy 
(cCSC). A/I, Classic example of a gravitational tract on FA in cCSC. The fellow eyes of these patients did not 
have SRF on SD OCT (A/V [lower image], B/V [upper image]) but had clear hyperfluorescent areas on FA and 
ICG angiography, indicating cCSC without active leakage (A/III- IV, B/I-II). C, D, Imaging of 2 patients belonging 
to subgroup 2 with unilateral, more localized leakage on FA and ICG angiography (C/III-IV, D/III-IV) and central 
SRF on SD OCT (C/V [lower image], D/V [lower image]). E, F, The REs and LEs of 2 patients as an example of 
subgroup 3. In the first patient, an irregular hyperfluorescent pattern was seen on FA and ICG angiography of the 
right eye (E/I-II). On SD OCT, there was a large retinal pigment epithelium detachment in association with serous 
SRF (E/V [upper image]). In the fellow eye, central mild hyperfluorescence was seen on FA, with hypofluorescence 
on ICG angiography (E/ III-IV). Also, minimal central SRF was present on SD OCT (E/V [lower image]). The 
second patient had diffuse leakage on FA and ICG angiography (F/I-II) accompanied by SRF on SD OCT (F/V 
[upper image]) in the RE. Imaging of the LE showed multifocal areas of atrophy on FA and ICG angiography (F/
III-IV) and retinal atrophy on SD OCT (F/V). Both eyes had choroidal folds on FA and ICG angiography (F/I-IV).
eye(s), and corresponding hyperfluorescent zones on ICG angiography (Figure 2A, B). 
No evidence of choroidal neovascularization, polypoidal choroidal vasculopathy, or 
other atypical findings were seen in this subgroup.
Phenotypic subgroup 2 (n=52) included patients with unilateral (instead of bilateral) 
abnormalities on FA that were otherwise typical for cCSC. In addition, subgroup 2 
included patients with no clear “hot spot” and/or more focal leakage on FA, with an 
absence of subretinal fluid on SD OCT but otherwise typical FA features of cCSC. 
Also, patients in whom ICG angiography imaging did not show clear hyperfluorescence 
corresponding with FA abnormalities were included in subgroup 2 (Figure 2C, D). 
Furthermore, these patients showed no evidence of choroidal neovascularization, 
polypoidal choroidal vasculopathy, or other atypical findings.
For patients in phenotypic subgroup 3 (n=43), the clinical picture was primarily 
compatible with cCSC, but with more atypical features suggestive of other macular 
diseases; alternatively, it possibly constituted a combination of cCSC and another 
diagnosis. For instance, atypical clinical features in patients in subgroup 3 included 
evidence of choroidal neovascularization, the presence of drusen, or (highly) myopic 
fundus changes (Figure 2E, F).
Association of Single Nucleotide Polymorphisms at Age-related Macular 
Degeneration Loci with Chronic Central Serous Chorioretinopathy
To investigate the extent to which cCSC and AMD overlap genetically, the 
association of 19 SNPs at previously described AMD loci was tested in 197 typical 
cCSC patients (subgroup 1) versus 1311 controls (Table 2). Of these 19 loci, only 
rs10490924 in ARMS2 remained significant (P=0.002; odds ratio [OR]=0.64) after 
correcting for multiple testing (Table 2).
Association of CFH Single Nucleotide Polymorphisms and Haplotypes with 
Chronic Central Serous Chorioretinopathy
To investigate the CFH locus in more detail, we tested 6 additional SNPs for association 
in 197 typical cCSC patients (subgroup 1) and 881 controls (Table 3). After correction 
for multiple testing, 2 CFH SNPs conferred an increased risk for cCSC (rs800292 
[P=7.5x10-4; OR=1.50] and rs1329428 [P=4.6x10-4; OR=1.47]) and 1 SNP was 
protective (rs1065489; P=0.003; OR=0.63; Table 3). 
Of the 5 observed CFH haplotypes, H3 (TGTCCT) was significantly associated 
(P=0.01) with cCSC. The H3 haplotype was protective against the development 
of cCSC (OR=0.54), being present in 15.7% of the control population and in 9% 
of cCSC patients. The H2 haplotype (CATTTG) showed a trend toward association 
(P=0.072), conferring risk for cCSC (OR=1.33) and being present in 20.8% of control 
individuals and in 25.8% of cCSC patients (Table 4).
Differences in Minor Allele Frequencies of Tested Single Nucleotide 
Polymorphisms and Haplotypes among Phenotypic Subgroups of Chronic 
Central Serous Chorioretinopathy
To investigate whether classifying cCSC into 3 distinct phenotypic subgroups had 
an effect on the underlying genetic associations, the minor allele frequencies of the 
significantly associated SNPs [(rs10490924 (ARMS2), rs800292 (CFH), rs1329428 
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(CFH), and rs1065489 (CFH)] were compared between subgroups 1, 2, and 3 (Table 5).
When comparing cCSC subgroups 1 and 2, none of the SNPs showed a difference 
in frequency, suggesting that these subgroups are genetically similar. When the 
atypical patients (subgroup 3) were compared with subgroup 1, rs10490924 in ARMS2 
(P=0.002) and rs800292 in CFH (P=0.002) showed a significant difference in allele 
frequencies between these clinical subgroups, suggesting that subgroups 1 and 3 are 
genetically different (Table 5).
Table 3. Complement Factor H Locus in Chronic Central Serous Chorioretinopathy
SNP Location
Alleles
(Major
/Minor)
MAF in
Subgroup 1
(n=197)
MAF 
among 
Controls 
(n=881)
Un-
adjusted
Allelic
P Value
Allelic Odds Ratio 
(95% CI)
rs3753394 Promotor C/T 0.245 0.295 0.027 0.78 
(0.60-1.00)
rs800292 
(I62V)
Exon 2 G/A 0.315 0.235 7.5x10-4 1.50 
(1.18-1.90)
rs1061170 
(Y402H)
Exon 9 T/C 0.310 0.350 0.065 0.83 
(0.66-1.05)
rs2284664 Intron 15 C/T 0.276 0.218 0.009 1.37 
(1.07-1.76)
rs1329428 Intron 15 C/T 0.526 0.431 4.6 x 10-4 1.47 
(1.17-1.83)
rs1065489 
(D936E)
Exon 18 G/T 0.118 0.176 0.003 0.63 
(0.45-0.87)
CI=confidence interval; MAF=minor allele frequency; SNP=single nucleotide polymorphism. For this 
analysis, 1-sided P values < 0.0083 were considered significant.
Table 4. Complement Factor H Haplotypes in Chronic Central Serous Chorioretinopathy
SNP
HF in Sub-
group 1
(n=197)
HF among 
Controls
(n=881)
Un-
adjusted
P-value
Odds Ratio (95% 
CI)Hap-
lo-types
rs
37
53
39
4
rs
80
02
92
rs
10
61
17
0
rs
22
84
66
4
rs
13
29
42
8
rs
10
65
48
9
H1 C G C C C G 0.291 0.328 0.164 0.83 (0.59-1.17)
H2 C A T T T G 0.258 0.208 0.072 1.33 (0.93-1.90)
H3 T G T C C T 0.090 0.157 0.010 0.54 (0.32-0.91)
H4 C G T C T G 0.125 0.132 0.480 0.96 (0.60-1.52)
H5 T G T C T G 0.102 0.076 0.150 1.37 (0.81-2.32)
CI=confidence interval; HF=haplotype frequency; SNP=single nucleotide polymorphism. For this analysis, 
1-sided P values < 0.01 were considered significant.
Ta
bl
e 
2.
 A
na
ly
si
s 
of
 1
9 
Ag
e-
Re
la
te
d 
M
ac
ul
ar
 D
eg
en
er
at
io
n 
Lo
ci
 in
 C
hr
on
ic
 C
en
tra
l S
er
ou
s 
C
ho
rio
re
tin
op
at
hy
Si
ng
le
 N
uc
le
ot
id
e 
Po
ly
m
or
ph
is
m
 (L
oc
us
)
Al
le
le
s 
(M
aj
or
/M
in
or
)
M
AF
 in
 S
ub
gr
ou
p 
1 
(n
=
19
7)
M
AF
 a
m
on
g 
C
on
tro
ls
(n
=
13
11
)
U
na
dj
us
te
d 
Al
le
lic
P 
va
lu
e
Al
le
lic
 O
dd
s 
Ra
tio
 
(9
5%
 C
I)
rs
10
49
09
24
 (A
RM
S2
)
G
/T
0.
17
0.
24
0.
00
2
0.
64
 (0
.4
9-
0.
85
)
rs
12
14
49
39
 (C
FH
)
G
/T
0.
25
0.
20
0.
03
1
1.
33
 (1
.0
3-
1.
70
)
rs
42
96
08
 (C
2-
CF
B)
G
/A
0.
16
0.
13
0.
13
3
1.
25
 (0
.9
4-
1.
68
)
rs
22
30
19
9(
C3
)
G
/C
0.
19
0.
17
0.
39
3
1.
16
 (0
.8
3-
1.
61
)
rs
96
21
53
2 
(T
IM
P3
)
A/
C
0.
05
0.
05
0.
80
7
1.
05
 (0
.6
5-
1.
68
)
rs
44
20
63
8 
(A
PO
E)
A/
G
0.
16
0.
17
0.
47
0
0.
89
 (0
.6
6-
1.
19
)
rs
37
64
26
1(
CE
TP
)
G
/T
0.
30
0.
32
0.
48
4
0.
92
 (0
.7
3-
1.
16
)
rs
94
30
80
 (V
EG
FA
)
T/
C
0.
44
0.
48
0.
21
1
0.
87
 (0
.7
0-
1.
08
)
rs
13
27
80
62
 (T
N
FR
SF
10
A)
T/
G
0.
40
0.
48
0.
00
4
0.
73
 (0
.5
9-
0.
90
)
rs
49
32
58
 (L
IP
C)
C
/T
0.
49
0.
46
0.
06
4
1.
23
 (0
.9
9-
1.
52
)
rs
10
03
39
00
 (C
FI
)
C
/T
0.
50
0.
48
0.
51
4
1.
08
 (0
.8
7-
1.
34
)
rs
38
12
11
1 
(C
O
L1
0A
1)
A/
T
0.
34
0.
36
0.
49
8
0.
92
 (0
.7
4-
1.
15
)
rs
13
08
18
55
 (C
O
L8
A1
-F
IL
IP
1L
)
G
/T
0.
12
0.
09
0.
07
4
1.
38
 (0
.9
8-
1.
93
)
rs
31
30
78
3 
(IE
R3
-D
D
R1
)
A/
G
0.
20
0.
19
0.
83
6
1.
03
 (0
.7
8-
1.
34
)
rs
81
35
66
5 
(S
LC
16
A8
)
C
/T
0.
21
0.
22
0.
60
0
0.
92
 (0
.7
1-
1.
20
)
rs
33
43
53
 (T
G
FB
R1
)
T/
G
0.
26
0.
25
0.
66
2
1.
06
 (0
.8
3-
1.
35
)
rs
80
17
30
4 
(R
AD
51
B)
A/
G
0.
36
0.
38
0.
46
7
0.
92
 (0
.7
3-
1.
14
)
rs
67
95
73
5 
(A
D
AM
TS
9)
C
/T
0.
46
0.
41
0.
04
7
1.
25
 (1
.0
1-
1.
54
)
rs
95
42
23
6 
(B
3G
AL
TL
)
T/
C
0.
44
0.
44
1.
00
0
1.
01
 (0
.8
1-
1.
25
)
C
I=
co
nf
id
en
ce
 in
te
rv
al
; M
AF
=
m
in
or
 a
lle
le
 fr
eq
ue
nc
y,
 F
or
 th
is
 a
na
ly
si
s,
 2
-s
id
ed
 P
 v
al
ue
s 
<
 0
.0
02
6 
w
er
e 
co
ns
id
er
ed
 s
ig
ni
fic
an
t.
43
2.1
Discussion
Both risk-conferring and protective associations of polymorphisms in the ARMS2 
and CFH genes with cCSC were identified in this study. Moreover, by introducing 
a subclassification of cCSC, our data demonstrate clear differences as well as a 
certain degree of phenotypic and genetic overlap between cCSC and AMD.
Chronic CSC is a heterogeneous disease that sometimes shows a clinical overlap 
with other macular diseases, such as polypoidal choroidal vasculopathy and AMD. 
Withdetailed phenotyping based on SD OCT, FA, and ICG angiography, we defined 
3 clinically distinctive subgroups, including typical cCSC (subgroup 1), slightly atypical 
cCSC (subgroup 2), and a third more atypical phenotypic subgroup of cCSC 
patients who had evidence of an overlap with other macular diseases (subgroup 3).
From an analysis of 19 SNPs at known AMD loci,20-22 1 SNP in ARMS2 remained 
significant after correction for multiple testing, and 3 SNPs at other AMD loci 
(CFH, TNFRSF10A, ADAMTS9) showed a trend toward association with typical 
cCSC (subgroup 1). The association of these SNPs with cCSC was not exactly in 
concordance with the strength of the previously reported association with AMD.20 
Indeed, the effect sizes for ARMS2 (rs10490924) and CFH (rs1061170, Y402H) are 
greater in AMD (ORs=2.76 and 2.25, respectively),20,24 whereas an inverse and 
weaker effect was observed in cCSC (ORs=0.64 and 0.83, respectively). A protective 
effect was observed for TNFRSF10A (rs13278062) in cCSC (OR=0.73), whereas 
an opposite and weaker effect was previously detected in AMD (OR= 1.15).20 
ADAMTS9 (rs6795735) conferred increased risk for both diseases, but with a less 
strong effect in AMD (OR=1.10) compared with cCSC (OR=1.37).20 For some of these 
associations the effect was mainly carried by the males (Table 6). 
Table 5. Comparison of Allele Frequencies among the Subgroups
SNP Location
MAF in 
Sub-
group 1
(n=197)
MAF in 
Sub-
roup 2
(n=52)
MAF in 
Sub-
group 3
(n=43)
MAF 
among 
Controls
(n=1311
/881)
MAF 
among
Those 
With AMD 
(n=1147)
P-value
Sub-
group 
1 vs.
Sub-
group 
2
Sub-
group 
1 vs.
Sub-
group 
3
rs10490924 
(A69S)
ARMS2 
exon 1
0.17 0.26 0.31 0.24 0.41 0.033 0.002
rs800292 
(I62V)
CFH exon 
2
0.31 0.26 0.15 0.24 0.18 0.337 0.002
rs1329428 CFH intron 
15
0.53 0.41 0.40 0.43 N/A 0.047 0.032
rs1065489 
(D936E)
CFH exon 
18
0.12 0.16 0.12 0.18 N/A 0.246 1
AMD=age-related macular degeneration; MAF=minor allele frequency. SNP=single nucleotide 
polymorphism For this analysis, 2-sided P values < 0.0125 were considered significant.
However, because cCSC predominantly occurs in male patients, the small number 
of female patients present in our cohort made the interpretation of sex-specific 
associations unreliable. Genotyping of more female cCSC patients can shed light 
on the occurrence of a sex-specific effect and on potential differences in disease 
etiology.
It is well known that AMD is a multifactorial disease in which a number of subcellular 
systems and pathways are involved, such as the complement system, angiogenesis, 
lipid metabolism, and the extracellular matrix.20 Our current findings suggest a partial 
pathophysiologic overlap of cCSC with AMD that could be connected with 2:1 of 
these associated pathways.
In both AMD and cCSC, the reported association with ARMS2 (rs10490924) has 
the strongest effect compared with other disease-associated SNPs (OR=2.76 for 
AMD and OR=0.64 for cCSC).20 Interestingly, the association of ARMS2 (rs10490924) 
with cCSC is protective, whereas the previously reported association with AMD 
confers risk.20,25 The potential protective effect of ARMS2 (rs10490924) in cCSC 
was not reported before. However, an association of ARMS2 (rs10490924) with 
a lesser incidence of serous retinal detachments has been reported in polypoidal 
choroidal vasculopathy, a disease that shows clinical overlap with cCSC.26 
Intriguingly, a history of CSC is more prevalent in patients with polypoidal choroidal 
vasculopathy and choroidal hyperpermeability,27 and CSC in combination with a 
type 1 neovascularization or polypoidal choroidal vasculopathy has also been 
described.28,29 The protective effect of ARMS2 (rs10490924) in both conditions may 
suggest a functional involvement of ARMS2 at the level of the RPE and/or choroid. 
Although the exact role of the ARMS2 protein product is unknown, a recent study 
demonstrated that ARMS2 interacts with components of the extracellular matrix.30 
Disturbances in the extracellular matrix at the level of the RPE and/or choroid could 
result in an increased susceptibility to cellular detachments, which may indicate a 
possible link between the supposed molecular function of ARMS2 and the clinical 
phenotype of cCSC.
Our data also suggest involvement of other extracellular matrix molecules. Although 
these results did not remain significant after correction for multiple testing and 
require replication in other cohorts for confirmation, it is worthwhile to consider their 
association. ADAMTS9 (rs6795735; P=0.045) encodes a metalloproteinase that 
cleaves large aggregated proteoglycans, has thrombospondin domains, and is an 
inhibitor of angiogenesis.31 COL8A1 (rs13081855; P=0.074) encodes collagen type VIII 
that is expressed in the endothelium of blood vessels and is involved in endothelial 
cell and vascular smooth muscle proliferation and migration.32,33 TNFRSF10A 
(rs13278062; P= 0.004) is part of the tumor necrosis factor-a receptor superfamily 
and acts as a death receptor after binding its cytokine ligand TNFSF10/TRAIL, 
known to play an important role in the induction of apoptosis,34 vascular smooth 
muscle proliferation, and regulation of angiogenic responses in the brain after 
stroke.35,36 These potential associations suggest that the extracellular environment 
as well as angiogenic processes may be involved in cCSC.
We also found a significant association with several SNPs in the CFH gene (rs800292, 
rs1329428, and rs1065489), but the effect sizes were slightly smaller than those 
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recently reported in a Japanese CSC cohort (e.g., OR= 1.47 for rs1329428 reported 
in the current cohort versus 1.79 reported by Miki et al17). This may partially be 
explained by genetic differences in the frequency of the minor alleles for the tested 
SNPs at the CFH locus that exist between the Japanese and Western European 
populations (hapmap.org; Table 7), as well as differences in phenotyping. Similar to 
our observation for ARMS2, CFH SNPs that confer risk for cCSC were previously 
found to be protective for AMD, whereas SNPs that were found to be protective 
for cCSC were previously found to increase risk for AMD.24 The H2 haplotype, 
previously found to be protective for AMD (OR=0.54),24 was found to increase risk 
for cCSC (OR=1.33). Conversely, the H3 haplotype that was previously not found 
to be associated with AMD was found to be protective for cCSC (OR=0.54).24 The 
observation that CFH SNPs have opposite effects in CSC versus AMD was also 
recently reported by Miki et al,17 but the underlying mechanisms that could explain 
these observations are unclear.
The functional implications of the associated CFH SNPs in the present cCSC cohort 
and their possible significance for the pathogenesis of cCSC are unknown, but there 
seems to be an important role for the CFH protein in the RPE and choroid. CFH is 
an inhibitor of the alternative complement pathway (AP), and choroidal cells play 
a central role in complement AP activity in the eye. C3, an acute phase protein 
and the central player in complement activation, is most highly expressed in the 
choroid.37,38 The CFH protein is the predominant cell surface-associated complement 
inhibitor in the RPE-choroid complex, where it down-regulates the complement AP 
activation via inhibition of C3 activity.39
The choroid seems to play a pivotal role in the pathogenesis of CSC because 
choroidal thickening, congestion, and hyperpermeability seem to be the most 
pronounced and extensive abnormalities in cCSC patients.40 In addition, patients 
with CSC show increased choroidal blood flow during exercise compared with 
controls.41 Homozygosity for the CFH rs1061170 (Y402H) risk allele was associated 
with increased choroidal blood flow and ocular perfusion pressure during exercise 
using Doppler flowmetry,42 a process that may be linked to the CFH-binding 
partner adrenomedullin via (steroid-) hormone-dependent nitric oxide bioactivity 
in vascular endothelial cells.39,43,44 Altered complement AP activity, extravasation of 
complement related proteins, and deposition of terminal complement membrane 
attack complexes may lead to RPE damage and dysfunction. Damage to the RPE 
cell layer, further destabilized by changes in the extracellular matrix and under 
stress from increasing pressure from the thickened choroid, could eventually result 
in subretinal fluid leakage.43,44
Three distinct phenotypic subgroups within our analyzed cCSC patient population 
were identified based on multimodal imaging, ranging from typical to less typical 
phenotypes. The minor allele frequencies of the SNPs (rs10490924, rs800292, 
rs1329428, and rs1065489) that were significantly associated with typical cCSC 
(subgroup 1) differed from the minor allele frequencies observed in the other 
subgroups. Subgroup 2 differs only slightly from the most typical subgroup (subgroup 
1), suggesting that considerable genetic overlap exists. In fact, the major distinction 
in the reported phenotypic criteria are bilateral versus unilateral occurrence. The 
atypical subgroup (subgroup 3) differs significantly from subgroup 1 for ARMS2 
(rs10490924; P=0.002) and CFH (rs800292; P=0.002) minor allele frequencies, which 
suggests that subgroup 3 is genetically different from the typical cCSC group. Based 
on the phenotypic criteria, subgroup 3 shows overlap with other maculopathies such 
as AMD, highly myopic macular changes, and polypoidal choroidal vasculopathy. The 
minor allele frequencies of these 2 SNPs in subgroup 3 were even similar to those 
normally observed in AMD, with the same direction of effect seen in AMD opposed 
to typical cCSC. Our results demonstrate that detailed phenotyping in cCSC patients 
is important to obtain reliable genetic results.
In conclusion, we show that genetic variants in ARMS2 and CFH are associated with 
cCSC. Detailed phenotyping and classification of cCSC are important to establish 
such genetic associations. Our findings indicate that complement dysregulation in the 
RPE/choroid, and potentially dysregulation of genes involved in extracellular matrix 
and angiogenesis factors, are involved in the pathogenesis of cCSC. Further genetic 
and phenotypic analysis of cCSC, as well as genotype-phenotype correlation analyses, 
can provide important clues about the genetic background and pathogenesis of 
cCSC and may lead to the identification of possible new preventive and therapeutic 
targets.
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Table 7. Minor Allele Frequencies of CFH SNPs in European (CEU) and Japanese (JPT) Population.
SNP
MA 
(HapMap-CEU)
MA frequency 
HapMap-CEU
MA frequency HapMap-JPT
CFH rs3753394 T 0.279 0.509
CFH rs800292 A 0.217 0.416
CFH rs2284664 T 0.195 0.406
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CFH = complement factor H; SNP = single nucleotide polymorphism; MA = minor allele 
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Abstract
Purpose: Chronic central serous chorioretinopathy (cCSC) has recently been 
associated to variants in the complement factor H gene. To further investigate the 
role of the complement system in cCSC, the genomic copy number variations in the 
complement component 4 (C4) gene were studied.
Methods: C4A and C4B copy numbers were analyzed in 197 cCSC patients and 303 
healthy controls using a Taqman copy number determination assay. Copy numbers 
of C4A, C4B and the total C4 load were compared between cases and controls, using 
a Fisher Exact test. For this analysis Bonferroni correction was performed for three 
tests, and P values <0.017 were considered to be significant. A logistic regression 
model was constructed to calculate the odds ratios (ORs) of each of the C4B copy 
numbers, using two copies as a reference. For this model P values <0.05 were 
considered to be significant.
Results: C4B genomic copy numbers differed significantly between cCSC patients 
and healthy controls (P=0.0018). Absence of C4B significantly conferred risk of cCSC 
(P=0.039, OR=2.61 [95% confidence interval (CI)=1.05–6.52]), whereas three copies 
of C4B significantly decreased the risk of cCSC (P=0.014, OR=0.45 [95%CI=0.23–
0.85]). The C4A genomic copy numbers and total C4 load did not significantly differ 
between cases and controls. 
Conclusions: This study showed that copy numbers of C4B are significantly associated 
with cCSC. Carrying no copies of C4B significantly increases the risk of cCSC, whereas 
carrying three C4B copies is protective. These findings reinforce the hypothesis of a 
possible involvement of the complement system in the pathogenesis of cCSC. 
Introduction 
Chronic central serous chorioretinopathy (cCSC) is characterized by fluid accumulation 
under the neuroretina. It has been postulated that this serous fluid derives from the 
choroid, and that it leaks through a dysfunctional retinal pigment epithelium (RPE) 
causing a detachment of the neuroretina.1-4 Classically, cCSC patients are relatively 
young (middle-aged) men who are still professionally active.6 Besides male sex, also 
the use of corticosteroids, type A personality and stress have been associated with 
cCSC.4,6,7 Although the exact pathophysiological mechanism of the disease remains 
unknown, we and others have previously suggested involvement of the complement 
system, and in particular the complement factor H (CFH) gene in cCSC.8,9 Interestingly, 
CFH variants that confer increased risk in cCSC have previously been described to be 
protective in age-related macular degeneration, and vice versa.9-11
The complement system consists of three major pathways: the classical, the lectin, 
and the alternative pathway.12 CFH is involved in the alternative pathway and can 
influence C3b production by blocking one of the two C3-convertases (C3bBb). The 
classical and lectin pathways also play an important role in C3b production mediated 
by the other C3-convertase (C4b2a), of which the complement component 4 (C4) 
protein is a key factor.13 
Copy number variations of the C4 gene have been associated with several eye 
diseases and autoimmune disorders (e.g. Vogt- Koyanagi-Harada and Beçhet’s 
disease).14-16 In addition, Banlaki et al. 17 have found that the genomic copy number 
of C4B is associated with cortisol release after adrenocorticotropic hormone (ACTH) 
stimulation. This is of particular interest considering that stress, which appears to be 
associated with cCSC,4 has a strong influence on the hypothalamic-pituitary-adrenal 
(HPA) axis and increases ACTH release.18 
Because of its role in the complement system, and its association with the HPA axis, 
we hypothesized that copy number variation in the C4 gene may be associated with 
cCSC. In this study we assessed the copy number variations of the C4 gene in a cCSC 
cohort. 
Materials and Methods
Subjects
In this study, 197 patients diagnosed with cCSC who visited the outpatient clinic 
of the department of Ophthalmology at the Radboud University Medical Center, 
Nijmegen, the Netherlands were included (Table 1). The diagnosis cCSC was based 
on an extensive ophthalmological examination including fundoscopy, spectral-
domain optical coherence tomography, fluorescein angiography and indocyanine 
green angiography. The definition of typical cCSC used in this study was based on 
the previously published subgroups by de Jong et al.,9 and patients in this study were 
phenotypes by an experienced retina specialist (CJFB) (Figure 1A-F). Additionally, a 
total of 303 control subjects were recruited from the blood bank of the Radboud 
University Medical Center, Nijmegen, the Netherlands (n = 154), and the European 
Genetic Database (EUGENDA, www.eugenda.org; provided in the public domain 
by the University Hospital of Cologne, Cologne, Germany and Radboud university 
medical center) (n = 149) (Table 1). For this last group fundus photographs were graded 
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to rule out any ophthalmological abnormalities at the moment of inclusion. Informed 
consent for the use of DNA for genetic studies was obtained from all subjects. This 
study followed the guidelines of the Declaration of Helsinki and was approved by the 
local ethics committee.
Copy number determination
DNA was isolated from peripheral blood using standard procedures. C4A and C4B 
copy numbers were determined by real-time PCR using Taqman® genotyping assays 
(Applied Biosystems, Thermo Fisher Scientific, Waltham, USA). The FAM-labeled 
C4A (Hs07226349_cn) or C4B (Hs07226350_cn) Taqman copy number assay was 
combined together with the VIC-labeled Ribonuclease P (RNaseP) reference assay 
(Catalog nr. 4403326), and Taqman genotyping mastermix (Catalog nr. 4381656). All 
samples were tested in duplicate for C4A and C4B on 384-wells plates using 10 ng of 
DNA in a total reaction volume of 10 μl. 
Samples with known copy numbers for either C4A (0-4) or C4B (0-3) were kindly 
provided by C. Yung Yu.19 These samples were included as a reference on each 
plate to facilitate accurate copy number determination, using the method described 
previously.19 In each run the amplification efficiencies of the C4A/C4B and RNaseP 
probes were calculated using a serial dilution (50-1.56 ng) of a sample with two C4A 
and C4B copies. The primer efficiencies of the probes were compared, and deemed 
Figure 1: Example of FA of an RE (A), and an LE (C), ICG angiography of an RE (B), and an LE (D), and spectral-
domain optical coherence tomography of an RE (E), and an LE (F) imaging of the phenotypic characteristics of 
the cCSC cohort used for this study. (A-F) The RE and LE of a patient demonstrate diffuse hyperfluorescent areas 
of leakage on FA and ICG angiography (A-D) and subretinal fluid beneath the fovea (E), illustrative for typical 
cCSC. FA, fluorescein angiography; ICG, indocyanine green; LE, left eye; RE, right eye.
Table 1. Demographics of the study population
cCSC patients Controls P value
No. of subjects 197 303 NA
Sex (male/female) 154/43 226/77 0.392
Mean age ±SD (years) 53 (±10) 53 (±11) 0.755
Age range (years) 29-74 29-77 NA
cCSC; chronic central serous chorioretinopathy, NA; not annotated SD; standard deviation
similar if they differed <2%, this was the case in all runs. Therefore, the efficiencies 
were not incorporated into the calculations of the copy numbers. Polymerase chain 
reaction was performed with a 7900HT thermocycler (Applied Biosystems, Thermo 
Fisher Scientific) using the following program: 2 minutes at 50°C, 10 minutes at 95°C, 
and 40 cycles of 15 seconds at 95°C and 60 secsonds at 60°C. Data were analyzed 
with the Copycaller software (V2.0; Applied Biosystems, Thermo Fisher Scientific). 
Copy numbers determined by the Copycaller software were corrected by using the 
trend line based on the reference samples, as described before.19 If the results were 
inconsistent between the Copycaller output and the values corrected with the trend 
line, samples were retested on a new plate in triplicate.
Statistics
The comparison of C4A, C4B and total C4 copy number distribution between cCSC 
patients and controls was performed by means of a Fisher Exact test using SPSS 
Statistics (V20; IBM Corp., Armonk, USA). Bonferroni correction for multiple testing 
was performed for three tests and P values < 0.017 were considered to be statistically 
significant. A logistic regression model was constructed to determine the odds ratios 
(ORs) for the various copy numbers of C4B. According to previously published studies, 
two genomic copy numbers of C4B are considered to be most common in the healthy 
population.16,20 We were able to confirm this in our cohort, and therefore this copy 
number was set as reference. In this model, P values <0.05 were considered to be 
significant. Graphs were generated using Graphpad Prism (V5; Graphpad Software, 
San Diego, CA, USA).
Results
The copy numbers of C4A and C4B were successfully determined in 197 cCSC 
cases and 303 controls. No significant difference was observed between cases and 
controls for the C4A genomic copy number (range: 0-6, P=0.649; Figure 2A). The C4B 
distribution was significantly different between cCSC patients and controls (range: 
0-4, P=0.0018; Figure 2B). Overall, cases carried lower copy numbers of C4B than 
the control population. The total C4 genomic copy number was not different in cases 
compared to controls (P=0.148; Figure 2C). Age and sex were not associated with 
either C4A, C4B, or total C4 genomic copy number (Table 2; data for C4A and total C4 
not shown). 
To assess the effect size of the different copy numbers of C4B on development of cCSC, 
a logistic regression was performed (Table 2). The logistic regression model based on 
the distribution of C4B between cases and controls was significant (P=0.0035, Table 2). 
Carrying no copies of C4B conferred increased risk of cCSC (P=0.039, OR=2.61, 95% 
confidence interval [CI]=1.05-6.52). A similar trend was observed for carriers of one 
copy of C4B, but the results were not significant (P=0.080, OR=1.47, 95% CI=0.96-
2.26). Carrying three C4B copies was associated with a significantly decreased risk 
of cCSC (P=0.014, OR=0.45, 95% CI=0.24-0.85), whereas no significant association 
with cCSC was observed in individuals carrying four copies of C4B (P=0.81). 
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Figure 2: Distribution of the genomic copy numbers of C4A (A), C4B (B), and total C4 (C) in patients with 
cCSC and controls. Displayed P values were generated with a Fisher Exact test. To correct for multiple testing, P 
values <0.017 were considered to be significant.
Table 2. Logistic regression model for C4B load
Overall significance model, P=0.0035
C4B copy nr. cCSC patients (n) Controls (n) P value OR 95% CI
Age 197 303 0.605 NA NA
Gender 197 303 0.346 NA NA
0 13 8 0.039 2.613 1.048-6.518
1 58 63 0.080 1.469 0.956-2.259
2 110 179 Ref. 1 NA
3 14 49 0.014 0.445 0.234-0.849
4 2 4 0.808 0.809 0.145-4.503
OR, Odds Ratio; CI, Confidence Interval, Ref, Reference
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Discussion
Our study results demonstrate that cCSC patients have a significantly different C4B 
load as compared to healthy controls (P=0.0018). Carrying no copies of C4B was 
associated with an increased risk of cCSC (OR=2.61, 95% CI=1.05-6.52), whereas 
carrying three C4B copies was associated with a decreased risk of cCSC (OR=0.45, 
95% CI=0.23-0.85). No association with cCSC was observed in individuals carrying 
four C4B copies, which is likely due to the limited sample size of this group (cases, 
n=4; controls, n=2). No significant differences were observed between cases and 
controls for C4A and total C4 load. 
The C4 gene lies within the RP-C4-CYP21-TNX (RCCX) locus located in the major 
histocompatability complex (MHC) region III on chromosome 6 of the human genome.20 
The MHC region contains an elevated level of genomic copy number variations that are 
presumably present to increase immunological diversity.21 Duplications and deletions 
in the region have led to the formation of haplotypes containing variable copies of the 
RCCX locus in the human population (Figure 3B).5,21,22 Haplotypes containing two or 
more duplications of the RCCX locus show extensive variability in their gene content, 
generally with complete duplications of the C4 gene (Figure 3B).22,23 The C4 gene 
encodes for the C4 protein, of which two variants have been described (C4A/C4B), 
differing in only four amino acids encoded by exon 26 (Figure 3A).24
Copy number variations of either C4A or C4B have been associated with several 
systemic diseases with ocular involvement, such as Vogt-Koyanagi-Harada disease, 
Figure 3: A schematic illustration of the RCCX locus. (A) A display of the two variants of the C4 gene, differing 
in four amino acids in exon 26 (p. 1101-1106). (B) An example of the structure of the RCCX locus with a single 
copy (upper panel) and two copies (lower panel) of the C4 gene. In case of duplication, a complete C4A or C4B 
and the CYP21 gene are duplicated, while the RP and TNX gene are only partially duplicated. The dotted lines 
indicate the approximate site were during recombination the duplication has occurred in the past. (Figure based 
on Banlaki et al. 2013).5 
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Behçet’s disease, and systemic lupus erythematosus (SLE).14-16 Hou et al. 14 have 
shown that a lower copy number of C4A and C4B increases the risk of Vogt-Koyanagi-
Harada, an autoimmune disorder characterized by bilateral granulomatous panuveitis. 
The same group15 has also demonstrated that higher copy numbers of C4A confer 
risk of Behçet’s disease, an autoinflammatory disease, which presents with acute 
anterior uveitis. Several studies16,25,26 have shown an association between low 
copy numbers of C4 and an increased risk for SLE, an autoimmune disease that is 
typically mediated by immune complexes. In the past, CSC has been described in SLE 
patients,27,28 but it remains unclear whether this is a primary manifestation of SLE, or 
whether it is a consequence of corticosteroid treatment for SLE.29,30 Several studies 
have reported a positive linear correlation between serum C4 and C4 genomic copy 
number,31-33 suggesting that the lower number of C4B copies in cCSC patients leads 
to lower systemic C4B levels. This may indicate that an overall lower activity of the 
complement system might be present in cCSC patients. 
Recently, low copy numbers of C4B have been associated with hyperreactivity of the 
HPA axis.17 Banlaki et al. 17 have shown that in patients with adrenal incidentaloma and 
low (<2 copies) C4B genomic copy number, baseline ACTH was significantly reduced 
compared to high (≥2 copies) genomic copy number of C4B. Moreover, a significantly 
higher cortisol response is observed after ACTH stimulation in the patients with low 
C4B genomic copy number.17 
These results are of interest in the context of cCSC because of the described clinical 
associations with stress and the use of corticosteroids that both exert physiological 
effects at the level of the HPA axis.18 Various relatively small studies have studied 
cortisol levels in cCSC patients. Although 24h urine samples showed elevated cortisol 
levels in cCSC patients in certain studies,34,35 these results are not observed in single 
serum measurements during set times in other studies.36,37 These discrepancies could 
be explained by variable cortisol fluctuations between individuals during the day, and 
therefore changes in endogenous cortisol levels cannot be ruled out as a hallmark 
of cCSC. It is possible that patients with cCSC generally have normal cortisol levels, 
but respond differently to stimulation of the HPA axis. Stress, which also appears to 
be associated with cCSC,2,38 stimulates the HPA axis and could lead to temporarily 
elevated cortisol levels in patients as compared to healthy individuals. How high 
levels of cortisol can lead to subretinal fluid accumulation is currently unknown. A 
study in rats suggested that the disease mechanism could be mediated by binding 
of corticosteroids to the mineralocorticoid receptor.39 In this study, activation of 
the mineralocorticoid receptor causes vascular effects similar to those observed in 
cCSC,39 but the underlying pathways still remain to be elucidated.
The mechanism through which low copy numbers of C4B may lead to 
hyperresponsiveness of the HPA axis is unclear. It has been hypothesized that it 
is not the C4B gene, but rather the neighboring CYP21A2 gene, that mediates this 
effect.17 The CYP21A2 gene encodes the enzyme 21-hydroxylase, which plays 
an important role in the steroid metabolism pathway by converting progesterone 
and 17-α-hydroxyprogesterone to 11-deoxycorticosterone and 11-deoxycortisol, 
respectively. Because of the genomic structure of the RCCX locus, variation in the 
CYP21A2 gene is in high linkage disequilibrium with variation in the neighboring 
C4 gene (C4A or C4B).17 Therefore, further exploration of the precise structure 
and specific variations present in the RCCX locus may reveal new insights into the 
pathogenesis of cCSC.
The current study and previous studies identified an association between complement 
genes and cCSC,8,9 suggesting that the complement system may be dysregulated 
in cCSC. Taken together, these findings may indicate that the immune system, 
influenced by environmental factors, such as stress, could play a pivotal role in the 
pathophysiology of cCSC. Further studies are necessary to determine the physiological 
effects of genetic variation at the C4 gene and the RCCX locus in cCSC. 
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Abstract
Importance: Chronic central serous chorioretinopathy (cCSC) is a chorioretinal disease 
with unknown disease etiology. The glucocorticoid receptor and the mineralocorticoid 
receptor, 2 glucocorticoid-binding receptors, might be involved in the pathogenesis 
of cCSC.
Objective: To assess the association of functional variants and haplotypes in the 
glucocorticoid receptor (NR3C1) and mineralocorticoid receptor genes (NR3C2) with 
cCSC.
Design, setting, and participants: In this case-control genetic association study, 336 
patients with cCSC and 1314 unaffected controls, collected at 3 university medical 
centers from September 1, 2009, to May 2016, underwent KASP genotyping for 
selected variants in NR3C1 (rs56149945, rs41423247 and rs6198) and NR3C2 
(rs2070951 and rs5522).
Main outcome measure: Genetic associations of 3 NR3C1 variants and 2 NR3C2 
variants with cCSC.
Results: Among the 336 patients (274 men and 62 women; mean [SD] age, 52[10] 
years), after correction for multiple testing, rs2070951 in the NR3C2 gene was 
significantly associated with cCSC (odds ratio, 1.29; 95% CI, 1.08-1.53; P=.004). 
Moreover, the GA haplotype of single nucleotide polymorphisms rs2070951 and 
rs5522 in NR3C2 conferred risk for cCSC (odds ratio, 1.39; 95% CI, 1.15-1.68; 
P=.004), whereas the CA haplotype decreased risk for cCSC (odds ratio, 0.72; 95% 
CI, 0.60-0.87; P<.001). Three known variants in NR3C1 that alter the activity of the 
glucocorticoid receptor (rs56149945, rs41423247 and rs6198) were not associated 
with cCSC.
Conclusions and Relevance: In this study, the variant rs2070951 and the GA haplotype 
in NR3C2 were associated with an increased risk for cCSC. Results of this genetic 
study support a possible role for the mineralocorticoid receptor in the pathogenesis 
of cCSC. Since these haplotypes have previously been associated with perceived 
stress, this study provides a clue to bridging clinical risk factors for cCSC to underlying 
genetic associations. 
Introduction
In central serous chorioretinopathy (CSC), it has been suggested that dysfunction 
of the retinal pigment epithelium (RPE) due to congestion, thickening, and 
hyperpermeability of the underlying choroid leads to subretinal fluid accumulation 
with an associated detachment of the neuroretina.1-5 The exact etiology of the 
disease is currently unknown, but clinical associations point towards an involvement 
of steroid signaling. Endogenous hypercortisolism (Cushing’s syndrome), exogenous 
glucocorticoid exposure, and possibly stress and type A personality are associated 
with CSC.6-11 It has been hypothesized that the glucocorticoid receptor (GR) and the 
mineralocorticoid receptor (MR), 2 glucocorticoid-binding receptors, may also be 
involved in the pathogenesis of CSC.2
The involvement of the MR in the pathogenesis of CSC has been suggested based 
on the results of studies in rats, in which choroidal findings similar to those seen 
in CSC occurred after intravitreal injection of either corticosterone or aldosterone.12 
Involvement of the MR was further supported by ophthalmological findings in patients 
with primary hyperaldosteronism (Conn syndrome).13 Moreover, studies evaluating 
the administration of MR antagonists for patients with cCSC have shown possible 
beneficial effects.12,14-17 However, clinical results were variable and not permanent, 
and no prospective randomized placebo-controlled clinical trials have been published 
to this date to study the role of MR antagonists in the treatment of CSC.2,16
The GR is the most widely expressed cortisol receptor in the body; it regulates 
metabolism and the cardiovascular system, and it plays a role in immune suppression 
and stress response.18 As stress and both exogenous and endogenous hypercortisolism 
may be involved in the etiology of CSC,4,7,10,11 the GR may also be an interesting player 
in the pathogenesis of CSC. 
There are several genetic variants in the genes encoding the MR and GR that are 
known to alter the MR and GR protein activity.19-26 The MR is encoded by the NR3C2 
gene (OMIM 600983), consisting of 10 exons, with 2 alternative 5’-UTR exons 1α and 
1β allowing tissue-specific promoter activation.27 The GR is encoded by the NR3C1 
gene (OMIM 138040), consisting of 10 exons of which 1 to 9α are translated into 
the functional GRα receptor.22 In this study, we assessed whether genetic variants in 
NR3C2 (rs2070951 and rs5522) and NR3C1 (rs56149945, rs41423247, and rs6198) 
are associated with cCSC. 
Key Points
Question: Are functional variants and haplotypes in the glucocorticoid receptor 
(NR3C1) and mineralocorticoid receptor (NR3C2) genes associated with chronic 
central serous chorioretinopathy (cCSC)?
Findings: In this case-control, genetic association study, rs2070951 in the NR3C2 
gene was significantly associated with cCSC. The GA haplotype of single-nucleotide 
polymorphisms rs2070951 and rs5522 in NR3C2 conferred risk for cCSC, whereas 
the CA haplotype decreased the risk for cCSC.
Meaning: Results of this genetic study support a possible role for the mineralocorticoid 
receptor in the pathogenesis of cCSC.
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Materials and methods
We included 336 patients with cCSC in this study. Phenotyping was performed from 
September 1, 2009, to May 1, 2016, by an experienced retina specialist (C.J.F.B.) 
and was based on results of a complete ophthalmological examination, including 
fundoscopy, optical coherence tomography, fluorescein angiography, and indocyanine 
green angiography. The patients showed the most typical clinical cCSC characteristics 
(serous subretinal fluid affecting the fovea on optical coherence tomography, a 
disease period of >3 months, ≥1 area of “hot spot” leakage [the point where fluid 
is presumed to leak into the serous fluid pocket] or diffuse leakage in combination 
with irregular retinal pigment epithelial window defects on fluorescein angiography, 
and a corresponding hyperfluorescence detected on indocyanine green angiography), 
described as phenotypic subgroup 1 in a previous article on genetic associations 
in cCSC.28 Patients with high myopia, evidence of choroidal neovascularization, 
polypoidal choroidal vasculopathy, and other atypical findings were excluded. For this 
study, neither previous nor current steroid use was considered an exclusion criterion. 
The patient cohort consisted of 234 patients from the Radboud university medical 
center (Nijmegen, the Netherlands), 72 patients from the Leiden University Medical 
Center (Leiden, the Netherlands), and 30 patients from the University Hospital of 
Cologne (Cologne, Germany). A total of 1314 unaffected individuals (ie, controls) 
enrolled in the European Genetic Database (www.eugenda.org) were included in the 
study; they has no signs of either cCSC or age-related macular degeneration when 
evaluated by multimodal imaging. The study adhered to the tenets of the Declaration 
of Helsinki,29 and was approved by the institutional review boards and the ethics 
committees of the Radboud university medical center, the Leiden University Medical 
Center, and the University Hospital of Cologne. Written informed consent was 
received from all participants.
Genotyping of selected variants was performed using KASP assays (LGC Genomics) 
according to manufacturer’s instructions. Specific primers with 5-carboxyfluorescein 
and 5’-hexachloro-fluorescein labels were designed per variant (NR3C1: rs6198, 
rs5614994, and rs41423247; NR3C2: rs5522 and rs2070951) (eTable 1 in the 
Supplement) and the polymerase chain reaction (PCR) conditions per primer pair were 
provided by LGC Genomics. Data were read with the 7900HT Fast Real-Time PCR 
system (Applied Biosystems by Life Technologies) and analyzed with SDS version 2.4 
(Applied Biosystems). 
Table 1. Demographic characteristics of the cCSC patients and controls
n Mean age ± stdev (years) Males (%)
cCSC cases
Nijmegen 234 52 ± 9 188 (80%)
Cologne 30 50 ± 9 24 (80%)
Leiden 72 52 ± 10 62 (86%)
Total 336 52 ± 10 274 (81,5%)
Controls 1314 70 ± 7 549 (42%)
cCSC, chronic central serous chorioretinopathy; stdev, standard deviation
Statistical Analysis
In IBM SPSS Statistics version 22 (SPSS Inc.), the 2-sided Pearson’s χ2 test was used 
to compare both the genotype and allele frequencies between cases and controls. 
Bonferroni correction for multiple testing was performed for 5 variants and P<.01 
was considered statistically significant. Logistic regression was performed for 
the associated rs2070951 variant with Firth bias-corrected likelihood ratio test 
implemented in EPACTS version 3.2.6 (Efficient and Parallelizable Association 
Container Toolbox, http://genome.sph.umich.edu/wiki/EPACTS), correcting for sex.30
Using a haplotype analysis, we assessed the combined effect of the 2 variants 
in NR3C2. Haplotype analysis was performed using R version 3.0.2 (R Core Team; 
https://www.R-project.org), using the haplo.stats package (version 1.6.8). The 2 most 
frequent haplotypes were separately used as a reference in the haplo.cc command, to 
determine odds ratios (ORs) for both haplotypes. A logistic regression analysis (haplo.
glm) including sex and haplotypes was performed using the most common haplotype 
as a reference. Only haplotypes with a frequency higher than 5% are shown. P<.05 
was considered statistically significant. 
Power analysis was performed with CaTS version 0.0.2 (University of Michigan), using 
a multiplicative model in a joint analysis.31 The power per variant was calculated 
based on the minor allele frequency in controls, a disease prevalence of 0.0001, and 
a variable genotype relative risk (1-2.6), and the graph was created with Graphpad 
Prism version 5.03 (Graphpad Software). 
Results
Among the 336 patients, 274 were men and 62 were women; the mean (SD) age was 
52 (10) years. The demographic characteristics of the patients and controls enrolled in 
this study are summarized in Table 1. All described variants were in Hardy-Weinberg 
equilibrium, both for controls and patients with cCSC. No statistically significant 
associations between cCSC and variants in the NR3C1 gene (rs56149945, 
rs41423247 and rs6198) were found (Table 2). After correction for multiple testing, a 
significant association between cCSC and the rs2070951 variant in the NR3C2 gene 
was observed (OR, 1.29; 95% CI, 1.08-1.53; P=.004,). No association between the 
variant rs5522 in NR3C2 and cCSC was found (Table 2). 
Haplotype analysis of the NR3C2 single-nucleotide polymorphisms rs2070951 and 
rs5522 showed a significant decreased risk for cCSC for the CA haplotype (OR, 0.72; 
95% CI, 0.60-0.87, P<.001) and an increased risk for the GA haplotype (OR, 1.39; 
95% CI 1.15-1.68, P=.004) (Table 3). To account for potential confounding effects of 
sex between cases and controls, we corrected for this factor in a logistic regression 
model. When including this variable in the model, the association of rs2070951 was 
independent of sex (OR, 1.28; 95% CI, 1.16-1.41; P=.009). Similarly, when correcting 
for sex in the haplotype analysis, setting the most common haplotype (GA) as 
reference, we found that the association of the 
A multiplicative model was used to calculate the power of the study, because this 
model produces a genetic relative risk score that is an estimation of the OR of an 
allelic model.32 For each variant, the power of detecting an association was calculated 
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Table 2. Association analysis of variants in NR3C1 and NR3C2 in cCSC patients
Minor Allele Fre-
quency
P value
 Variant Gene Location
Major/
Minor 
allele
Controls Patients
Geno-
type
Allelic OR (95% CI)
rs56149945 NR3C1 Exon 2 A/G 0.0415 0.0357 .37 .50
0.86
(0.55-1.34)
rs41423247 NR3C1 Intron 2 C/G 0.360 0.390 .16 .15
1.14
(0.95-1.35)
rs6198 NR3C1
Exon 9
UTR
A/G 0.169 0.158 .334 .48
0.92
(0.73-1.16)
rs2070951 NR3C2 c.-2 C/G 0.464 0.527 .008 .0040
1.29
(1.08-1.53)
rs5522 NR3C2 Exon 2 A/G 0.129 0.137 .84 .57
1.08
(0.83-1.38)
cCSC, chronic central serous chorioretinopathy; CI, confidence interval; MAF, Minor allele frequency; OR, 
odds ratio; UTR, untranslated region. Bonferroni correction for multiple testing was performed for 5 variants 
and p-values < 0.01 were deemed significant
Figure 1: Power calculation for each variant in a cohort of 336 patients with chronic central serous chorioretinopathy 
patients and 1314 unaffected controls. For each variant, the power to detect a certain genotype relative risk 
was assessed using a multiplicative model, with minor allele frequency in controls and disease frequency of 
0.0001 as input. The 80% power detection limits per variant were 1.35 (rs2070951), 1.36 (rs41423247), 1.46 
(rs6198), 1.52 (rs5522), and 1.95 (rs56149945).
for the current cohort size. For all variants, genotype relative risks less than 2 could 
be detected with 80% power using this cohort. The detection limits of the genetic 
relative risk at 80% power were 1.35, 1.36, 1.46, 1.52, and 1.95 for rs2070951, 
rs41423247, rs6198, rs5522, and rs56149945, respectively (Figure 1). 
Discussion
In this study, we analyzed a possible association with cCSC for 3 known functiona 
variants in NR3C1 and 2 known functional variants in NR3C2. The rs2070951 variant 
in NR3C2 was significantly associated with cCSC, whereas the rs5522 variant was 
not associated with cCSC. The NR3C2 CA and GA haplotypes were both significantly 
associated with cCSC, with a protective and a risk-conferring effect, respectively. 
Odds ratios of the associated NR3C2 variant and the haplotypes were similar to 
previously described associations for the CFH (OMIM 134370) and ARMS2 (OMIM 
611313) genes, and lower compared to the previously described associations in the 
C4A (OMIM 120810), C4B (OMIM 120820), and CDH5 (OMIM 601120) genes.28,33-35 
The 3 variants in the NR3C1 gene (encoding the GR) were not associated with cCSC, 
which may suggest that MR functionality is more relevant than GR functionality in the 
etiology of cCSC. However, a larger cohort size is required to exclude the involvement 
of the 4 variants that were not associated with cCSC in this study.
An abnormal response to the administration of corticosteroids in a subset of patients 
with cCSC is the strongest risk factor for the disease with described ORs of up to 37.9 
However, the precise mechanism of action of steroids in the pathogenesis of cCSC 
is unknown. One study showed that both mineralocorticoids and glucocorticoids 
can activate the MR on choroidal endothelial cells in a rat model.12 In this animal 
model, MR activation resulted in vessel dilation via up-regulation of the endothelial 
vasodilatory calcium-dependent potassium channel KCa2.3,2,12 producing choroidal 
thickening that is also commonly observed in patients with cCSC.2 The MR is also 
present on retinal pigment epithelial cells, and clearance of subretinal fluid through 
the retinal pigment epithelium towards the choriocapillaris may be influenced by 
Table 3. Haplotype analysis of NR3C2 in cCSC patients
Frequency
Haplo-
type
rs2070951 rs5522 P value Controls Patients
Direction 
of effect
OR 
(95% 
CI)
Direction 
of effect
OR 
(95% 
CI)
H1 C A <.001 0.408 0.336 Base NA Protective
0.72 
(0.60-
0.87)
H2 C G .54 0.127 0.137 NS
1.32 
(1.00-
1.75)
NS
0.95 
(0.73-
1.24)
H3 G A .004 0.463 0.527 Risk
1.39 
(1.15-
1.68)
Base NA
cCSC, chronic central serous chorioretinopathy; CI, confidence interval; Freq, frequency; NA, not 
annotated; NS, not significant; OR, odds ratio
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differences in MR haplotypes.36 In addtion, on Müller glial cells, the MR regulates 
water homeostasis in the eye; dysregulation of this mechanism may contribute to 
the intraretinal edema observed in a subset of cCSC patients.2,37 However, direct GR 
overactivation without MR involvement seems to be sufficient to induce cCSC in 
some patients because synthetic glucocorticoids with strong selectivity for GR over 
MR have also described as a risk factor for the disease.7,9
Both variants in NR3C2 that were tested in this study influence the transactivational 
capacity of the MR after exposure to both cortisol and dexamethasone,21 and they 
have been shown to affect salivary cortisol levels, especially during the morning 
cortisol awakening peak.9,21,38 The rs2070951 G variant, which is associated with 
cCSC in this study, leads to lower expression of MR and reduced transactivation. 
One study showed that male carriers of the rs2070951 GG genotype in NR3C2 had 
a higher systolic blood pressure.20 This finding is particularly relevant in the context 
of cCSC because hypertension is a known risk factor for the disease.39,40 The effect 
of this genetic variant on systolic blood pressure was observed only in male patients, 
which is interesting because cCSC is more common in men than in women.41 In our 
dataset, the association for rs2070951 was also observed only in male cCSC patients 
when the data was stratified for sex (males: OR, 1.21; 95% CI, 1.04-1.58; P=.02 vs 
females: OR, 1.21; 95% CI, 0.84-1.75; P=.31, eTable 2 in the Supplement). However, 
this is likely owing to the limited number of female patients with cCSC included in 
the analysis, and based on the current data we therefore cannot definitively conclude 
that sex differences exist in this genetic association. 
Haplotypes in NR3C2 have previously been associated with differences in perceived 
chronic stress,26 another postulated risk factor for cCSC.11,42-44 We found that the 
haplotype of the single-nucleotide polymorphism rs2070951 and rs5522, GA, which 
has been previously associated with increased susceptibility to stress,26 conferred 
risk for developing cCSC in our cohort. The haplotype that was associated with an 
optimistic attitude (and a tendency to recover from or adjust easily to misfortune or 
change), CA,45 was protective against the development of cCSC. This finding could 
indicate that, for patients with cCSC who have the GA haplotype, both the MR-
mediated pathways and chronic stress are of significant importance, whereas other 
not-yet-identified factors could play a bigger role in patients with cCSC who have 
the CA haplotype. In addition, there is a likelihood that patients with the different 
haplotypes carry additional unknown genetic variants that might also contribute to 
an increased or decreased cCSC risk. 
Clinical studies that tested the potential of MR antagonists in the treatment of cCSC 
have yielded mixed results.14-17 Our findings may partly explain this variable response 
to MR antagonists because carriers of different MR haplotypes may respond 
differently to MR antagonists. The results of our study may lead to the stratification 
of patients with cCSC into subgroups, based on MR haplotype. Treatment of these 
stratified patient subgroups with MR antagonists could result in group-specific 
effects. For patients with the CA haplotype, other (thus far unknown) factors could 
contribute to the development of CSC to a greater extent. The results of this study 
may therefore indicate that a more personalized treatment approach in cCSC may 
be useful. Further studies on the response to treatment of patients with who have 
different MR genotypes are needed to test this hypothesis.
Limitations
Our study contains some limitations. The sample size of our cohort is insufficient to 
detect genetic variants with low ORs. A larger cohort is needed to completely rule out 
the association of the 4 remaining variants with cCSC.
Conclusions
In this study rs2070951 in the NR3C2 gene, encoding the MR receptor, is significantly 
associated with cCSC. Additionally, haplotypes of NR3C2 that have previously been 
associated with perceived stress also associate with cCSC in this study, which may be 
a first clue bridging clinical risk factors for cCSC to underlying genetic associations. 
Functional effects of this variant and the associated haplotype in the MR gene may 
contribute to the disease mechanisms of cCSC. 
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Abstract
Purpose: To investigate genetic associations in Caucasian patients with acute central 
serous chorioretinopathy (aCSC), and to assess genetic differences between aCSC 
and chronic CSC (cCSC).
Methods: A total of 135 aCSC patients, 272 cCSC patients, and 1385 control 
individuals were included. Eight single nucleotide polymorphisms (SNPs) were 
genotyped for ARMS2 (rs10490924), CFH (rs800292, rs1061170, rs1065489, 
rs1329428, rs2284664, rs3753394), and NR3C2 (rs2070951). Also, C4B gene copy 
numbers were analyzed.
Results: Three SNPs in the CFH gene were significantly associated with aCSC: 
rs800292 (P = 0.003, OR = 1.53 [95% CI = 1.15-2.03]), rs1061170 (P = 0.002, OR 
= 0.64 [95% CI = 0.48-0.86]), and rs1329428 (P = 5.87 × 10-6, OR = 1.83 [95% CI = 
1.40-2.38]). A significant difference was found in the distribution of C4B gene copy 
numbers in aCSC patients compared to controls (P = 0.0042). No differences could be 
found among the selected variants between aCSC and cCSC patients.
Conclusions: Three variants in the CFH gene and copy number variations in C4B were 
found to be significantly associated with the risk of aCSC development. Despite the 
differences in clinical presentation, acute and chronic CSC may share a similar genetic 
predisposition based on our present analysis. Other genetic and/or non-genetic risk 
factors may be more influential in the differentiation toward an acute or a chronic 
phenotype of CSC.
Introduction
Acute central serous chorioretinopathy (aCSC) is a sudden-onset and relatively 
common macular disease.1 It is characterized by a neuroretinal detachment with 
serous subretinal fluid (SRF) accumulation as seen on optical coherence tomography 
(OCT).2 Patients with aCSC characteristically show a single focal “hot spot” of leakage 
on fluorescein angiography (FA).3 This leakage occurs because of a small defect in 
a focally detached retinal pigment epithelium (RPE), which normally constitutes 
the outer blood-retina barrier.3,4 Acute CSC has been described to be a self-limiting 
condition and visual acuity recovers completely in most cases.5
In contrast to aCSC, the phenotype of chronic CSC (cCSC) is characterized by 
prolonged and usually persistent SRF accumulation, larger and/or multiple RPE 
detachments, often more diffuse RPE leakage, and more extensive multifocal atrophic 
RPE changes.1 A timely diagnosis and treatment is required in order to accelerate 
SRF resolution, and to prevent irreversible photoreceptor damage, vision loss and 
decreased vision-related quality of life.6 It is hypothesized that a congested and 
hyperpermeable choroid lies at the pathophysiological basis of CSC, as part of the 
pachychoroid spectrum.1,7 Dysfunction of the RPE, secondary to these choroidal 
abnormalities, would then result in SRF leakage and neuroretinal detachment, but 
the exact etiology of the disease is still unknown.7,8 There is ongoing debate about 
whether aCSC and cCSC form two distinct entities, or whether they belong to a 
continuum of the same disease.9,10
Recently, single nucleotide polymorphisms (SNPs) in the ARMS2 gene and the CFH 
gene (involved in the complement system) were found to be significantly associated 
with cCSC.11-13 An association of these SNPs was previously identified in age-related 
macular degeneration (AMD), pointing to a genetic and pathophysiologic overlap 
between CSC and AMD. An important role for the choroid has been postulated in 
both diseases, which both manifest at the choriocapillaris-Bruch’s membrane-RPE-
neuroretina interface. Interestingly, some risk-conferring alleles in ARMS2 and CFH 
in AMD were found to be protective in cCSC and vice versa.11 We also identified an 
association of a SNP in the NR3C2 gene that encodes the mineralocorticoid receptor in 
cCSC.14 Furthermore, genomic copy number variations in the complement component 
4 (C4B) gene were shown to be associated with cCSC.15 To the best of our knowledge, 
no genetic studies have been performed to date in patients with an acute phenotype 
of CSC characterized by only a single focal leak on FA and without any other signs of 
chronicity. Additionally, clinically distinct aCSC and cCSC phenotypes have not been 
compared genetically thus far.
In the present study, we therefore assessed whether SNPs in ARMS2 (rs10490924), 
CFH (rs800292, rs1061170, rs1065489, rs1329428, rs2284664, rs3753394), and 
NR3C2 (rs2070951), and the copy numbers of C4B gene are associated with aCSC 
in a Caucasian patient cohort. Furthermore, these genetic variants were compared 
between Caucasian aCSC and cCSC patients, to assess whether there are significant 
differences in these genetic risk factors that could indicate that these disease subtypes 
are (patho)genetically distinct.
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Figure 1: Clinical features visible on multimodal imaging of the left eye of a 41-year-old male patient (A-F) 
with acute central serous chorioretinopathy (aCSC) and the right eye of a 40 year-old male patient (G-L) 
with chronic CSC (cCSC). (B) Fluorescein angiography (FA) revealed a single “hot spot” of leakage and no 
atrophic retinal pigment epithelium (RPE) changes in the aCSC patient. (C) On mid-phase indocyanine green 
angiography (ICGA) a small hyperfluorescent lesion was observed at the location of the “hot spot” on FA. (D) 
Fundus autofluorescence (FAF) imaging showed granular hyper-autofluorescent changes at the site of the serous 
neuroretinal detachment. (E and F) Optical coherence tomography (OCT) scan at first presentation revealed a 
subretinal serous fluid (SRF) accumulation (E), which resolved after four weeks (F). (H) FA imaging in the cCSC 
patient revealed a large area of atrophic RPE changes and multiple leakage spots. (I) ICGA imaging in this 
patient revealed diffuse choroidal hyperpermeability which was slightly larger than the area of leakage visible on 
FA, and FAF imaging showed a mixture of intense areas of hyper-autofluorescence together with granular hypo-
autofluorescent changes. At diagnosis, foveal SRF and a small RPE detachment were observed on the OCT scan 
of the cCSC patient (K), which both resolved within three weeks after treatment with half-dose photodynamic 
therapy (L).
Methods
A total of 135 Caucasian subjects with aCSC was included in the study. Subjects 
were selected from a large cohort of CSC patients from three referral centers: 47 
patients from the Department of Ophthalmology at Leiden University Medical Center 
(Leiden, the Netherlands), 72 patients from the Rotterdam Eye Hospital (Rotterdam, 
the Netherlands), and 16 patients from University Hospital of Cologne (Cologne, 
Germany).
Phenotyping of aCSC patients was performed by two experienced retina specialists 
(SY, CJFB), who had to agree on the aCSC phenotype being typical, which was based 
on findings on fundoscopy, OCT, FA, and indocyanine green angiography (ICGA) when 
available. For purposes of comparison to chronic CSC strict criteria for the diagnosis 
of aCSC were used. Also, only patients who met the definition of aCSC were included 
when there was at least one follow-up visit and complete resolution of SRF during 
the first CSC episode (Figure 1). For this study, aCSC was identified on multimodal 
imaging as a combination of: 1. Documented serous SRF accumulation on OCT; 2. A 
single focal leakage point (“hot spot”) on FA; 3. Atrophic RPE alterations (including RPE 
detachments) limited to less than one optic disc diameter in size in the affected eye. 
Also, the contralateral eyes were not allowed to show any signs of chronicity, such as 
presence of atrophic RPE changes or chronic SRF leakage. Patients with other possible 
causes of SRF accumulation such as choroidal neovascularization, or polypoidal 
choroidal vasculopathy were excluded. In this study, previous steroid use was not an 
exclusion criterion.
The control group consisted of Caucasian individuals enrolled in the European Genetic 
Database (EUGENDA; www.eugenda.org), in whom no signs of maculopathy were 
found when evaluated by multimodal imaging, and 176 subjects from the blood bank 
of the Radboud University Medical Center (Nijmegen, the Netherlands). The control 
group for the analysis of ARMS2 and CFH included 826 controls, whereas the analysis 
of NR3C2 and C4B included 1385 and 250 controls, respectively. Additionally, to 
assess the genetic difference between aCSC and cCSC we included a cohort of 272 
Caucasian patients with typical cCSC (Figure 1), as described in a previous genetic 
analysis on cCSC by our group.11 Both controls and a subgroup of the cCSC patients 
were genotyped in previous studies.11,14,15 Approval for this study was obtained at 
the local institutional review boards in all participating centers and the study was in 
accordance with the tenets of the Declaration of Helsinki. Written informed consent 
was obtained from all subjects prior to blood collection for genetic analysis.
SNP and copy number genotyping
DNA was isolated from peripheral blood by using standard procedures. The choice 
of the most relevant genetic variants to be analyzed was based on findings in earlier 
studies.12-15 Genotyping of the selected SNPs was performed using KASP assays (LGC 
Genomics; Berlin, Germany) as described previously according to the manufacturer’s 
instructions. Data were read out with the 7900HT Fast Real-Time PCR system 
(Applied Biosystems by Life Technologies, Austin, TX, USA) and were analyzed with SDS 
(version 2.4, Applied Biosystems). C4B copy numbers were measured as previously 
described using a TaqMan genotyping assay (Hs07226350_cn, Applied Biosystems, 
Thermo Fisher Scientific, Waltham, MA, USA) with RNaseP as a reference assay.15
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Statistical analysis
The allele frequency of the SNPs was compared between aCSC and unaffected 
controls or cCSC patients using a 2-sided Pearson’s chi-square test (IBM SPSS 
Statistics, version 22, SPSS Inc., Chicago, IL, USA). The C4B copy numbers distribution 
was compared with a 2-sided Fisher’s exact test and a logistic model correcting 
for gender was performed setting two copies of C4B as a reference, as previously 
described.15 Bonferroni correction for multiple testing was performed for nine 
variants and P-values <0.0056 were considered statistically significant. The combined 
effect of the selected six variants in CFH was assessed using a haplotype analysis 
correcting for gender. Haplotype analysis was performed using R (v3.0.2) using the 
haplo.stats package (v1.6.8). The two most frequent haplotypes were separately 
used as a reference in the haplo.glm command to determine odds ratios (ORs) for 
the haplotypes with a frequency >5% and the aggregate of the haplotypes with a 
frequency <5%.
Results
Of the 135 aCSC patients included, 92 patients (68%) were men, with a mean age of 
47 ± 10 years (Table 1). Fifty-six aCSC patients (41%) underwent an ICGA imaging and 
none had a sign of choroidal neovascularisation. Recent steroid use (< 3 months prior 
to diagnosis) was reported in 29 aCSC patient (21%). The demographic characteristics 
of aCSC patients, cCSC patients and controls are summarized in Table 1. 
Association of SNPs in ARMS2, NR3C2, and CFH genes with aCSC
No association could be found with the rs10490924 variant in ARMS2 in aCSCs (Table 
2). An initial significant association in the rs2070951 variant in NR3C2 was lost after 
correction for multiple testing (Table 2). Among the six tested variants in CFH gene, 
five variants showed an association with aCSC. Among these, two variants, rs1065489 
(P = 0.019, odds ratio (OR) = 0.63 [95% confidence interval (CI) = 0.43-0.93]) and 
rs2284664 (P = 0.013, OR = 1.44 [95% CI = 1.08-1.93]) showed an association, which 
was lost after correction for multiple testing (Table 2). Three variants were significantly 
associated with aCSC after correction for multiple testing: rs800292 (P = 0.003, OR = 
1.53 [95% CI = 1.15-2.03]), rs1061170 (P = 0.002, OR = 0.64 [95% CI = 0.48-0.86]), 
and rs1329428 (P = 5.87 × 10-6, OR = 1.83 [95% CI = 1.40-2.38]).
Association of CFH haplotypes with aCSC
Haplotype analysis corrected for gender identified five haplotypes in the CFH gene 
Table 1. Demographic characteristics of the study population
aCSC 
patients
cCSC 
patients
Controls ARMS2 
& CFH Controls C4B
Controls 
NR3C2
Number of subjects 135 272 826 250 1385
Number of males 92 (68%) 216 (79%) 424 (51%) 198 (79%) 635 (46%)
Mean age ± SD 
(years)
47 ± 10 51 ± 10 64 ± 12 51 ± 10 51 ± 10
aCSC = acute central serous chorioretinopathy; cCSC = chronic central serous chorioretinopathy; SD = 
standard deviation 
with a frequency above 5% and an aggregate of the haplotypes with a frequency 
lower than 5%. When using the most common haplotype (H1) as a reference, an 
association with aCSC was found for the risk-conferring H2 (P = 0.003, OR = 1.75 
[95% CI = 1.21-2.53]), H4 (P = 0.0180, OR = 1.69 [95% CI = 1.09-2.6]) and H5 (P = 
0.001, OR = 2.3 [95% CI = 1.39-3.83]), of which H2 and H5 were significant after 
correction for multiple testing (Table 3). Using the H2 haplotype as a reference, a 
protective effect for the H1 (P = 0.003 OR = 0.57 [95% CI = 0.39-0.83]) and H3 
(P = 0.010, OR = 0.54 [95% CI 0.33-0.86]) haplotypes was identified, but only the 
association with H1 remained after correction for multiple testing. 
C4B copy number determination in aCSC
Carriers of two copies of the C4B gene were more frequent in the aCSC group (68%) 
compared to the control group (57%), whereas carrying three C4B gene copies 
was observed less frequently in the aCSC group (5.3% versus 18% in controls) (see 
Figure 2, Supplemental Digital Content 1, which demonstrates the C4B gene copy 
distribution). The distribution of C4B in aCSC patients compared to controls was 
significantly different after correction for multiple testing (P = 0.0042). The effect size 
of different C4B copy numbers on aCSC was assessed by a logistic regression model 
corrected for gender. The overall model was not significant (P = 0.051) (Table 4), but 
carriers of three C4B copies appeared to have a reduced risk of aCSC (P = 0.002, OR 
= 0.27 [95% CI = 0.12-0.63]) (Table 4).
Table 2. Analysis of 8 single nucleotide polymorphisms (SNPs) in acute central serous chorioretinopathy
SNP (gene)
Alleles 
(Major
/Minor)
aCSC
(n)
MAF 
aCSC
Controls
(n)
MAF 
controls
Un-adjusted 
allelic 
P-value
Allelic odds 
ratio (95% CI)
rs10490924 
(ARMS2) G/T 132 0.174 812 0.217 0.111
0.76
(0.54-1.07)
rs2070951 
(NR3C2) C/G 132 0.538 1385 0.468 0.0287
1.33
(1.03-1.71)
rs800292 (CFH) G/A 133 0.320 798 0.235 3.06×10-3
1.53
(1.15-2.03)
rs1061170 
(CFH) T/C 133 0.259 803 0.353 2.82×10
-3
0.64
(0.48-0.86)
rs1065489 
(CFH) G/T 134 0.119 794 0.177 0.0199
0.63
(0.43-0.93)
rs1329428 
(CFH) C/T 133 0.579 787 0.429 5.87×10
-6
1.83
(1.40-2.38)
rs2284664 
(CFH) C/T 134 0.287 805 0.219 0.0132
1.44
(1.08-1.93)
rs3753394 
(CFH) C/T 131 0.263 800 0.293 0.324
0.86
(0.64-1.16)
aCSC = acute central serous chorioretinopathy; CI = Confidence interval; MAF = minor allele frequency; 
SNP = single nucleotide polymorphism; P-values < 0.0055 were considered significant.
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Differences between aCSC and cCSC
The minor allele frequencies of the tested ARMS2, NR3C2, and CFH variants were not 
significantly different between aCSC and cCSC patients (See Table 5, Supplemental 
Digital Content 2, which demonstrates minor allele frequencies in aCSC versus 
cCSC). Haplotype H4 in CFH showed a higher frequency in aCSC compared to cCSC 
(0.164 in aCSCs versus 0.111 in cCSCs, P = 0.0250, OR = 1.78 [95% CI = 1.08-
2.95]), but this was not significant after correction for multiple testing (See Table 6, 
Supplemental Digital Content 3, which demonstrates CFH haplotypes in aCSC versus 
cCSC). The distribution of C4B copy numbers was not significantly different between 
aCSC and cCSC patients (P = 0.345, see Figure 2, Supplemental Digital Content 1), 
and the logistic regression model was also not significant (P = 0.472) (See Table 7, 
Supplemental Digital Content 4, which demonstrates logistic regression model for 
C4B load in aCSC versus cCSC).
Discussion
To the best of our knowledge, this is the first study to analyze potential genetic 
associations specifically in aCSC patients, and to compare them with known genetic 
associations that were previously identified in cCSC. We have found a significant 
association between three variants in the CFH gene and copy numbers of the C4B 
gene in patients with aCSC compared to healthy individuals. Among these CFH 
variants, two SNPs were risk-conferring and one was protective. Additionally, the H1 
haplotype in the CFH gene was protective, whereas H2 and H5 were risk-conferring 
for aCSC. Three copy number of C4B conferred a protective effect for aCSC. No 
association was found between polymorphisms in ARMS2 or NR3C2 and the risk of 
aCSC. Finally, no significant differences were identified in these variants between 
aCSC and cCSC patients. 
Genetic variation in different components of the complement system, which is an 
essential part of innate immunity,16 such as factor H (FH) and complement component 
4B (C4B) proteins, have previously been associated with cCSC. Of the six tested 
variants in the CFH gene, five variants were associated with aCSC of which three 
were significant after correction for multiple testing. When comparing our findings 
Table 4. Logistic regression model for C4B load
Overall significance model P-value = 0.051
Controls (n = 250) aCSC patients (n = 133) P-value Odds ratio (95% CI)
Male sex 198 (79%) 91 (68%) 0.066 1.58 (0.97-2.57)
C4B copy number
0 6 (2.4%) 4 (3.0%) 0.788 1.20 (0.33-4.39)
1 55 (22%) 32 (24%) 0.704 0.91 (0.54-1.51)
2 142 (57%) 90 (68%) Base Base
3 44 (18%) 7 (5.3%) 0.002 0.27 (0.12-0.63)
4 3 (1.2%) 0 0.999 NA
aCSC = acute central serous chorioretinopathy; CI = Confidence interval; NA = not annotated; P-values 
.0055 were considered significant.
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in aCSC patients with available literature in cCSC patients, our data confirmed the 
protective effect of rs1061170, and the risk-conferring effects of rs1329428 and 
rs800292. However, for these variants the observed effect size in aCSC was larger 
than previously described in Caucasian cCSC patients, respectively, rs1061170 (OR 
= 0.64 versus 0.83), rs1329428 (OR = 1.83 versus 1.47) and rs800292 (OR = 1.53 
versus 1.50).11
Additionally, as observed in cCSC patients, the H1 haplotype in CFH was found to 
be protective for aCSC. Similar to the single variants, the protective effect of the H1 
haplotype was stronger for aCSC compared to cCSC (OR = 0.57 versus 0.83).11 The 
H2 and H5 haplotypes which were previously reported to increase the risk of cCSC, 
showed the same association in aCSC patients and their effect size was again larger 
in aCSC patients compared to cCSC (OR = 1.75 versus 1.33 and OR = 2.30 versus 
1.37, respectively).11 It has been suggested that factor H, which is encoded by the 
CFH gene, can influence the choroidal hemodynamic properties.17 Also, it has been 
suggested that an altered activity of factor H protein could cause RPE damage and 
dysfunction,11,17 but the exact mechanism of factor H in the etiology of CSC is still 
unknown. Both an absence and low copy numbers of C4B are known to increase the 
risk of cCSC, whereas carrying three copies is protective against cCSC.15 In our study, 
this protective effect was confirmed in aCSC patients, with an even larger effect size 
(OR = 0.27) compared to previous reports of cCSC.15 
Exogenous administration of glucocorticoids, or an endogenous excess (Cushing 
syndrome) was previously found as an important risk factor in development of CSC.18 
The glucocorticoid receptor and mineralocorticoid receptor are the most important 
targets for glucocorticoids, and therefore their involvement in the pathogenesis of 
CSC is conceivable.1 We have previously found a significant association of a genetic 
variant in the NR3C2 gene, encoding the mineralocorticoid receptor, with an increased 
risk of cCSC.14 In the present study, we did not find a significant association between 
the rs2070951 SNP in NR3C2 with aCSC patients after correction for multiple 
testing, which could have occurred due to a lack of statistical power. Future larger 
studies can shed a light on whether this finding is indeed due to a lack of power or 
if it reflects a true difference in NR3C2 rs2070951 risk SNP load between aCSC and 
healthy individuals.
In a previous study, we have found an association between genetic variations in the 
ARMS2 gene and cCSC.11 A possible mechanistic explanation for this association was 
speculated to be the potential interaction of the ARMS2 protein with the extracellular 
matrix at the level of the choroid and RPE, which are also primarily affected in 
CSC.11 Although the mechanism of action is not fully understood, presence of the 
rs10490924 variant in the ARMS2 gene was shown to be protective against cCSC 
development.11 This association with the rs10490924 SNP in ARMS2 was not found 
in the current aCSC cohort. Again, this may be due to a lack of power, but could also 
indicate a difference in genetic predisposition between aCSC and healthy controls.
Acute CSC and cCSC generally show contrasting clinical presentations in terms of 
extent of retinal abnormalities and final visual outcome.1,19 There is currently no 
consensus on the classification of CSC, the definition of chronicity, and the exact 
period of time after which CSC should be considered chronic differs between studies, 
ranging from two to six months.20-23 Besides a time based definition, cCSC is usually 
distinguished from aCSC by its more extensive retinal abnormalities on multimodal 
imaging, which includes multiple focal or diffuse leakage spots and widespread 
bilateral RPE alterations.2,9 A typical aCSC, on the other hand, presents with a single 
leakage spot, with only very few RPE changes. Although some patients with cCSC 
have a history of aCSC, many patients present with a chronic phenotype at the first 
presentation.9,24 Therefore, it is still unclear whether these two are part of a continuum 
with the same pathophysiological background, or if they are essentially different 
entities. A combination of genetic and non-genetic risk factors such as steroid use, 
hypertension, and pregnancy,25-27 may play a role in the aspect and severity of CSC, 
and the risk of progression of aCSC towards a chronic disease course.
Our data suggest a genetic overlap between aCSC and cCSC. No genetic difference 
could be found when comparing the selected variants in the cCSC and aCSC cohort. 
However, the effect size of the genetic variants associated with both aCSC and cCSC 
appears to be systematically larger in aCSC compared to cCSC. The lack of a significant 
difference between aCSC and cCSC with regard to the associated genetic variants 
may be partially caused by the small sample size of the current aCSC cohort, and 
thus a limited power. The larger effect size observed for aCSC suggests that genetic 
risk factors may play a larger role in the development of aCSC. It has been previously 
suggested that in multifactorial retinal diseases with genetic involvement such as 
age-related macular degeneration, patients who develop the disease at a younger 
age have a stronger genetic predisposition.28,29 A similar mechanism could explain the 
larger genetic predisposition among aCSC patients, who are generally younger than 
cCSC patients.9 Other limitations in the present study concern the control groups 
with different sample sizes, which might have influenced the observed associations. 
Also, there might be ethnical differences between German and Dutch patients, whom 
we considered as one Caucasian population. 
In conclusion, variants rs800292 and rs1329428 in CFH gene were found to be 
significantly associated with a higher risk of aCSC, whereas variant rs1061170 in 
this gene was protective against aCSC. Three copy number of the C4B gene was 
protective against aCSC, and copy number of the gene differed between aCSC 
patients and controls. These specific CFH SNPs and the C4B copy numbers showed an 
even stronger association with aCSC than previously reported for cCSC. Our findings 
indicate that despite the differences in clinical presentation, acute and chronic CSC 
might share genetic risk and protective factors, at least among the currently known 
variants. Presumably, other non-genetic risk factors, or other currently unknown 
genetic variants are more influential in the differentiation toward an acute or a 
chronic disease course in CSC. Future genotype-phenotype correlation analyses in 
larger cohorts may provide important clues about interaction between these different 
risk factors.
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Figure 2: (supplementary) Distribution of C4B copy numbers. (A) Comparison between the C4B distribution 
among acute central serous chorioretinopathy (CSC) and controls, (B) and acute CSC and chronic CSC.
Supplementary Files
Table 7 (supplementary). Logistic regression model for C4B load aCSC versus cCSC
cCSC patients
(n = 220)
aCSC patients (n 
=133)
P-value
Odds ratio
(95% CI)
Male sex 216 (79%) 91 (68%) 0.026 1.75 (1.07-2.88)
C4B copy number
0 12 (5.4%) 4 (3.0%) 0.247 0.50 (0.16-1.61)
1 66 (30%) 32 (24%) 0.142 0.69 (0.41-1.14)
2 126 (57%) 90 (68%) Base Base
3 15 (6.8%) 7 (5.2%) 0.361 0.64 (0.25-1.66)
4 1 (0.4%) 0 (0%) 1.000 NA
aCSC = acute central serous chorioretinopathy; cCSC = chronic central serous chorioretinopathy; CI = 
confidence interval; NA = not annotated; P-values <0.0055 were considered significant. 
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Abstract
Importance: To date, several targeted genetic studies on chronic central serous 
chorioretinopathy (cCSC) have been performed; however, unbiased genome-wide 
studies into the genetics of cCSC have not been reported. To discover new genetic 
loci associated with cCSC and to better understand the causative mechanism of this 
disease, we performed a genome-wide association study (GWAS) on patients with 
cCSC.
Objective: To discover new genetic loci and pathways associated with cCSC and to 
predict the association of genetic variants with gene expression in patients with cCSC.
Design, Setting and Participants: This case-control GWAS was completed in the 
general community, 3 referral university medical centers, and outpatient care on 
European individuals with cCSC and population-based control participants. Genotype 
data was collected from May 2013 to August 2017, and data analysis occurred from 
August 2017 to November 2017.
Main outcomes and measurements: Associations of single-nucleotide polymorphisms, 
haplotypes, genetic pathways, and predicted gene expression with cCSC. 
Results: A total of 521 patients with cCSC (median age 51 years; interquartile 
range [IQR], 44-59 years; 420 [80.6%] male) and 3577 European population-based 
control participants (median age, 52 years; IQR, 37-71 years; 1630 [45.6%] male) 
were included. One locus on chromosome 1 at the complement factor H (CFH) gene 
reached genome-wide significance and was associated with an increased risk of cCSC 
(rs1329428; odds ratio [OR], 1.57 [95% CI, 1.38-1.80]; P = 3.12x10-11). The CFH 
haplotypes H1 and H3 were protective for cCSC (H1: OR, 0.64 [95% CI, 0.53-0.77]; P 
= 2.18 × 10−6; H3: OR, 0.54 [95% CI, 0.42-0.70]; P = 2.49 × 10−6), whereas haplotypes 
H2, H4, H5, and the aggregate of rare CFH haplotypes conferred increased risk (H2: 
OR, 1.57 [95% CI, 1.30-1.89]; P = 2.18 × 10−6; H4: OR, 1.43 [95% CI, 1.13-1.80]; P = 
2.49 × 10−3; H5: OR, 1.80 [95%CI, 1.36-2.39]; P = 4.61 × 10−5; rare haplotypes: OR, 
1.99 [95%CI, 1.43-2.77]; P = 4.59 × 10−5). Pathway analyses showed involvement of 
the complement cascade and alternative open reading frame (ARF) pathway in cCSC. 
Using PrediXcan, we identified changes in predicted expression of complement genes 
CFH, complement factor H related 1 (CFHR1), complement factor related 4 (CFHR4), 
and membrane cofactor protein (MCP/CD46). Additionally, the genes potassium 
sodium-activated channel subfamily T member 2 (KCNT2) and tumor necrosis factor 
receptor superfamily member 10a (TNFRSF10A) were differentially expressed in cCSC 
patients.
Conclusions and relevance: In this GWAS on cCSC, we identified a locus on 
chromosome 1 at the CFH gene that was significantly associated with cCSC, and we 
report protective and risk-conferring haplotypes in this gene. Pathway analyses were 
enriched for complement genes, and gene expression analysis suggests a role for 
CFH, CFHR1, CFHR4, CD46, KCNT2, and TNFRSF10A in the disease. Taken together, 
these results underscore the potential importance of the complement pathway in the 
causative mechanism of cCSC.
Introduction
Central serous chorioretinopathy (CSC) is characterized by subretinal fluid 
accumulation between the neuroretina and the retinal pigment epithelium (RPE).1-
3 Patients usually present with clinical symptoms of metamorphopsia and central 
vision impairment.4,5 Although acute CSC can show spontaneous resolution within 
3 months, patients with chronic CSC (cCSC) have prolonged presence of fluid with 
progressive loss of vision, permanent RPE alterations, and a reduced quality of life.4 
Generally, CSC occurs more frequently in males (9.9 per 100 000) than females (1.7 
per 100 000) and often presents at an age at which patients are still professionally 
active.6 
The exact causative mechanism of cCSC is unknown, but clinical and experimental 
studies have implicated dysfunction of the RPE and hyperpermeability of the choroid 
in CSC.4 The disease has been associated with the use of corticosteroids, stress, 
and type A personality. Reports of familial occurrences of cCSC support a genetic 
component for the disease.1,3,4,7-11 Genetic studies on cCSC have been limited to 
candidate gene approaches; several associations have been reported with single-
nucleotide polymorphisms (SNPs) in the genes age-related macular degeneration 
susceptibility 2 (ARMS2), cadherin 5 (CDH5), complement factor H (CFH) and nuclear 
receptor subfamily 3 group C member 2 (NR3C2), as well as copy number variations 
in the complement factor 4B (C4B) gene.12-16 
Unbiased genome-wide association studies (GWAS) have identified hundreds 
of genomic loci implicated in complex diseases, such as age-related macular 
degeneration (AMD), myopia, and glaucoma.17 Such approaches have shed light on 
the genetic architecture of these diseases; however, establishing functional links 
between identified loci and disease remains challenging. Besides having direct effects 
on protein function or structure, SNPs can also influence the expression of nearby 
(cis) or distal (trans) genes. Such regulatory genetic variants are called expression 
quantitative trait loci (eQTL).18 Several eQTL databases, linking genotype information 
to tissue expression of genes, have been established. One of the largest of these 
projects is the GTEx project, in which expression profiles of 44 tissues of 449 donors 
have been collected in version 6.18 These eQTL databases offer functional information 
on SNPs identified in GWAS, contribute to a better understanding of the studied 
disease trait, and can be used to predict expression in genotyped samples.19
In this study, we performed a GWAS involving European patients with cCSC and 
population control participants to identify new cCSC disease loci and to increase our 
knowledge on the causative mechanism of this disease. Additionally, we performed 
pathway analyses to discover new pathways implicated in cCSC. Using publicly 
available eQTL data, we aimed to identify new candidate genes predicted to be 
differentially expressed in patients with cCSC compared with control participants. 
Key points
Question: Which genetic loci associate with chronic central serous chorioretinopathy 
(cCSC) when using an unbiased genome-wide approach?
Findings: In this case-control genome-wide association study, a locus containing 
multiple variants in the CFH gene was associated with cCSC. Additionally, pathway 
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analysis implicated the complement system and based on genetic data, components 
of the complement system were predicted to have an association with altered 
expression in patients with cCSC. 
Meaning: This study of participants with cCSC demonstrates the potential role of the 
CFH gene and the complement system in the causative mechanism of cCSC. 
Methods
Study participants 
Genomic DNA was extracted from blood using standard procedures. In total, 546 
European patients with cCSC recruited from the outpatient clinics of the Radboud 
university medical center (Radboudumc), Nijmegen, the Netherlands, University 
Hospital of Cologne (UHC), Cologne, Germany, and Leiden University Medical 
Center (LUMC), Leiden, the Netherlands, were included. Grading of all patients was 
performed by an experienced retinal specialist (C.J.F.B.), and was based on extensive 
ophthalmological examination including fundoscopy, spectral-domain optical 
coherence tomography, fluorescein angiography and indocyanine green angiography. 
Diagnosis of cCSC was based on subgroups 1 and 2, which have been previously 
described.13 Briefly, patients that were included in this study showed the presence 
of serous fluid on optical coherence tomography in 1 or both eyes, either bilateral 
(subgroup 1) or unilateral (subgroup 2) RPE irregularities with 1 or more hot spots 
of leakage on fluorescein angiography, and corresponding hyperfluorescence on 
indocyanine green angiography.13 Patients diagnosed with acute CSC as recognized 
by a focal leakage spot (ink blot) or a smokestack pattern on fluorescein angiography, 
with less than 1 disc diameter of adjacent atrophic RPE alterations, and/or a duration 
of disease of less than 3 months were excluded from the study. Patients in whom 
evidence of another explanatory diagnosis or complication was present (subgroup 3), 
such as polypoidal choroidal vasculopathy, choroidal neovascularization, drusen or 
other signs of AMD, were excluded from this study.
This study was carried out in accordance with the tenets of the Declaration of Helsinki 
and was approved by the local ethics committees of the Radboudumc, LUMC and 
UHC. Written informed consent was obtained for all subjects involved in the study. 
Genotyping data of controls was obtained from the Nijmegen Biomedical Study 
(NBS), a population-based survey conducted by the Department for Health Evidence 
and the Department of Laboratory Medicine of the Radboudumc. (eMethods in 
supplement, http://www.nijmegenbiomedischestudie.nl/).20 In this population-based 
study, no ophthalmologic grading was performed. Only controls for which genotyping 
was available on the OmniExpress platform (n=3654) were included in this study. 
Genotype data was collected from May 2013 to August 2017, and data analysis 
occurred from August 2017 to November 2017.
The mean age of patients with cCSC and control participants was compared with a 
Mann-Whitney U test. The sex distribution was compared with a X2 test using SPSS 
version 22 (IBM). All values of P<.05 were deemed significant. 
Genome-wide association and haplotype analyses 
Genotyping was performed with the OmniExpress-12 or OmniExpress-24 chips, 
and data were imputed with the Haplotype Reference Consortium release 1.1.2016. 
After stringent quality control (eMethods in the Supplement), 521 patients with 
cCSC and 3577 NBS control participants were included in the analysis, carrying 
11 261 291 autosomal SNPs and 265 428 X-chromosomal SNPs. Single-variant 
association analysis was performed using the Firth bias-corrected likelihood ratio 
test implemented in EPACTS (version 3.2.6, http://genome.sph.umich.edu/wiki/
EPACTS; Univeristy of Michigan),21 correcting for sex and the first 2 components of 
the ancestry analysis, to correct for potential population stratification (eMethods in 
the Supplement). To assess the potential role of confounding by AMD, the analysis 
was repeated in patients and controls below younger than 51 years.
Haplotype analysis, combining multiple variants in the CFH gene, was performed 
with the haplo.stats22 (version 1.7.7) package in R (R Foundation for Statistical 
Computing).23 The SNPs described by Hageman et al.24 and the CFH SNPs that were 
previously associated with cCSC were used as input.12,13 Haplotypes with a frequency 
greater than 1% were analyzed individually, while rare haplotypes (with a frequency 
less than 1%) were aggregated. Haplotype association with cCSC was performed 
using the haplo.glm in R, correcting for sex and the first 2 principal components of 
the ancestry analysis. The analysis was performed using the most common protective 
haplotype (H1) and cCSC risk-carrying haplotype (H2) as references. The frequency 
of the haplotypes in patients with cCSC and control participants was obtained using 
the haplo.cc command in R. 
Pathway and PrediXcan analysis
We used GWAS summary statistics to perform competitive gene-set analysis to 
identify pathways associated with cCSC using 2 different programs: MAGMA (version 
1.06, https://ctg.cncr.nl/software/magma) and VEGASv2 (version 2, https://vegas2.
qimrberghofer.edu.au/vegas2v2).25,26 Additionally, PrediXcan (Hakyimlab; https://
github.com/hakyim/PrediXcan) was used to predict gene expression levels based on 
publicly available eQTL data of GTEx.27 PrediXcan was performed on all 44 provided 
GTEx tissues using genetic variants in 17 742 genes. We selected the genes that 
were associated in at least 1 tissue after Bonferroni correction for multiple testing (P 
< .05/17742 genes = 2.21x10-6) and were nominally associated (P < .05) in at least 
50% of the tissues they were expressed in. (The eMethods in the Supplement provide 
further clarification). This study had sufficient power to detect common variants 
with OR greater than 1.5 and had more than 80% power to detect the lead variant 
(eMethods and eFigure 1 in the Supplement).
Results
Genome-wide association analysis
A total of 546 patients with cCSC were recruited from Radboudumc (n = 319), UHC 
(n = 74), and LUMC (n = 153). In addition, 3654 European population-based control 
participants were included. After quality control (eFigures 2 and 3 in the Supplement), 
a total of 521 European patients with cCSC (median age, 51 years; interquartile range 
[IQR], 44-59 years; 420 [80.6%] male) and 3577 controls (median age, 52 years; IQR, 
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37-71 years; 1630 [45.6%] male; eTable 1 in the Supplement) were analyzed for 11 
261 291 autosomal and 265 428 X-chromosomal SNPs. Because of the significant 
difference in sex between patients with cCSC and control participants (eTable 1 in the 
Supplement, P = 1.78 x 10-50), sex was included as a covariate in the analysis along 
with 2 principal components of the ancestry analysis.
The GWAS identified 20 SNPs that reached genome-wide significance (using a cutoff 
value for significance set at P < 5.0x10-8) that all resided at 1 locus on chromosome 
1 in the CFH gene (lead variant: rs1329428; odds ratio [OR], 1.57 [95% CI, 1.38-
1.80]; P = 3.12 x 10-11; Figure 1; Table 1; eFigure 5, and eTable 2 in the Supplement). 
Additionally, six suggestive signals (P < 1x10-6) were foundon chromosome1 (OR, 
0.64 [95%CI,0.54-0.77]; P = 6.69 × 10−7), chromosome 8 (OR, 42.25 [95% CI, 9.55-
186.89]; P = 1.33 × 10-7), chromosome 9 (OR, 8.36 [95%CI, 3.67-19.06]; P = 6.28 
× 10-7), chromosome 15 (OR, 206.11 [95%CI, 4.50-9436.68]; P = 7.84 × 10-7), 
chromosome 17 (OR, 5.25 [95%CI, 2.94-9.48]; P = 1.51 × 10-7), and chromosome20 
(OR,0.67 [95%CI,0.57-0.79]; P = 7.14 × 10-7; Figure 1; Table 1). Conditioned analysis 
of the lead SNP on chromosome 1 did not reveal any other independent signal in 
the CFH gene (eFigure 4 in the Supplement), but did retain the suggestive signal at 
the CD46 gene on chromosome 1 indicating that the CD46 signal is independent of 
the CFH association (unconditioned and conditioned data are shown in eFigure 4 
the Supplement). Stratified analysis on patients and controls younger than 51 years 
identified associations with the same 20 SNPs in the CFH gene, but ORs were higher 
for the lead variant than in the complete cohort (OR, 1.89 [95% CI, 1.56-2.32]; P = 
1.23 x 10-10; eTable2 in the Supplement). 
Haplotype analysis 
To further characterize the association at the CFH gene, haplotype analysis was 
performed. A logistic model corrected for sex and 2 principal components was 
performed using either the most common cCSC protective (H1) haplotype or the most 
common cCSC risk-conferring (H2) haplotype as reference (Table 2). The H2, H4, and 
H5 haplotypes, all containing the minor allele of the lead variant, were associated with 
an increased risk of cCSC (H2: OR, 1.57 [95% CI, 1.30-1.89]; P = 2.18 × 10-6; H4: OR, 
1.43 [95% CI, 1.13-1.80]; P = 2.49 × 10-3; H5: OR, 1.80 [95% CI, 1.36-2.39]; P = 4.61 
× 10-5). The H1 and H3 haplotypes, containing the major allele of the lead variant, 
were protective (H1: OR, 0.64 [95% CI, 0.53-0.77]; P = 2.18 × 10-6; H3: OR, 0.54 
[95% CI, 0.42-0.70]; P = 2.49 × 10-6). Additionally, the aggregate of rare haplotypes 
also increased the risk of cCSC (OR, 1.99 [95% CI, 1.43-2.77]; P = 4.59 × 10-5). All 
associations were significant after Bonferroni correction for multiple testing for 10 
tests (using a cutoff value of P < .005).
Gene-set/Pathway analysis
Using the GWAS summary statistics, we performed competitive gene-set analysis 
using 2 programs. MAGMA identified 3 pathways that were associated with cCSC 
after correction for multiple testing (Table 3, genes in eTable 3 in the Supplement). 
Two of the pathways are implicated in the complement cascade, and 1 is the ARF 
pathway. We identified the same reactome pathways of the complement cascade 
using VEGAS2. However, these findings were not significant after correction for 
multiple testing (using a cutoff value of P < 1 x 10-5; Table 3, genes in eTable 4 in the 
Supplement). 
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3.1
PrediXcan analysis 
For each individual, we predicted the association of genotypes with expression levels 
of 17 742 genes in 44 different GTEx (version 6) tissues using PrediXcan. The predicted 
gene expression of genes at the CFH locus (CFH, CFHR1, CFHR4 and KCNT2) was 
different between cCSC patients and controls after correction for multiple testing, 
using a cutoff value for significance of P < 2.82 x 10-6 (for example, CFH in subcutaneous 
adipose tissue: OR, 1.09 [95% CI, 1.05-1.13]; P = 1.17 × 10-6; CFHR1 in subcutaneous 
adipose tissue: OR, 1.15 [95% CI, 1.10-1.21]; P = 1.85 × 10-8; CFHR4 in liver: OR, 0.91 
[95% CI, 0.85-0.98]; P = 1.29 × 10-6; KCNT2 in gastroesophageal junction: OR, 3.70 
[95% CI, 2.27-6.04]; P = 1.62 × 10-7; full results in Table 4). Additionally, we observed 
altered predicted expression of the CD46 and TNFRSF10A genes (Table 4, results of 
all tissues in eTable 5 in the Supplement).
Discussion
In this unbiased genome-wide association study of cCSC, we identified a locus for 
cCSC on chromosome 1, at the CFH gene, that had previously been described in 2 
targeted candidate gene studies.12,13 We discovered protective and risk haplotypes 
in CFH and found evidence for involvement of rare CFH haplotypes in the disease. 
Moreover, using gene-set analysis and publicly available expression databases, we 
uncovered additional evidence for altered regulation of the complement system in 
cCSC and identified novel candidate genes and pathways implicated in this disease.
So far, to our knowledge, the association of cCSC with the CFH gene is the only genetic 
association for cCSC that has been replicated in multiple independent studies.12,13,28 
The effect size of the lead-variant (rs1329428) in CFH in this unbiased study was 
higher compared to the previous targeted study,13 but lower compared to the study 
by Miki et al. 12 (with ORs in the 3 studies 1.57, 1.47, and OR=1.79, respectively). 
Stratified analysis of patients younger than 51 years to excluded potential confounding 
with AMD showed the same genome-wide significant 20 SNPs with similar direction 
of effect, confirming the cCSC specific association. Additionally, haplotype analysis 
of the CFH locus confirmed a previously reported protective effect of CFH-H3,13 
and identified associations with the protective CFH-H1 and risk carrying CFH-H2, 
CFH-H4, and CFH-H5 haplotypes. The risk associated with the CFH-H5 haplotype 
was higher than the risk caused by the single lead variant alone and higher to our 
knowledge than any previously reported SNP in CFH, with an OR of 1.80 for CFH-H5 
compared to OR of 1.57 for rs1329428. Interestingly, an aggregate of all haplotypes 
with a frequency of less than 1% also showed a higher risk for cCSC (OR, 1.99). Higher 
ORs of CFH-H5 and the rare haplotype aggregate suggest that other (rare) variants in 
these haplotypes might play a role in cCSC.
The factor H protein, encoded by the CFH gene, is able to block the formation of 
C3-convertases and therefore is an important regulator of the complement system.29 
The CFH gene has been widely studied for its role in AMD, and, interestingly, variants 
that confer risk for AMD are protective for cCSC and vice versa.13 These genetic 
associations imply that these 2 diseases might have an opposite disease mechanism, 
with an overactivation of the complement system in AMD29 and a reduced activity of 
the complement system in cCSC. 
In the current study, we further substantiated the involvement of the complement 
system in cCSC. Pathway analysis with MAGMA and VEGAS2 showed associations of 
2 gene sets of the complement system. We used PrediXcan to predict the expression 
of genes based on the genotype information of patients with cCSC and control 
participants. Unfortunately, no eye-specific or retina-specific eQTL database is 
publicly available, and these tissues are not yet implemented in GTEx nor in any other 
large eQTL data set. Therefore, as an indicator for general differences, we used all 
GTEx tissues and observed that the expression of 4 complement genes (CFH, CFHR1, 
CFHR4 and CD46) was predicted to be different in patients with cCSC compared to 
control participants. All GTEx tissues that express CFH showed an upregulation of 
CFH, suggesting that complement system activity may be reduced in cCSC (Table 4). 
Depending on the tissue, CFHR1 showed upregulation or down-regulation, indicating 
that regulation of this gene might be tissue specific; meanwhile CFHR4 was consistently 
down-regulated (Table 4). The factor H-associated (FHR) proteins, encoded by the 
CFHR genes, show sequence similarities to factor H and can compete with factor H 
for C3b binding and in this manner can influence complement activation.30 Deletions 
of CFHR1 have been found to be protective for AMD and CFHR4 deletions have 
been implicated in atypical hemolytic uremic syndrome,30 but the genes have not 
previously been associated with cCSC. to our knowledge.
Interestingly, we also observed an association with another complement gene 
independent of the CFH locus: CD46 was identified as one of the sub-threshold hits 
in the GWAS (Table 1), and PrediXcan predicted up-regulation of CD46 expression 
(Table 4). The CD46 gene encodes the membrane cofactor protein (MCP/CD46), a 
complement inhibitor that blocks all pathways of the complement cascade through 
inactivation of C3b and C4b.31,32 In light of the clinical characteristics of cCSC, in 
which patients present with hyperpermeability of the choroid and with fluid leakage 
through the retinal pigment epithelium, the involvement of CD46 is particularly 
interesting. It is an important regulator in the maintenance of epithelial cell barrier 
integrity through interaction with, for example, cadherins and integrins.32,33 Previous 
studies have shown that the activation of CD46 leads to a decrease in transepithelial 
resistance and loss of tight junctions in intestinal cells and a decreased membrane 
adhesion in RPE cells.32,33 The predicted increased CD46 expression in patients 
with cCSC therefore suggests a downregulation of complement activity, similarly as 
observed for factor H, and in addition destabilization of the integrity of the RPE, 
one of the main hallmarks of CSC. Together, both the complement and epithelial 
regulatory function of CD46 make it an interesting protein for further study in cCSC.
Taken together, the associations and predicted altered expression of CD46, CFH, 
CFHR1, and CFHR4 with cCSC imply a reduced activity of the complement system 
in cCSC. To date and to our knowledge, limited information is available on the actual 
activity of the complement system in patients with cCSC. One study did not find 
obvious systemic alterations in blood complement components of patients with 
cCSC, but this study had limited power, and CD46, FHR1, and FHR4 levels were not 
measured.34 Combined with previously described associations of CFH and C4B12-14 
and the associations described here, a central role for the complement system in the 
disease mechanism of cCSC emerges. Larger studies measuring systemic complement 
regulators and activation products in patients with cCSC (specifically FH, FHR1, 
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FHR4, C4B, and CD46) are warranted.
Besides consolidating the involvement of the complement system, we also identified 
a new cCSC candidate pathway and 2 new cCSC candidate genes. MAGMA identified 
an association between cCSC and the ARF pathway. This pathway is involved in 
ribosomal biogenesis, and activation of the pathway leads to termination of ribosomal 
RNA production and cell cycle arrest.35 In addition, PrediXcan showed decreased 
expression of TNFRSF10A and up-regulation of KCNT2. Involvement of TNFRSF10A in 
cCSC was suggested previously in our candidate gene study of the main AMD loci. We 
showed a protective effect for a TNFRSF10A variant, which was also observed in this 
study (OR, 0.74 [95% CI, 0.64-0.85]; P = 1.47 x 10-5; data not shown) and the largest 
AMD GWAS (OR, 0.90; P = 4.5 x 10-11).13,36 The KCNT2 gene encodes a potassium 
sodium-activated outward rectifier channel (KCNT2) with an unknown function. The 
ARF pathway and TNFRSF10A and KCNT2 genes are interesting candidates for cCSC, 
but their exact role in the eye remains to be elucidated. 
Limitations
To our knowledge, this study includes the largest reported cohort of European patients 
with cCSC; however, even larger sample sizes are necessary to find associations 
with rare variants or variants with a low effect size. Additionally, in this study, only 
European individuals were included, and therefore genetic associations in other 
races/ethnicities still remain to be discovered. Replication of this study by centers in- 
or outside of Europe will be necessary to increase sample size, determine population 
specific associations, and replicate the suggestive signals observed in this study. 
The use of PrediXcan on the GTEx data allows for prediction of expression levels in 
44 tissues, excluding the eye. Although we only regarded those genes that showed 
differential expression in at least 50% of tissues they were expressed in, this does not 
necessarily mean that this also applies to expression in the retina. Likewise, retina-
specific genes might have been missed due to tissue-specific expression. A retina-
specific eQTL database would be necessary to determine these associations, but to 
date, such a database has not been available. 
Conclusions
In this study, we describe a GWAS for cCSC and confirmed the association of 
genetic variants in CFH with the disease. Additionally, we identified CFHR1, CFHR4, 
CD46, KCNT2, and TNFRSF10A as cCSC candidate genes because of their genetic 
associations and predicted altered expression. With CFH, CFHR1, CFHR4, and CD46 
being important regulators of the complement cascade, this study strengthens the 
involvement of the complement system in cCSC. Further work on the expression 
of the proteins encoded by these genes is warranted. Additionally, the use of next-
generation sequencing techniques, such as exome sequencing, will enable the 
identification of (rare) coding variants influencing protein function of these genes and 
might provide more insight in the causative mechanisms of cCSC.
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Supplementary Files
eMethods
DNA extraction and study participants
Genomic DNA isolation was performed from blood using a Hamilton Microlab STAR 
autoload system with an integrated Chemagen MSM I separation module (Hamilton 
Robotics GmbH, Martinsried, Germany). DNA isolation was performed using the 
Chemagic DNA blood kit special (PerkinElmer) according to the manufacturer’s 
instructions. An integrated barcode system was used throughout the process to track 
all samples and isolated DNA fractions. Following DNA isolation, concentrations of 
DNA fractions were determined (Hamilton Microlab Starlet robot with integrated 
Tecan Infinite 200 Pro reader).
In the Nijmegen Biomedical Study 21,756 age- and gender-stratified randomly 
selected inhabitants of the municipality of Nijmegen received an invitation to 
complete a postal questionnaire on, e.g., lifestyle and medical history, and to donate 
an 8.5 ml blood sample in a serum separator tube and a 10 ml EDTA blood sample. 
The response to the questionnaire was 43% (n=9,350), and 69% (n=6,468) of the 
responders donated blood samples
Quality Control and Filtering
The 3,654 NBS controls were genotyped with the HumanOmniExpress-12 (n=1034) 
or Infinium OmniExpress-24 (n=2620) bead chips. cCSC patients (n=547) were 
genotyped in three separate batches. Using the HumanOmniExpress-12 genotyping 
of 114 cCSC samples was performed by the Illumina facility of the Department of 
Genetics, University Medical Center Utrecht, The Netherlands, under supervision of 
B.P.C. Koeleman in May 2013 (cCSC1). To expand the study, two additional batches of 
cCSC patients were genotyped at the Genome Analysis Center, Helmholtz Zentrum 
München, Germany with the Infinium OmniExpress-24 bead chip, 96 samples in 
December 2014 (cCSC2) and 336 samples in August 2017 (cCSC3). 
Quality control steps were applied to the separate batches using PLINK (v1.90b4.1, 
https://www.cog-genomics.org/plink/1.9/).1,2 Samples with a call rate of <97% or 
discordant reported gender were removed (71 controls and 7 cCSC patients). In 
each batch, SNPs that had genotype call rates <98% and/or showed deviations from 
Hardy-Weinberg equilibrium (P < 10-6) were excluded and only variants with a minor 
allele frequency (MAF) >1% were retained. The cCSC3 data was lifted from GRCh38 
to genome build GRCh37, to match the other batches (http://genome.ucsc.edu/cgi-
bin/hgLiftOver).3 Only variants common to all datasets were kept and the data of the 
various batches was merged into one dataset. Strand inconsistencies were identified 
between batches with a flipscan implemented in PLINK and variants were flipped until 
concordance was reached in all datasets. Only variants with a call rate >98% in the 
full dataset were preserved, leaving 589,487 autosomal and 13,282 X-chromosomal 
variants that could be used for down-stream analysis. 
Population stratification and cryptic relatedness
In order to assess population stratification, the dataset was merged with the 
Hapmap3 data containing individuals of known genetic ancestry.4 Data was pruned 
with a window size of 50kb, step size of 5 and variance inflation factor of 2 and 
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a principal component analysis (PCA) was performed with PLINK. Only individuals 
of European ancestry were retained for further analysis (Excluded 2 controls and 
13 cCSC patients). Cryptic relatedness within the dataset was analyzed with KING 
(v2.0).5 A kinship coefficient threshold of <0.0884 was used to remove duplicates 
and individuals with a first or second degree relationship from the dataset (4 controls 
and 5 cCSC patients). Plots of the PCA and KING analyses were made with R (v3.2.0, 
https://cran.r-project.org/). In total, 521 cCSC patients and 3,577 controls remained 
for downstream analysis.
Imputation 
After quality control a total of 589,487 autosomal and 13,282 X-chromosomal variants 
were used to impute the dataset. Autosomal genotype data was phased using Eagle 
(v2.3),6 while the X chromosome was phased with ShapeIT (v2. r790).7 After phasing, 
the data was imputed with the Haplotype Reference Consortium (HRC) release 
1.1.2016 using the Michigan Imputation server (https://imputationserver.sph.umich.
edu).8,9 SNPs were filtered on an imputation quality score of R2 > 0.3 for common 
variants (MAF >5%) and a R2 > 0.8 for low frequency variants (MAF <5%).
Pathway and PrediXcan analysis
In both MAGMA and VEGAS, first gene-based P-values were calculated which were 
used as input for the competitive gene-set analysis on predefined gene-sets. MAGMA 
gene-sets were downloaded from the molecular signatures database v6.1 (MSigDB, 
http://software.broadinstitute.org/gsea/msigdb, C2: curated gene-sets, canonical 
pathways) and 100,000 permutations were performed to apply empirical multiple 
testing correction.10 In VEGASv2 permutations ranging from 1,000 to 1,000,000 were 
performed depending on the p-value, and the provided biosystems gene-pathway 
annotation file was used, which includes genes from gene ontology, curated gene-
sets from MSigDB, PANTHER, and pathway commons.11
Transcriptome prediction models of the GTEx (V6) data containing 44 tissues, based 
on the 1000 genomes files were downloaded from PredictDB (http://predictdb.
hakyimlab.org/).12 As PrediXcan does not allow for covariate implementation, the 
covariates gender, PC1 and PC2 were regressed out on the phenotype using the lm 
and resid function in R (fit=lm(Disease~Sex+PC1+PC2), resid(fit)), and the resulting 
residuals were used as input for the analysis as recommended by PrediXcan in its 
google forum discussions.13 Because the resulting residuals were continuous, the 
linear regression option was used to perform the association analysis. 
Power calculation 
Power analysis was performed implementing the effective sample size calculation for 
alleles [neff=4/(1/ncases+1/ncontrols)]
14 in an altered version of the pwr (v.1.2.1) R package 
provided by Dr. L.G. Fritsche (https://github.com/ilarsf/gwasTools). Power calculation 
input parameters for the current study were 521 cases and 3,577 controls, α=5x10-8 
and α=1x10-6. Top variants were plotted according to their odds ratio (OR) and their 
MAFs in controls. 
A. B.
eFigure 2. Principal component analysis (PCA) of the cCSC patients and controls.Graphical representation of the 
first 2 principal components of the PCA analysis, before (A) and after (B) filtering based on European ancestry. 
Various colours indicate the Hapmap3 samples according to the legend, orange depicts the controls and light 
green depicts the cCSC patients. Dotted line in A depicts cut-off used to exclude samples.
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eFigure 1. Power of the cCSC GWAS. The black line indicates the power of the current study at genome-wide 
significance (P=5x10-8), whereas the green line indicates power to detect suggestive signals (P=1x10-6). The 
lead variant in CFH is depicted in red, and suggestive signals are depicted in blue.
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A. B.
eFigure 3. Kinship analysis of cCSC patients and controls. Kinship analysis was performed with KING, and 
estimated kinship coefficients of individuals in the study were calculated (A). Individuals with a kinship > 0.0884 
were removed from the analysis (B).
eFigure 5. Quantile-quantile plot of the cCSC GWAS. Each round represents a genetic variant with its expected 
and observed chi-square statistics. The black line indicates the predicted ratio between observed an expected 
chi-square statistics. The red line indicates deviations due to inflation Lambda=1.03. 
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eFigure 4. Conditioned analysis. Conditioned analysis of the lead variant on chromosome 1was performed 
to identify independent signals on chromosome 1. No independent signal was found in the CFH gene (B), the 
additional signal in the CD46 gene was independent of the lead variant (D).
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eTable 1. Demographic characteristics of the GWAS cohort
Discovery cohort
 n Median age in years (IQR) Males (%)
cCSC patients
Nijmegen 307 51 (44-59) 242 (79%)
Cologne 71 51 (43-59) 55 (78%)
Leiden 143 51 (44-59) 123 (86%)
Total 521 51 (44-59) 420 (81%)
 
Controls
NBS 3577 52 (37-71) 1630 (46%)
P-value cCSC patients vs Controls 0.192 1.78E-50
cCSC, chronic central serous chorioretinopathy; GWAS, genome-wide association study; NBS, Nijmegen 
Biomedical Study; Age difference between cCSC patients and controls was compared with a Mann-Whitney 
U test, and gender differences were compared with a chi-square test. 
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Abstract
Background: Chronic central serous chorioretinopathy (cCSC) is a multifactorial 
eye disease characterized by subretinal fluid accumulation that leads to vision loss. 
Clinically, cCSC is associated with stress, hypercortisolism and corticosteroid use, and 
is more frequent in males (80%) than in females (20%). Current genetic studies on 
cCSC have thus far focused on common variants, but familial occurrence of cCSC also 
suggests a role for rare variants in the disease susceptibility. Therefore, in this study, 
we performed exome sequencing of cCSC patients to elucidate the role of rare  
(protein-altering) variants in the disease. 
Methods: Exome sequencing was performed on 269 cCSC patients and 1,586 
controls. Data were processed according to the Genome-Analysis-Toolkit (GATK) best 
practices. Principal component analysis was performed to check for genetic ancestry 
and only unrelated subjects of European descent were retained. Burden, SKAT and 
SKAT-O tests were performed using 2 different grouping criteria. One group included 
protein-altering variants only, while the other contained synonymous and splice site 
variants as well. The gene-based analyses were performed using the SKAT R-package 
correcting for two principal components using two approaches; (1) on the entire 
cohort correcting for sex and (2) on males and females separately. Additionally, the 
gene-based associations of genes at previously reported cCSC loci were investigated. 
Results: After filtering, the dataset contained 263 cCSC patients (208 males [79%]) 
and 1352 controls (671 males [50%]) carrying 197,915 protein-altering variants in 
16,370 genes and 330,689 exonic variants in 18,173 genes. Analysis stratified by sex 
identified significant associations with the PIGZ (PSKAT=9.19x10-7 & PSKAT-O=2.48x10-6), 
DUOX1 (PSKAT=1.03x10-6), RSAD1 (PSKAT=1.92x10-7 & PSKAT-O=8.57x10-8) and 
LAMB3 (PBurden=1.40x10-6 & PSKAT-O=1.14x10-6) genes in female cCSC patients, after 
correction for multiple testing. The number of rare variant carriers in these genes was 
significantly higher in the female cCSC cohort compared to female controls (45,5% vs. 
18.5%, P=1.92x10-6, OR=3.67 [95%CI=2.09-6.46]). No significant associations were 
identified in the entire cohort nor in the male patients. 
Conclusions: In this exome study on cCSC patients, we have identified PIGZ, DUOX1, 
RSAD1 and LAMB3 as new susceptibility genes for cCSC in females. The sex-specific 
associations suggest a possible interaction between genetic factors and sex for cCSC, 
and indicate that rare (protein-altering) variants play a role in the etiology of cCSC in 
females. 
Keywords (3-10): exome sequencing, central serous chorioretinopathy, CSC, Burden, 
SKAT, SKAT-O
Background
Central serous chorioretinopathy (CSC) is a vision-threatening eye disease 
characterized by serous fluid accumulation between the neuroretina and retinal 
pigment epithelium (RPE), supposedly secondary to a dysfunctional choroid and 
outer blood-retina barrier of the RPE.1 The incidence of cCSC is estimated to be 
1.7 in 100,000 in women and 9.9 in 100,000 in men with most cohorts confirming 
this ~80% male predominance.1,2 Two distinct forms of CSC have been described, 
distinguished by the duration of symptoms and extend of the RPE alterations. Acute 
CSC usually resolves spontaneously within ~3 months, whereas in chronic CSC 
(cCSC) fluid accumulation persists and more widespread RPE atrophy occurs.1 The 
etiology of CSC is unknown, but associations with stress, hypertension and the use 
of corticosteroids have been described.1 A genetic component for the disease was 
suggested because of familial occurrence of CSC,3,4 and so far a limited number of 
genetic studies have been performed for cCSC. 
Candidate gene studies have described associations between cCSC and common 
single nucleotide polymorphisms (SNPs) in the CFH, ARMS2, CDH5 and NR3C2 
genes,5-8 as well as copy number variations of the C4B gene.9 Additionally, the first 
genome-wide association study on cCSC confirmed the role of CFH in the disease.10 
Other genes suggested to be involved in the genetics of cCSC include CD46, CFHR1, 
CFHR4, KCNT2, TNFRS10A and VIPR2.10,11 So far, only common variants have been 
associated with cCSC, however, familial clustering of cCSC has also hinted towards a 
possible role for rare variants in disease susceptibility.3,4 
Therefore, to elucidate the role of rare (protein-altering) variants in cCSC we performed 
exome sequencing on 269 cCSC patients. We performed single-variant association 
and gene-based tests, on the entire cohort and stratifying the analyses for sex. 
Additionally, we investigated the gene-based associations of genes at loci that have 
previously been associated with cCSC. Here, we report new genetic susceptibility 
loci and suggest a sex-specific genetic component for cCSC and further broaden our 
knowledge on the disease etiology. 
Materials & Methods
Library preparation and sequencing
cCSC patients 
In this study, 269 cCSC patients who visited the outpatient clinic of the Department of 
Ophthalmology of the Radboud university medical center, Nijmegen, the Netherlands 
were included. Patients were diagnosed with cCSC based on multimodal retinal 
imaging as described previously.6,10 DNA of cCSC patients, isolated from blood, was 
purified with the QIAamp DNA purification kit (Qiagen), according to manufacturer’s 
instructions. 3µg of purified DNA was used as input for the SureSelectXT target 
enrichment system for Illumina paired-end multiplexed sequencing (Version B4, 
August 2015, Agilent Technologies). 
Library preparation was performed according to the manufacturer’s instructions. 
Samples were hybridized with the SureSelect All Exon V4 (Agilent Technologies) 
capture library and post-hybridization addition of the index tags was performed on the 
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Dynabeads MyOne Streptavidin T1 beads (ThermoFisher Scientific). Midway and final 
quality checks were performed with Tapestation high sensitivity D1000 screentape 
(Agilent Technologies) and a Qubit dsDNA high sensitivity assay (ThermoFisher 
Scientific). A total of 8 samples was pooled for sequencing in one lane. Sequencing 
was performed at the Department of Genetics of Maastricht University Medical 
Center+, Maastricht, The Netherlands, using an Illumina HiSeq2000 with 2*100bp 
chemistry. 
Controls
As population controls, 1586 parents that were part of a large cohort of intellectual 
disability trios were used;12 no ophthalmologic imaging was available for these 
individuals. Control samples were sequenced with the Agilent SureSelect V4 
enrichment kit in a diagnostic setting at the Beijng Genomics Institute (BGI) in 
Copenhagen between August 2013 and March 2015. Sequencing was performed on 
an Illumina HiSeq instrument with 101-bp paired-end reads.12 The median coverage 
of the exomes of both cCSC patients and controls was 75X.
This study was performed according to the guidelines of the Declaration of Helsinki 
and was approved by the local ethics committee. Written informed consent was 
obtained for all subjects involved in the study.
Variant calling
Bam to FastQC extraction was performed for both controls and cCSC patient data 
with Picard-tools (v 1.90). Files of patients and controls were processed together 
to minimize batch effects.13 Duplicate reads were marked with Picard-tools and 
reads were aligned to the reference genome (GRCh37.p5 with alternate haplotypes 
excluded) using BWA-MEM (version v.0.7.12). Sequencing data was processed 
according to the Genome-Analysis-Toolkit (GATK) best practices (v3.8). Briefly, base 
recalibration was performed using the following known sites: dbsnp version 144, Mills 
and 1000G gold standard and 1000G phase1 high confidence insertion/deletions 
(INDELs). Variant calling was performed with haplotypecaller in g.vcf mode specified 
on the SureSelect V4 regions flanked with 200bp. Individual g.vcfs were merged into 
batches of 200 samples and joint genotyping on the whole cohort was performed per 
chromosome using genotypeGVCFs with the newQual option. Sites with a minimal 
average coverage of 15X in both the cCSC patients and control datasets were retained 
for downstream analyses.
Variant quality score recalibration (VQSR)
Variant recalibration was performed with GATK (v3.8) using the recommended 
settings.13 For SNPs, Hapmap3.3 and OmniExpress 2.5 chip sites were used as 
truth and training sets, while the 1000G phase1 data was used for training only. For 
INDELs, the Mills and 1000G gold dataset was used as truth and training sets. For 
both SNPs and INDELs “dbsnp v138 excluding sites after dbsnp v129 sites” were used 
to indicate known variants. The following arguments were used during the generation 
of the variant recalibration model for SNPs: Quality by Depth (QD), Mapping Quality 
(MQ), MQRankSum, ReadPosRankSum, Fisher strand (FS), Strand odds ratio (SOR), 
InbreedingCoeff, and MQCap = 60. For INDELs the MQ option was removed, as 
recommended. The variant recalibration model was applied to the dataset for SNPs 
and INDELs separately and the data was filtered based on the 99.5 and 99 sensitivity 
tranche, respectively. 
Population stratification, Cryptic relatedness & Sex-check
All variants overlapping with the Hapmap3 data were extracted and combined with 
the original Hapmap3 data containing individuals of various genetic ancestries. The 
merged dataset was pruned using PLINK (v1.90b3y), with a window size of 50kb, 
stepsize of 5kb and variant inflation factor of 2. Principal component analysis (PCA) 
was performed on the data to account for population admixture. The first 2 PCA 
components were plotted with R (v 3.2.0), and ancestry labels were added to the 
Hapmap data. After filtering only individuals from European descent were retained 
(Figure S1 in the Supplement). 
To assess cryptic relatedness between individuals in the dataset, kinship coefficients 
were calculated with KING (v2.0).14 Proportion of zero identity by state (IBS) was 
plotted against the estimated kinship coefficient with R (v 3.2.0) (Figure S2 in the 
Supplement). Samples were removed that had a kinship coefficient indicative of 
being either first degree (0.177-0.354), second degree (0.177-0.0884) or third degree 
(0.0884-0.0442) relatives. Finally, reported sex was compared with the data available 
for the X chromosome using the sex-check option in PLINK, with a threshold of 
F<0.35 for women and F>0.7 for men. 
Variant filtering
Variants located in low complexity regions of the genome were removed.15 Multiallelic 
variants were extracted with VCFtools (v0.1.13) and split using the splitMultiallelic 
and LeftAlingandTrimVariants option in GATK (v3.8). After splitting, biallelic and 
multiallelic SNPs and INDELs were combined and tested for Hardy-Weinberg 
equilibrium P>1x10-8 and a minor allele count of 1. Variants from the adult-onset 
cancer genes captured in the American College of Medical Genetics and Genomics 
recommendations for incidental findings (BRCA1, BRCA2, MLH1, MSH2, MSH6, 
PMS2, MUTYH) were removed to reduce the risk of secondary findings.16 Remaining 
variants were annotated with TabAnno (https://github.com/zhanxw/anno). In order to 
perform the downstream gene analysis, two different groupfiles were made using a 
Python script (available on request). The protein-altering variant groupfile contained 
nonsynonymous, stop gain/loss, start gain/loss, codon gain/loss, frameshift and 
essential splice site variants, while the exonic groupfile included both protein-altering 
variants and synonymous, exon and variants in the complete splice site.
Statistical analysis
Data was converted to binary PLINK files and imported into the SKAT R-package (v. 
1.2.1).17,18 As the SKAT package does not offer a function to analyze a large set of 
single variants, one large “dummy” geneset was generated containing all the variants 
in the input file. The association of each variant was calculated with a loop through 
the “dummy” geneset (Script File 1 in the Supplement). The SKAT R-package uses the 
efficient resampling method to also include extremely rare variants in the analysis.17 
The SKAT null model adjusted for small sample size was performed for a binary 
phenotype correcting for two principal components and sex (for the entire cohort) 
with the resampling method “bootstrap.fast”. The generated file was also used to 
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calculate the variant weights based on minor allele frequency using the “Get_Logistic_
Weights” function of the SKAT package (v. 1.2.1).17,18
Next, a minor allele frequency (MAF) weighted Burden, SKAT, and SKAT-O analysis 
was performed with the “SKATBinary.SSD.All” option. These analyses were performed 
on either the entire cohort or the cohort stratified by sex using the protein-altering 
and exonic groupfiles. The default settings were used for kernel (linear.weighted), 
imputation methods (bestguess), number of resampling (2x106) and p-value calculation 
(hybrid). Only genes with at least two variants were retained and multiple testing 
correction was performed using Bonferroni correction. Plots were generated with the 
R-package CMplot. An example of the gene-based test pipeline is available in Script 
File 1 in the Supplement. Sanger sequencing was performed to confirm the presence 
of the variants in the top- and suggestive genes of the different gene-based tests 
in the cCSC patients (P<5x10-5). Additionally, Burden, SKAT and SKAT-O p-values 
of previously associated cCSC genes and genes in their 100kb up- and downstream 
region were extracted from the dataset. 
The number of rare variant carriers (MAF < 0.05) in the four identified cCSC 
susceptibility genes was counted per gene in female and male cCSC patients and 
controls. The carrier and non-carrier groups were compared between controls and 
cCSC patients using a Chi-square test or Fisher’s exact test when at least 25% of the 
cells had an expected count <5. Odds ratios for single variants in the susceptibility 
genes were calculated using the Firth corrected likelihood method in SAS (v9.4),19 
when variants were significantly associated with cCSC, because the SKAT single 
variant analysis only provides P-values and no risk estimates. Haplotypes in the LAMB3 
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Figure 1: Manhattan plot of gene-based analysis in female cCSC patients. Burden (blue), SKAT (green) 
and SKAT-O (purple) association results are depicted for the female cohort including 55 cCSC patients vs. 
681 controls, using the protein-altering (A) and exonic (B) group files. The dark horizontal line indicates the 
significance threshold after correction for multiple testing: 0.05/17,370 genes=2.88x10-6 (A), 0.05/14,935 
genes=3.35x10-6 (B), while the dotted line indicates the suggestive threshold of P=5x10-5.
gene were constructed with the haplo.stats R-package as described before.10,20
Results
Quality control
In this study, 269 cCSC patients and 1586 controls were analyzed by exome 
sequencing. Among these samples 232 controls and six cCSC patients were not 
of European descent, and were therefore excluded from downstream analysis. 
Additionally, three control samples were removed due to cryptic relatedness (n=2) or 
uncertain sex based on the X-chromosome data (n=1). After individual quality control 
the dataset contained 263 cCSC patients (208 males [79%]) and 1352 controls (671 
males [50%]). For these individuals, joint genotyping with GATK resulted in a dataset 
containing 746,264 SNPs and 45,048 INDELs. Of these 3,793 SNPs and 1,661 INDELs 
were multi-allelic, and were split. Additional quality control included HWE filtering (P 
= 1x10-8) and removal of the low complexity regions of the genome.15 Finally, a total 
of 579,602 variants remained for downstream analysis, of which 547,595 were SNPs 
and 32,007 were INDELS.
Unbiased single variant association and gene-based analyses
Single variant association analysis corrected for sex and two principal components 
did not identify any genome-wide significant hits in the entire datasets, nor in the 
datasets stratified by sex (Figure S3 in the Supplement). To increase power to detect 
associations, gene-based analyses using the Burden, SKAT and SKAT-O tests were 
performed. These analyses were carried out on the entire cohort and on male and 
female cohorts stratified by sex, testing either all protein-altering variants or using 
all exonic variants. The number of genes and variants included in the gene-based 
analyses is described in Table 1. 
In the protein-altering variant analysis, genome-wide significant associations with the 
PIGZ (PSKAT=9.19x10-7 & PSKAT-O=2.48x10-6) and DUOX1 (PSKAT=1.03x10-6) genes were 
identified in females (Table 2, Figure 1A). Additionally, suggestive associations in the 
protein-altering analysis (P<5x10-5) were identified in the entire cohort, as well as the 
male and female cohort for NOP14, RSPO2, LAMB3, TDGF1 and RSL1D1 (Figure1A, 
Table S2 and Figure S4 the Supplement). Gene-based analyses of the exonic variants 
identified genome-wide significant associations in the RSAD1 (PSKAT=1.92x10-7 & PSKAT-
O=8.57x10
-8) and LAMB3 (PBurden=1.40x10
-6 & PSKAT-O=1.14x10-6) genes in the female 
cohort (Table 2, Figure 1B). Gene-based analysis of the exonic variant on the entire 
Table 1. Number of variants and genes included in the gene-based analyses
Protein-altering variants# Exonic variants#
Variants (n) Genes 
(n)
Bonferroni 
correction
p-value
threshold
Variants 
(n)
Genes 
(n)
Bonferroni 
correction
p-value
threshold
All individuals 197,915 16,370 3.05x10-6 330,689 18,173 2.75x10-6
Males 135,468 15,083 3.31x10-6 232,667 17,348 2.88x10-6
Females 123,898 14,935 3.35x10-6 215,244 17,370 2.88x10-6
#Only genes with more than 2 variants were retained and used for Bonferroni correction
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cohort and the male cohort did not identify any genome-wide associations. Suggestive 
hits for the entire cohort and the stratified male and female cohorts were identified in 
ALX1, NOP14, G3BP1, RNF144A, C5orf63, NOB1, LOC283332, ZNF713, SPATA7, 
C1QL3, GAPVD1, ZNF300P1, LIPH and OR5H14 (Figure 1B, Table S2 and Figure S4 in 
the Supplement). 
Rare variant carrier frequency in PIGZ, DUOX1, LAMB3 and RSAD1 in cCSC 
patients and controls
Gene-based analyses identified four cCSC-associated susceptibility genes in the 
female cohort. An overview of all variants found in PIGZ, DUOX1, LAMB3 and RSAD1 in 
females is presented in Table S2 in the Supplement. The PIGZ gene-based association 
was explained by 14 rare (MAF <0.05) and 4 common (MAF >0.05) nonsynonymous 
variants. The number of rare variant carriers was higher in the female cCSC patient 
group compared to the female controls (Table 3, P=0.014, Odds ratio (OR)=3.67 [95% 
confidence interval (CI)=1.42-9.47]). The p.A124V variant in PIGZ was individually 
associated with cCSC in females (P=0.0003, OR=16.40 [95% CI= 3.64-73.94]) (Table 
S2 in the Supplement). 
The DUOX1 gene-based association was composed of 12 rare and 2 common 
nonsynonymous variants and 1 rare stop-gain variant. Of the rare variants, 3 were 
found in the cCSC group, whereas 11 were found in the control group. The number 
of carriers was significantly higher in the cCSC group compared to controls (Table 
3, P= 0.039, OR=3.74 [95%CI=1.19-11.77]) The p.R925W variant was individually 
associated with cCSC (P=0.03, OR=62.69 [95%CI=1.52->999.99]), and was only 
found in the female cCSC group (Table S2 in the Supplement).
In the LAMB3 gene, a total of 49 variants was observed in females. These variants 
included 31 nonsynonymous, 13 synonymous, 3 intronic variants near splice sites 
and 2 stop-gain variants. Three of the synonymous variants were common, while the 
remaining 46 variants were rare. In the control group 94 individuals (13.8%) carried 
at least one LAMB3 rare variant, while 17 (30.9%) female cCSC patients carried one 
or more rare variants in LAMB3 (Table 3, P=0.00056, OR=2.83 [95%CI=1.53-5.22]). 
Haplotype analysis identified a significant association with cCSC for a haplotype 
carrying 7 variants in LAMB3 (p.S97S, p.N181D, p.V527M, p.Y588Y, p.S708S, 
p.N690S, p.A926D) which had a frequency of 7.3% in the cCSC patients and 1.6% in 
the control cohort (Table S3 in the Supplement, P=7.22x10-5, OR=6.60 [95%CI=2.61-
16.67]).
Table 2. Significant gene-based association results for the female cCSC cohort using the Burden, SKAT and 
SKAT-O tests
Gene Variants
Burden
p-value
SKAT
p-value
SKAT-O
p-value
PIGZ Protein-altering 6.99x10-3 9.19x10-7# 2.48x10-6#
DUOX1 Protein-altering 7.18x10-3 1.03X10-6# 4.23x10-6
RSAD1 Exonic 7.14x10-5 1.92x10-7* 8.57x10-8*
LAMB3 Exonic 1.40x10-6* 4.51x10-6 1.14x10-6*
# Significant after Bonferroni correction for 14,935 genes; P≤3.35x10-6
* Significant after Bonferroni correction for 17,370 genes; P≤2.88x10-6 
A total of 11 variants was present in RSAD1 in females, of these 9 were nonsynonymous 
(7 rare, 2 common) variants, 1 was a common synonymous variant, and 1 was a rare 
intronic variant. The number of rare variant carriers was higher among female cCSC 
patients, compared to the control group (Table 3, P= 0.017, OR=7.80 [95%CI=1.81-
33.55]). Three variants were only observed in the patient group (p.P250L, p.V299I, 
p.R317Q).
In total, 18.5% of the female control individuals carried at least one rare variant in 
PIGZ, DUOX1, LAMB3 or RSAD1, whereas this number was 45.5% in the female cCSC 
patients. The number of rare variant carriers in these genes was significantly higher 
in the female cCSC patients group compared the control group (Table 3, P=1.92x10-6, 
OR=3.67 [95%CI=2.09-6.46]). In males, no differences in the number of carriers 
of PIGZ, DUOX1, LAMB3 or RSAD1 rare variants were observed between controls 
and cCSC patients (Table S4 in the Supplement). Also, the total number of carriers 
of at least one variant in these 4 genes was not different in males (Table S4 in the 
Supplement). 
Gene-based association of genes located in known cCSC loci
Genes at previously associated cCSC loci and genes within ±100kb of the top-
associated variant were extracted from the dataset including the ARMS2-HTRA1, 
C4-RCCX, CD46, CDH5, KCNT2-CFH-CFHR1/4, NR3C2, TNFRS10A and VIPR2 loci. In 
total, 56 genes were located in these regions, of which 39 genes contained at least 
2 protein-altering variants and 44 genes had at least 2 variants in the exonic regions. 
The gene-based association results of these genes were extracted from the genome-
wide analysis. However, no associations were identified between these genes and 
cCSC after correction for multiple testing (Table S5 in the Supplement, Threshold 
P<0.00114 [corrected for 44 genes in the exonic variant analysis] and P<0.00128 
[corrected for 39 genes in the protein-altering variant analysis]).
Table 3. Female carriers of rare variants (MAF <0.05) in PIGZ, DUOX1, LAMB3 and RSAD1
Gene Nr. rare
variants
in gene
Nr. carriers
in controls
(ntotal=681)
Nr. carriers
in cCSC patients
(ntotal=55)
P-value OR (95% CI)
PIGZ 14 22 (3.2%) 6 (10.9%) 0.014 3.67 (1.42-9.47)
DUOX1 13 14 (2.1%) 4 (7.3%) 0.039 3.74 (1.19-11.77)
LAMB3 46 93 (13.8%) 17 (30.9%) 5.57x10-4 2.83 (1.53-5.22)
RSAD1 8 5 (0.7%) 3 (5.5%) 0.017 7.80 (1.81-33.55)
Variant in 
1 or more genes
126 (18.5%) 25 (45.5%) 1.92x10-6 3.67 (2.09-6.46)
Nr. number; P-values are calculated with Chi-square test or Fisher’s exact when at least 25% of the cells had 
an expected count <5.
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Discussion
In this study, in order to increase our knowledge and understanding of the genetics of 
cCSC, we performed exome sequencing on a cohort of cCSC patients. Using a gene-
based approach, we identified 4 new candidate genes for the disease in female cCSC 
patients specifically. 
Due to a relative small sample size this study had limited power to identify single-
variant associations, especially for rare variants, therefore, three different gene-based 
analyses with varying assumptions were performed. Previous studies have shown that 
the CFH gene carried both protective and risk-conferring variants,5,6 therefore, we 
used the SKAT test, which assumes variants within a gene can have both directions 
of effect. The Burden test on the other hand relies on the assumption that all variants 
in a gene have the same direction of effect, and the SKAT-O test combines both 
assumptions into one test.18 The gene-based analyses were performed using two 
different inclusion criteria. One analysis contained protein-altering variants only, since 
they are most likely to affect protein function. The other analysis contained all exonic 
variants, including synonymous (silent) variants and splice site variants, of which the 
effect on protein function is more difficult to predict. Nevertheless, such variants 
may alter gene expression levels and were therefore included in the analysis.21 In the 
female cohort we identified a significant burden of protein-altering variants in two 
genes (PIGZ and DUOX1) and a significant burden of exonic variants in two additional 
genes (LAMB3 and RSAD1). 
Nearly half of the females in the cCSC cohort carried at least one variant in the 4 
identified cCSC susceptibility genes (45.5%), while this number was significantly 
lower in the female control cohort (18.5%, P=1.92x10-6). Carrying a rare variant in 
one of these genes increases the risk for developing cCSC 3.7-fold in females, while 
carrying a variant in RSAD1 even increases risk 7.8-fold. Notably, a number of high-
risk variants were identified in the gene-based tests, including the p.A124V variant 
in PIGZ (P=0.0003, OR=16.40 [95% CI= 3.64-73.94]) and the p.R925W variant in 
the DUOX1 gene (P=0.03, OR=62.69 [95%CI=1.52->999.99]), and three variants 
(p.P250L, p.V299I, p.R317Q) in RSAD1 were observed only in the patient group 
but not in the controls. The number of carriers of rare variants in the PIGZ, DUOX1, 
LAMB3 and RSAD1 genes was not different between male cCSC patients and controls 
(Table S4 in the Supplement, 15.9% vs. 20.4%, respectively, P=0.146), indicating that 
the observed associations with cCSC are sex-specific. Replication in an independent 
female cCSC cohort is recommended to substantiate these findings. 
Interestingly, genome-wide significant associations were only observed in female 
cCSC patients but not in the males. The enrichment of rare variants in these genes 
in females is likely not due to population stratification, sequencing artefacts or the 
presence of related individuals, because stringent quality control was performed to 
avoid these confounders. It remains unclear why no associations in the male cCSC 
cohort were observed, despite accounting for the largest proportion of the cohort. 
One could hypothesize that cCSC is more genetically heterogeneous in males, 
and that a larger sample size is therefore necessary to identify associations in this 
group. The biological mechanism behind these sex-specific associations remains 
to be elucidated, but sex-biased gene expression or regulation could be one of the 
contributing factors.22,23 Interactions between sex and genetics have been described 
for other complex traits such as hypertension, schizophrenia and juvenile idiopathic 
arthritis,23-25 and for cCSC the previously described CDH5 association was observed 
in males only.7 In light of future clinical trials and genetic studies on cCSC, sex-
stratification should be taken into account to further elucidate a possible interaction 
between sex, genetics and possibly treatment outcome. 
For cCSC specifically, an interaction between genetic variants and sex hormone 
regulation and expression seems likely, since the association of cCSC with the stress 
axis, hypercortisolism and the use of corticosteroids has been described extensively, 
and pregnancy is known to increase the risk of CSC in females.1,26 An interaction with 
the steroid hormone system has already been described for LAMB3 and DUOX1,27,28 
and all four identified susceptibility genes are expressed in different tissues of the eye 
including the retina and RPE (Figure S5 in the Supplement).29 
The LAMB3 gene encodes the beta chain of laminin-5, which increases the adhesion 
properties of RPE cells and promotes the epithelial appearance of these cells in 
vitro.30 Laminin-5 shows upregulation in endometrial biopsies after treatment with 
progesterone and 17β-estradiol,27 suggesting a hormonal regulation of the gene. 
The dual oxidase 1 protein encoded by DUOX1, is a member of the NADPH oxidase 
family and generates hydrogen peroxide, an important reactive oxygen species 
(ROS). DUOX1 is mainly expressed in thyroid and lung epithelial cells, however after 
serum starvation both rods and cones expressed DUOX1 indicating that it plays a 
role in ROS response in these cells as well.31 Furthermore, the expression of DUOX1 
is stimulated by testosterone in skin keratinocytes, indicating a steroid hormone-
dependent activation of this gene at least in these cells.28 No steroid response has 
been described yet for the PIGZ and RSAD1 genes and their general function is 
still obscure.32,33 In light of the cCSC phenotype, for all four genes the effect of the 
identified variants on the disease mechanisms needs to be determined. Additionally, 
future experiments may focus on determining if a steroid hormone response is also 
present in the retina, RPE and/or choroid for these genes, and if the identified rare 
variants might alter this response. 
Conclusions
In this exome sequencing study on a cohort of cCSC patients and population controls, 
we identified PIGZ, DUOX1, LAMB3 and RSAD1 as new susceptibility genes for cCSC 
in females specifically. Our results suggest that the contribution of rare genetic risk 
variants is different between the sexes and that the cCSC disease mechanism might 
differ between males and females. Further genetic studies and clinical trials on cCSC 
may take a sex-interaction component for cCSC into account.
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Figure S2. Kinship analysis of cCSC patients and controls. Kinship analysis was performed with KING, and 
estimated kinship coefficients of individuals in the study were calculated (A). Individuals with a kinship > 
0.0442 were removed from the analysis (B).
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A. B.
Figure S1. Principal component analysis (PCA) of the cCSC patients and controls.Graphical representation of the 
first 2 principal components of the PCA analysis, before (A) and after (B) filtering based on European ancestry. 
Various colours indicate the Hapmap3 samples according to the legend, orange depicts the controls and light 
green depicts the cCSC patients. 
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Figure S5. Gene expression of DUOX1, LAMB3, PIGZ and RSAD1 in different tissues. Pan-Human Gene Expression 
levels of the four susceptibility genes in females according to the eyeintegration database v0.63 (27). Whole blood 
(red), Cornea (green), retina (blue) and retinal pigment epithelium (RPE, purple) expression levels are depicted. 
Figure S3. Single variant analysis of the exome sequencing results in cCSC patients and controls. Single variant 
analysis was performed with correction for 2 principal components and gender in the complete cohort (263 
cCSC patients vs. 1352 controls [blue]), while for the females (55 cCSC patients vs. 681 controls [green]) 
and males (208 cCSC patients vs. 671 controls [purple]) only correction with the 2 principal components was 
applied. The dark horizontal line indicates the significance threshold after correction for multiple testing of 5x10-
8, while the dotted line indicates the suggestive threshold of P=1x10-6.
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Table S2. Variants observed in the DUOX1, PIGZ, LAMB3 and RSAD1 genes in the female cohort
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rs764911806 5 nonsyn c.C411G p.D137E 0,50 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 1,00E-04 0,25 45 N(1) 15,8 T (0.361) B (0.036) 0,147
rs200421952 14 nonsyn c.G1627A p.A543T 0,55 0,64 2.46 (0.06-102.04) 1,00E+00 0 2 0 1,47E-03 7,00E-04 1,61 58 N(0.953) 13,6 T (0.159) B (0.124) 0,001
rs201198610 15 nonsyn c.T1778C p.F593S 0,54 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 6,00E-04 1,29 155 D(0.558) 20,9 T (0.45) B (0.138) 0,012
rs370633829 15 nonsyn c.G1786A p.G596R 0,044 0,12 37.16 (0.40-
>999.99)
1,00E+00 1 0 9,09E-
03
0 7,50E-05 1,53 125 N(0.643) 24,4 T (0.068) D (0.999) 0,234
rs143304688 17 stopgain c.C1948T p.Q650* 0,55 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 1,70E-03 . . A(1) 44,0 . . 0,773
rs368978619 18 nonsyn c.T2152A p.L718M 0,57 0,64 2.46 (0.06-102.04) 1,00E+00 0 2 0 1,47E-03 2,00E-04 0,06 15 N(1) 8,1 T (0.266) B (0.003) 0,004
rs373898472 21 nonsyn c.G2750T p.W917L 0,54 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 3,00E-05 3,56 61 D(1) 17,0 T (0.831) D (0.957) 0,021
rs145668427 21 nonsyn c.C2773T p.R925W 0,0024 0,03 62.69 (1.52-
>999.99)
1,00E+00 2 0 0,018 0 2,40E-03 0,99 101 D(1) 34,0 D (0.004) D (1) 0,048
rs148902727 21 nonsyn c.C2794T p.R932C 0,57 0,64 2.46 (0.06-102.04) 1,00E+00 0 2 0 1,47E-03 5,00E-04 3,23 180 D(1) 26,6 D (0.014) D (1) 0,038
rs16939752 24 nonsyn c.T3076C p.C1026R 0,33 0,30 1.35 (0.77-2.37) 1,09E-03 15 146 0,136 0,107 0,127 0,98 180 P(0.899) 15,4 T (0.364) B (0) 0,026
rs777590867 24 nonsyn c.G3170C p.G1057A 0,051 0,08 12.41 (0.77-
199.80)
1,00E+00 1 1 0,01 7,34E-04 1,52E-05 1,46 60 D(1) 10,9 T (0.38) Prob. D (0.661) 0,014
rs2458236 27 nonsyn c.C3532T p.L1178F 0,99 0,91 0.98 (0.65-1.47) 2,24E-17 37 467 0,336 0,343 0,674 0,85 22 P(0.999) 20,5 T (0.439) B (0.002) 0,09
rs142004175 28 nonsyn c.G3644A p.R1215H 0,56 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 1,60E-03 3,38 29 D(1) 33,0 D (0.002) D (1) 0,059
rs138894830 28 nonsyn c.G3656A p.R1219Q 0,51 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 1,30E-03 3,38 43 D(1) 23,8 T (0.277) Prob. D (0.706) 0,332
rs773444369 33 nonsyn c.C4462T p.R1488C 0,55 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 4,50E-05 2,20 180 D(1) 33,0 D (0) D (1) 0,116
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rs74554271 2 nonsyn c.C65T p.P22L 0,54 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 2,00E-04 0,26 98 N(1) 16,23 D (0.015) B (0.002) 0,021
rs780890452 3 nonsyn c.C308T p.T103I 0,53 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 9,98E-05 2,40 89 D(1) 15,80 D (0.018) B (0.036) 0,214
rs200901195 3 nonsyn c.G323A p.R108K 0,53 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 2,00E-04 0,29 26 D(1) 9,08 T (1) B (0) 0,475
rs199852771 3 nonsyn c.C344T p.P115L 0,60 0,75 1.76 (0.06-54.12) 1,00E+00 0 3 0 2,20E-03 4,00E-04 -0,93 98 N(1) 0,00 T (0.407) B (0) 0,123
rs144088027 3 nonsyn c.C371T p.A124V 0,00046 0,00030 16.40 (3.64-73.94) 1,00E+00 4 3 0,036 2,20E-03 5,70E-03 -1,40 64 N(1) 0,00 T (1) B (0.002) 0,144
rs150001262 3 nonsyn c.G464A p.R155H 0,53 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 1,30E-03 0,66 29 D(1) 23,20 T (0.129) D (1) 0,128
rs148186466 3 nonsyn c.G725T p.G242V 0,63 0,85 1.364 (0.052-
36.04)
1,00E+00 0 4 0 2,94E-03 2,00E-04 0,78 109 D(0.821) 16,08 T (0.164) Prob. D (0.934) 0,327
rs574365 3 nonsyn c.G796A p.A266T 0,58 0,56 0.87 (0.55-1.39) 2,11E-12 24 334 0,218 0,245 0,744 0,20 58 P(1) 0,27 T (0.323) B (0.001) 0,063
rs140946995 3 nonsyn c.C821T p.A274V 0,57 0,64 2.46 (0.06-102.04) 1,00E+00 0 2 0 1,47E-03 1,50E-03 1,61 64 N(1) 0,00 T (1) B (0.136) 0,064
rs148546943 3 nonsyn c.C864A p.N288K 0,54 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 1,57E-04 0,52 94 .(.) 0,03 T (0.49) B (0.002) 0,011
rs149631795 3 nonsyn c.C1010T p.A337V 0,55 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 4,00E-04 0,76 64 N(1) 7,99 T (0.164) Prob. D (0.919) 0,078
rs4916589 3 nonsyn c.G1019A p.R340Q 0,75 0,72 0.93 (0.63-1.38) 9,96E-23 43 557 0,391 0,409 0,596 0,46 43 P(1) 8,52 T (0.505) B (0) 0,166
rs150517093 3 nonsyn c.C1078T p.R360W 0,54 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 4,00E-04 -2,76 101 N(1) 0,00 T (0.188) B (0.001) 0,009
rs1147238 3 nonsyn c.T1250C p.V417A 0,47 0,42 1.24 (0.73-2.09) 3,51E-05 18 189 0,164 0,139 0,141 0,98 64 P(0.947) 7,25 T (0.252) B (0.007) 0,081
rs150414171 3 nonsyn c.G1401C p.M467I 0,11 0,09 7.45 (0.71-77.77) 1,00E+00 1 2 9,09E-
03
1,47E-03 1,90E-03 3,82 10 D(0.937) 25,20 D (0.036) D (1) 0,043
rs17855662 3 nonsyn c.G1461A p.M487I 0,14 0,19 0.55 (0.23-1.33) 8,97E-02 5 117 0,045 0,086 0,084 2,20 10 N(0.712) 22,10 T (0.143) Prob. D (0.524) 0,431
rs202156268 3 nonsyn c.G1466A p.G489E 0,50 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 3,00E-05 3,82 98 D(0.931) 24,90 D (0.005) D (0.998) 0,297
rs146219795 3 nonsyn c.G1591A p.V531M 0,042 0,12 37.16 (0.40-
>999.99)
1,00E+00 1 0 9,09E-
03
0 5,00E-04 -0,60 21 N(1) 2,73 T (0.18) Prob. D (0.539) 0,01
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rs140470350 1 syn c.C15T p.F5F 0,53 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 2,60E-03 . . . . . . 0,096
rs2228339 2 syn c.C138T p.T46T 0,77 0,76 1.07 (0.68-1.70) 2,84E-11 26 308 0,236 0,226 0,245 . . . . . . 0,044
rs2076356 3 syn c.A291C p.S97S 0,06 0,07 1.44 (0.97-2.14) 2,06E-18 46 454 0,418 0,333 0,659 . . . . . . 0,023
rs2235542 5 nsyn c.A541G p.N181D 0,00015 <0.0001 5.11 (2.33-11.22) 9,99E-01 9 24 8,18E-
02
1,76E-02 2,26E-02 0,953 23 P(1) 5,937 T(0.461) B(0.036) 0
rs150895872 5 nsyn c.G548A p.R183H 0,57 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 1,40E-03 0,015 29 N(1) 12,49 T(0.282) B(0.004) 0,054
rs121912482 6 nsyn c.G628A p.E210K 0,55 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 . 1,461 56 A(0.922) 22,5 T(0.398) B(0.238) 0,988
rs141059189 8 syn c.C927T p.D309D 0,51 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 3,00E-04 . . . . . . 0,028
rs886045867 8 syn c.A943C p.R315R 0,53 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 . . . . . . . 0,875
rs52814161 9 nsyn c.T1015C p.Y339H 0,15 0,15 2.37 (0.72-7.75) 1,00E+00 3 18 2,73E-
02
1,32E-02 1,72E-02 1,190 83 N(1) 7,697 T(0.287) B(0) 0,008
rs114875539 9 nsyn c.G1051A p.E351K 0,57 0,64 2.46 (0.06-102.04) 1,00E+00 0 2 0 1,47E-03 1,60E-03 1,145 56 N(1) 17,25 T(0.333) D(0.998) 0
rs548096567 9 nsyn c.C1069T p.R357W 0,037 0,12 37.16 (0.40-
>999.99)
1,00E+00 1 0 9,09E-
03
0 0 0,351 101 N(1) 33 D(0.004) D(1) 0,157
rs2076351 10 syn c.G1149A p.P383P 0,69 0,90 0.82 (0.04-17.55) 1,00E+00 0 7 0 5,14E-03 5,90E-03 . . . . . . 0,003
rs779219301 10 nsyn c.G1189A p.G397R 0,52 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 5,38E-05 5,261 125 D(1) 29,4 D(0.001) D(1) 0,38
1:209801457 10 nsyn c.A1211G p.H404R 0,53 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 . 4,536 29 N(0.859) 13,61 D(0.017) B(0.101) 0,307
rs2229468 11 nsyn c.T1312A p.S438T 0,54 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 3,00E-04 -0,062 58 P(1) 4,981 T(1) B(0.002) 0,056
rs762400142 11 syn c.G1347A p.G449G 0,54 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 0 . . . . . . 0,018
1:209800257 12 stgain c.C1552T p.Q518X 0,54 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 . . . A(1) 38 . . 0,015
rs771727419 12 nsyn c.G1574C p.G525A 0,54 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 1,55E-05 5,575 60 D(1) 24,9 D(0.008) D(1) 0,102
1:209800233 12 nsyn c.G1576A p.D526N 0,56 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 . 1,497 23 N(0.98) 17,93 D(0.016) D(0.974) 0,005
rs2076349 12 nsyn c.G1579A p.V527M 0,00091 0,0005 3.83 (1.79-8.19) 9,99E-01 9 32 8,18E-
02
2,35E-02 2,76E-02 -0,266 21 P(1) 10,99 T(0.068) P(0.596) 0,007
rs767004520 13 nsyn c.C1654T p.R552C 0,031 0,12 37.16 (0.40-
>999.99)
1,00E+00 1 0 9,09E-
03
0 1,00E-04 2,557 180 D(0.999) 34 D(0.006) D(1) 0,02
rs2179402 13 syn c.T1716C p.C572C 0,19 0,19 1.32 (0.87-1.99) 2,94E-14 36 369 0,327 0,271 0,747 . . . . . . 0,014
rs370280436 13 nsyn c.G1721A p.R574H 0,57 0,64 2.46 (0.06-102.04) 1,00E+00 0 2 0 1,47E-03 7,64E-05 0,516 29 N(0.978) 21,9 T(0.069) B(0.039) 0,002
rs771720883 13 syn c.G1728A p.P576P 0,52 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 1,00E-04 . . . . . . 0,024
rs2229465 13 syn c.T1764C p.Y588Y 0,00019 <.0001 4.91 (2.25-10.74) 9,99E-01 9 25 8,18E-
02
1,84E-02 2,45E-02 . . . . . . 0,002
rs760667887 13 nsyn c.G1853A p.R618H 0,54 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 3,01E-05 -4,245 29 N(1) 0,066 T(0.574) B(0) 0
rs80356682 13 stgain c.C1903T p.R635X 0,14 0,09 7.45 (0.71-77.77) 1,00E+00 1 2 9,09E-
03
1,47E-03 1,30E-03 . . A(1) 36 . . 0,007
1:209799027 13 nsyn c.G1942A p.V648M 0,55 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 . 0,301 21 N(0.976) 21,2 T(0.052) B(0.048) 0,017
1:209799011 13 nsyn c.G1958T p.S653I 0,50 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 . 0,199 142 N(1) 24,6 D(0.005) P(0.641) 0,019
rs2229466 14 nsyn c.A2069G p.N690S 0,00014 <0.0001 5.11 (2.33-11.22) 9,99E-01 9 24 8,18E-
02
1,76E-02 2,21E-02 0,225 46 P(1) 0,003 T(0.243) B(0.003) 0,271
rs2072937 14 syn c.T2124C p.S708S 0,00014 <0.0001 5.11 (2.33-11.22) 9,99E-01 9 24 8,18E-
02
1,76E-02 2,21E-02 . . . . . . 0,041
rs778247685 15 nsyn c.C2209T p.R737C 0,039 0,12 37.16 (0.40-
>999.99)
1,00E+00 1 0 9,09E-
03
0 1,51E-05 -0,134 180 N(1) 16,04 T(0.061) P(0.876) 0,052
rs113745536 15 syn c.G2298A p.K766K 0,57 0,64 2.46 (0.06-102.04) 1,00E+00 0 2 0 1,47E-03 8,00E-04 . . . . . . 0,005
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1:209796424 16 nsyn c.G2459A p.G820D 0,52 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 . 4,023 94 D(1) 29,5 D(0.004) D(1) 0,088
rs151006337 17 nsyn c.C2564G p.A855G 0,55 0,64 2.46 (0.06-102.04) 1,00E+00 0 2 0 1,47E-03 1,00E-04 0,396 60 N(1) 4,838 T(0.074) B(0.039) 0,01
rs539752226 17 nsyn c.T2588G p.I863S 0,57 0,64 2.46 (0.06-102.04) 1,00E+00 0 2 0 1,47E-03 . 2,704 142 N(0.842) 24,7 D(0.001) P(0.808) 0,452
rs199946321 17 nsyn c.C2632T p.R878C 0,53 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 7,49E-05 1,177 180 D(0.999) 34 D(0) D(1) 0,049
rs2076222 18 nsyn c.C2777A p.A926D 0,00014 <0.0001 5.11 (2.33-11.22) 9,99E-01 9 24 8,18E-
02
1,76E-02 2,21E-02 3,355 126 P(0.06) 24,5 D(0.002) D(0.999) 0,001
rs775023132 18 nsyn c.T2813C p.I938T 0,56 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 1,50E-05 2,485 89 D(0.605) 26,5 D(0.021) D(0.979) 0,035
rs777389254 18 nsyn c.G2833A p.V945M 0,54 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 1,50E-05 1,167 21 N(0.986) 27 D(0.049) D(0.999) 0,032
rs143164025 18 syn c.G2871A p.A957A 0,63 0,75 1.76 (0.06-54.12) 1,00E+00 0 3 0 2,20E-03 2,00E-04 . . . . . . 0,031
rs140769823 19 nsyn c.A2945G p.D982G 0,59 0,75 1.76 (0.06-54.12) 1,00E+00 0 3 0 2,20E-03 1,60E-03 2,079 94 N(0.857) 17,12 T(0.574) B(0) 0,578
1:209791343 19 nsyn c.T2960G p.L987R 0,53 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 . 3,490 102 D(0.942) 29 D(0.006) P(0.821) 0,017
rs147527725 20 nsyn c.G3068A p.R1023Q 0,07 0,08 12.41 (0.77-
199.80)
1,00E+00 1 1 9,09E-
03
7,34E-04 3,00E-04 0,063 43 N(1) 18,77 T(0.55) B(0.244) 0,171
rs147931502 22 nsyn c.A3479G p.H1160R 0,52 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 7,00E-04 1,698 29 N(0.998) 12,25 T(0.119) B(0.201) 0,097
rs745444340 22 nsyn c.G3487A p.G1163R 0,53 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 3,00E-05 -0,135 125 N(1) 0,188 T(0.677) B(0.003) 0,032
rs901375494 Intr15 . G>A 0 0,50 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 . . . . . . . 0,053
rs757259426 Intr2 . G>A 0 0,048 0,12 37.16 (0.40-
>999.99)
1,00E+00 1 0 9,09E-
03
0 0,00E+00 . . . . . . 0,065
rs375846575 Intr6 . G>C 0 0,56 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 6,02E-05 . . . . . . 0,38
rs2290862 3 nsyn c.G355A p.A119T 0,55 0,70 0.93 (0.62-1.38) 1,66E-22 41 534 0,373 0,392 0,613 -0,041 58 P(1) 8,627 T(0.446) B(0) 0,09
rs2290861 3 nsyn c.T377C p.L126S 0,55 0,70 0.93 (0.62-1.38) 1,66E-22 41 534 0,373 0,392 0,614 4,026 145 P(1) 18,49 T(0.455) B(0) 0,304
17:48557374 3 nsyn c.A403C p.T135P 0,54 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 . 0,959 38 D(0.975) 23 D(0.002) D(0.999) 0,066
rs201488851 4 nsyn c.C512T p.T171M 0,50 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 2,00E-04 1,188 81 N(0.983) 24 T(0.105) D(0.996) 0,002
rs7210579 4 syn c.A582G p.V194V 0,55 0,62 1.12 (0.72-1.75) 4,12E-11 28 321 0,255 0,236 0,243 . . . . . . 0,083
rs137932823 4 nsyn c.G745C p.D249H 0,53 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 1,00E-03 3,211 81 D(0.939) 24,3 D(0.003) P(0.74) 0,02
rs541139014 4 nsyn c.C749T p.P250L 0,031 0,12
37.16 (0.40-
>999.99) 1,00E+00 1 0
9,09E-
03 0 4,60E-05 1,761 98 D(0.999) 19,12 T(0.059) P(0.895) 0,21
rs143685560 5 nsyn c.G895A p.V299I 0,021 0,12
37.16 (0.40-
>999.99) 1,00E+00 1 0
9,09E-
03 0 2,00E-04 0,130 29 N(1) 9,465 T(1) B(0.028) 0,099
rs778299565 6 nsyn c.G950A p.R317Q 0,039 0,12
37.16 (0.40-
>999.99) 1,00E+00 1 0
9,09E-
03 0 4,62E-05 3,475 43 D(0.997) 26,6 D(0.038) D(0.992) 0,281
rs374609288 7 nsyn c.C1072G p.L358V 0,52 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 2,00E-04 1,226 32 N(0.997) 22,9 D(0.007) B(0.201) 0,079
17:48561127 0 . G>A 0 0,53 0,54 4.09 (0.04-381.40) 1,00E+00 0 1 0 7,34E-04 . . . . . . . 0,236
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Table S4. Male rare variant (MAF <0.05) carriers in PIGZ, DUOX1, LAMB3 and RSAD1
Gene
No. rare
variants
in gene
Controls 
(n=671)
cCSC 
patients 
(n=208)
P-value OR (95% CI)
LAMB3 32 81 (12.1%) 20 (9.6%) 0.38 0.78 (0.46-1.30)
PIGZ 19 35 (5.2%) 7 (3.4%) 0.35 0.63 (0.28-1.45)
DUOX1 23 24 (3.6%) 8 (3.8%) 1.00 1.08 (0.48-2.44)
RSAD1 4 7 (1.0%) 1 (0.5%) 0.69 0.46 (0.06-3.73)
Variant in 1 or more genes 137 (20.4%) 33 (15.9%) 0.15 0.74 (0.49-1.12)
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Table S5. Gene-burden results of genes in the known cCSC loci                 
All individuals Males Females
exonic protein altering exonic protein altering exonic protein altering
Gene Locus Va-
ri-
ants
Burden SKAT SKAT-O Va-
ri-
ants
Burden SKAT SKAT-O Vari-
ants
Burden SKAT SKAT-O Vari-
ants
Bur-
den
SKAT SKAT-O Va-
ri-
ants
Burden SKAT SKAT-O Vari-
ants
Burden SKAT SKAT-O
ARMS2 ARMS2-HT-
RA1
6 0,358 0,681 0,498 5 0,593 0,865 0,725 5 0,377 0,602 0,500 4 0,635 0,633 0,636 4 0,784 0,781 1,000 4 0,784 0,781 1,000
HTRA1 ARMS2-HT-
RA1
10 0,763 0,910 0,918 6 0,844 0,632 0,866 9 0,716 0,859 0,887 5 0,885 0,470 0,637 4 0,807 0,571 0,913 2 0,634 0,634 0,634
PLEKHA1 ARMS2-HT-
RA1
18 0,572 0,267 0,432 12 0,118 0,248 0,201 15 0,209 0,149 0,254 10 0,020 0,096 0,036 11 0,157 1,000 0,274 9 0,204 0,854 0,349
CR1L CD46 8 0,542 0,844 0,645 7 0,546 0,877 0,663 7 0,673 1,000 0,779 6 0,671 1,000 0,775 7 0,689 0,801 0,797 6 0,673 0,879 0,773
CD46 CD46 10 0,405 0,689 0,504 7 0,347 0,666 0,431 7 0,163 0,151 0,195 5 0,131 0,147 0,165 7 0,373 0,050 0,072 6 0,389 0,049 0,071
CD34 CD46 16 0,219 0,033 0,047 9 0,113 0,033 0,047 12 1,000 0,575 0,712 7 0,795 0,539 0,667 10 0,0091 0,0016 0,0026 6 0,0067 0,0017 0,0027
BEAN1 CDH5 24 0,758 1,000 0,892 16 0,583 0,668 0,694 16 0,589 0,633 0,756 9 0,525 0,594 0,635 17 1,000 0,390 0,554 10 1,000 1,000 1,000
CDH5 CDH5 39 0,787 0,892 1,000 23 0,867 0,577 0,798 25 0,549 0,596 0,721 15 0,321 0,264 0,434 29 0,122 1,000 0,247 17 0,126 0,982 0,228
CFHR2 CFH 6 0,090 0,389 0,136 4 0,193 0,494 0,270 6 0,249 0,685 0,342 4 0,326 0,729 0,432 4 0,128 0,507 0,193 3 0,424 0,678 0,590
CFHR4 CFH 7 0,294 0,146 0,242 4 0,262 0,709 0,400 6 1,000 0,410 0,607 4 0,255 0,709 0,391 2 0,069 0,069 0,071 NA NA NA NA
KCNT2 CFH 26 0,733 0,188 0,271 11 0,140 0,057 0,119 14 0,552 0,278 0,384 4 0,033 0,130 0,100 17 0,086 0,204 0,135 8 0,957 0,539 0,957
CFHR5 CFH 24 0,374 0,358 0,524 19 0,350 0,338 0,497 17 0,943 0,641 0,813 15 0,952 0,613 0,787 17 0,085 0,050 0,091 13 0,064 0,047 0,080
CFH CFH 33 0,717 0,333 0,515 19 0,276 0,464 0,423 24 0,184 0,073 0,126 14 0,059 0,128 0,099 23 0,182 0,924 0,315 13 0,254 0,562 0,373
NR3C2 NR3C2 15 0,227 0,737 0,348 8 0,109 0,782 0,185 12 0,332 0,881 0,485 5 0,159 0,783 0,233 14 0,465 0,593 0,641 7 0,379 0,677 0,581
ARHGAP10 NR3C2 31 0,570 0,630 0,742 16 0,202 0,932 0,276 24 0,866 0,363 0,523 12 0,282 1,000 0,378 18 0,419 1,000 0,590 7 0,422 1,000 0,548
PPT2 RCCX 4 0,170 0,109 0,151 3 0,789 0,793 1,000 4 0,128 0,143 0,190 3 0,454 0,455 0,455 2 0,210 0,210 0,210 2 0,210 0,210 0,210
STK19 RCCX 10 0,590 0,600 0,754 4 0,187 0,519 0,380 8 0,846 0,965 0,966 3 0,638 0,763 0,741 5 0,058 0,210 0,149 3 0,105 0,294 0,294
ZBTB12 RCCX 8 0,482 0,617 0,566 5 0,372 0,776 0,481 5 0,516 0,599 0,608 2 0,343 0,721 0,721 5 1,000 1,000 1,000 3 0,603 0,603 0,603
FKBPL RCCX 7 0,699 0,729 0,852 6 0,889 0,746 0,885 7 0,740 0,264 0,394 6 1,000 0,283 0,416 6 1,000 0,289 0,433 5 1,000 0,270 0,406
RDBP RCCX 10 0,040 0,018 0,040 8 0,046 0,021 0,028 7 0,035 0,011 0,020 5 0,012 0,010 0,017 7 0,541 0,490 0,710 5 0,718 0,906 0,906
DOM3Z RCCX 19 1,000 0,777 1,000 9 1,000 0,783 1,000 15 1,000 0,502 0,673 8 0,600 0,478 0,586 13 1,000 0,443 0,607 5 0,526 0,299 0,371
EGFL8 RCCX 14 0,655 0,223 0,332 10 0,064 0,162 0,107 10 1,000 0,374 0,495 7 0,119 0,201 0,194 10 0,320 0,323 0,426 7 0,184 1,000 0,298
CFB RCCX 17 0,350 0,703 0,505 11 0,204 0,646 0,310 15 0,836 1,000 1,000 9 0,891 0,895 1,000 13 0,117 0,101 0,149 9 0,0060 0,056 0,012
ATF6B RCCX 21 0,173 0,682 0,268 11 0,248 1,000 0,373 16 0,522 1,000 0,668 8 0,402 0,808 0,578 13 0,070 0,124 0,116 9 0,569 0,804 0,835
SLC44A4 RCCX 25 0,483 0,641 0,656 15 0,404 0,706 0,597 14 0,257 1,000 0,431 10 0,348 0,837 0,527 21 1,000 0,611 0,774 12 0,870 0,863 1,000
EHMT2 RCCX 36 0,208 0,183 0,284 16 0,153 0,073 0,113 22 0,656 0,538 0,745 11 0,548 0,317 0,471 25 0,129 0,108 0,159 12 0,086 0,070 0,101
C2 RCCX 24 0,811 0,645 0,786 20 0,660 0,591 0,728 18 0,682 0,676 0,811 14 0,679 0,654 0,787 14 1,000 0,316 0,430 13 1,000 0,393 0,512
AGER RCCX 31 0,209 0,745 0,324 20 0,275 0,368 0,385 25 0,320 0,818 0,475 15 0,397 0,521 0,535 19 0,384 0,582 0,545 11 0,396 0,713 0,509
SKIV2L RCCX 45 0,922 0,283 0,429 24 0,798 0,215 0,327 33 0,596 0,050 0,080 19 0,343 0,077 0,125 30 0,447 0,420 0,601 14 0,167 0,273 0,262
NOTCH4 RCCX 72 0,685 1,000 0,856 47 0,544 0,939 0,740 55 0,591 1,000 0,769 32 0,756 0,695 0,863 49 0,093 0,220 0,150 29 0,074 0,448 0,128
TNXB RCCX 116 0,519 0,404 0,576 84 0,221 0,346 0,351 87 0,228 0,048 0,085 63 0,048 0,050 0,066 71 0,394 0,159 0,251 52 0,284 0,141 0,238
GPSM3 RCCX 2 0,221 0,221 0,221 NA NA NA NA 2 0,094 0,094 0,094 NA NA NA NA 2 1,000 1,000 1,000 NA NA NA NA
MIR1236 RCCX 3 0,104 0,379 0,196 NA NA NA NA 2 0,076 0,279 0,123 NA NA NA NA 1 NA NA NA NA NA NA NA
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All individuals Males Females
exonic protein altering exonic protein altering exonic protein altering
Gene Locus Va-
ri-
ants
Burden SKAT SKAT-O Va-
ri-
ants
Burden SKAT SKAT-O Vari-
ants
Burden SKAT SKAT-O Vari-
ants
Bur-
den
SKAT SKAT-O Va-
ri-
ants
Burden SKAT SKAT-O Vari-
ants
Burden SKAT SKAT-O
RNF5 RCCX 3 0,530 0,482 0,575 NA NA NA NA 3 0,591 1,000 0,716 NA NA NA NA 2 0,037 0,037 0,037 NA NA NA NA
RNF5P1 RCCX 3 0,544 0,544 0,544 NA NA NA NA 3 0,372 0,372 0,372 NA NA NA NA 3 0,729 0,729 0,729 NA NA NA NA
AGPAT1 RCCX 4 0,793 0,357 0,723 NA NA NA NA 3 0,347 0,747 0,541 NA NA NA NA 3 0,115 0,115 0,115 NA NA NA NA
TNFRSF10C TNFRSF10A 7 0,755 0,554 0,699 3 0,970 0,267 0,269 3 0,786 0,809 0,926 NA NA NA NA 7 0,176 0,335 0,338 3 0,079 0,079 0,079
CHMP7 TNFRSF10A 6 0,544 0,791 0,815 6 0,544 0,791 0,815 4 0,527 0,753 0,787 4 0,527 0,753 0,787 2 0,585 0,585 0,585 2 0,585 0,585 0,585
R3HCC1 TNFRSF10A 18 0,936 0,829 1,000 8 0,674 0,980 0,779 15 0,836 0,687 0,813 6 0,632 1,000 0,736 13 0,785 1,000 1,000 6 0,934 1,000 1,000
TNFRSF10D TNFRSF10A 20 0,483 0,030 0,051 10 0,330 0,505 0,454 12 0,786 0,114 0,181 8 0,317 0,535 0,439 18 0,337 0,179 0,275 8 0,823 0,782 1,000
TNFRSF10A TNFRSF10A 18 0,893 0,049 0,089 15 0,271 0,017 0,030 14 0,575 0,119 0,203 12 0,890 0,057 0,100 12 0,250 0,193 0,317 10 0,097 0,118 0,143
LOXL2 TNFRSF10A 36 0,881 0,518 0,707 15 0,470 0,061 0,112 29 0,360 0,182 0,290 11 1,000 0,603 0,806 23 0,131 0,569 0,218 10 0,079 0,102 0,148
VIPR2 VIPR2 19 0,608 0,659 0,809 7 0,818 0,649 0,815 11 0,603 0,754 0,798 4 0,764 0,683 0,781 15 0,867 0,590 0,800 5 0,954 0,307 0,307
WDR60 VIPR2 41 0,499 0,282 0,415 27 0,547 0,843 0,733 29 0,417 0,355 0,512 20 0,396 0,817 0,569 22 0,979 0,596 0,754 13 1,000 0,495 0,674
Yellow color indicated P-values < 0.05. Correction for multiple testing was applied for 42 for the exonic groupfile (P<0.0119) and for 37 genes
 for the protein altering groupfile (P<0.001351). No genes were significantly associated after correction for multiple testing. 
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Figure S4. Gene-burden analysis all cCSC individuals and the male cCSC cohort. Burden (blue), SKAT (green) 
and SKAT-O (purple) association results are depicted for the complete cohort of 263 cCSC patients and 1352 
controls corrected for gender and 2 principal components, using the Exonic (A) and Protein Altering (B) group 
files. The results the gene-burden test in the 208 male cCSC patients and 671 male controls, for both group 
files are also depicted (C+D). The dark horizontal line indicates the significance threshold after correction 
for multiple testing: 0.05/18,173 genes=2.75x10-6 (A), 0.05/16,370 genes=3.05x10-6 (B), 0.05/17,348 
genes=2.88x10-6 (C) and 0.05/15,083 genes=3.31x10-6 (D), while the dotted line indicates the suggestive 
threshold of P=5x10-5.
Script File S1
#Convert data to plink files and make a dummy gene list based on the variants 
in the bim files
#In the following format:
#dummygene    SNP1
#dummygene    SNP2
awk ‘{print(“dummygene””\t”$2)}’ input.bim | sort -k2 -u > SNPsets_dummy.txt
#Generate weight file based on minor allele frequency
R
library(SKAT)
#Generate the File.SSD and File.Info
Generate_SSD_SetID(“input.bed”, “input.bim”, “input.fam”, “SNPsets_dummy.
txt”, “File.SSDdummy”, “File.Infodummy”)
#read the covariate file and fam file if applicable
FAM_Cov<-Read_Plink_FAM_Cov(“input.fam”, “input_cov.txt”, Is.binary=TRUE, 
flag1=0, cov_header=TRUE)
SSD.INFOdummy<-Open_SSD(“File.SSDdummy”, “File.Infodummy”)
#Get genotype matrix of the dummy geneset
dummy_geneset<-Get_Genotypes_SSD(SSD.INFOdummy, 1, is_ID = TRUE)
weight<-Get_Logistic_Weights(dummy_geneset, par=0.07, par2=150)
weights<-data.frame(weight)
weights[,2] <- colnames(dummy_geneset)
weights = weights[, c(2,1)]
write.table(weights, file=”snp_weights.txt”, col.names=FALSE, row.names=FALSE, 
sep=”\t”, quote = FALSE)
#perform single variant association with dummy geneset dataset
#Define the covariates if applicable
Phenotype = FAM_Cov$Phenotype
PC1 = FAM_Cov$PC1
PC2 = FAM_Cov$PC2
Sex = FAM_Cov$Sex
#Run the null model
obj<-SKAT_Null_Model_MomentAdjust(Phenotype ~ PC1 + PC2 + Sex, type.
Resampling=”bootstrap.fast”)
#Run the loop through the genotype matrix and output the p-values
single_pvalue <- NULL
for(snp in colnames(dummy_geneset)){out <- SKATBinary_Single(dummy_
geneset[,snp], obj); single_pvalue <- rbind(single_pvalue, data.frame(snp, 
out$p.value, out$method.bin, out$m))}
#print the output file
write.table(single_pvalue, file=”Single_pvalue_all.txt”, col.names=TRUE, row.
names=FALSE, sep=”\t”, quote = FALSE)
#Run the burden, SKAT and SKAT-O test using the snp_weights_file.txt
Generate_SSD_SetID(“input.bed”, “input.bim”, “input.fam”, “groupfile.txt”, 
“File.SSD_groupfile”, “File.Info_groupfile”)
#read the covariate file and fam file if applicable
FAM_Cov<-Read_Plink_FAM_Cov(“input.fam”, “input_cov.txt”, Is.binary=TRUE, 
flag1=0, cov_header=TRUE)
SSD.INFO_groupfile<-Open_SSD(“File.SSD_groupfile”, “File.Info_groupfile”)
Phenotype = FAM_Cov$Phenotype
PC1 = FAM_Cov$PC1
PC2 = FAM_Cov$PC2
Sex = FAM_Cov$Sex.x
obj<-SKAT_Null_Model_MomentAdjust(Phenotype ~ Sex + PC1 + PC2, type.
Resampling=”bootstrap.fast”)
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custom_weights<-Read_SNP_WeightFile(“snp_weights.txt”)
#Burden test
out.burden<-SKATBinary.SSD.All(loaded_SSD, obj, method=”Burden”, obj.
SNPWeight=custom_weights, kernel=”linear.weighted”)
#SKAT test
out.skat<-SKATBinary.SSD.All(loaded_SSD, obj, method=”SKAT”, obj.
SNPWeight=custom_weights, kernel=”linear.weighted”)
#SKAT-O test
out.skato<-SKATBinary.SSD.All(loaded_SSD, obj, method=”SKATO”, obj.
SNPWeight=custom_weights, kernel=”linear.weighted”)
#keep only genes with more than 2 variants and perform correction for multiple 
testing
out.burden_select <- out.burden[out.burden$N.Marker.Test>1,] 
out.burden_select$FDR <- p.adjust(out.burden_select$P.value, method=”fdr”)
out.burden_select$Bonf <- p.adjust(out.burden_select$P.value, 
method=”bonferroni”)
write.table(out.burden_select, file=”burden_output_groupfile.txt”, col.
names=TRUE, row.names=FALSE, sep=”\t”, quote = FALSE)
out.skat_select <- out.skat[out.skat$N.Marker.Test>1,] 
out.skat_select$FDR <- p.adjust(out.skat_select$P.value, method=”fdr”)
out.skat_select$Bonf <- p.adjust(out.skat_select$P.value, method=”bonferroni”)
write.table(out.skat_select, file=”skat_output_groupfile.txt”, col.names=TRUE, 
row.names=FALSE, sep=”\t”, quote = FALSE)
out.skato_select <- out.skato[out.skato$N.Marker.Test>1,] 
out.skato_select$FDR <- p.adjust(out.skato_select$P.value, method=”fdr”)
out.skato_select$Bonf <- p.adjust(out.skato_select$P.value, 
method=”bonferroni”)
write.table(out.skato_select, file=”skato_output_groupfile.txt”, col.
names=TRUE, row.names=FALSE, sep=”\t”, quote = FALSE)
#plot the data in CMplot
library(CMplot)
ref_genes=read.table(“genes_location.txt”, header=T)
data_combined1 <- merge(out.burden_select[,c(1,2)], out.skat_select[,c(1,2)], 
by=”SetID”, all=TRUE)
data_combined2 <- merge(data_combined1, out.skato_select[,c(1,2)], by=”SetID”, 
all=TRUE)
data_combined3 <- merge(ref_genes, data_combined2 , by=1, no.dups=TRUE)
colnames(data_combined3) = c(“GENE”,”CHR”,”BP”,”burden”,”skat”,”skato”)
nrow(data_combined3)
#genome-wide significant line --> 0.05/nrow=pvalue_cutoff
data_combined3[is.na(data_combined3)] <- 1
CMplot(data_combined3, plot.type=”m”, multracks=TRUE, threshold=c(pvalue_
cutoff,suggestive_line),threshold.lty=c(1,2), 
    threshold.lwd=c(1,1), threshold.col=c(“black”,”grey”), amplify=TRUE,bin.
size=1e6,
    chr.den.col=NULL, signal.col=c(“red”,”green”),signal.cex=c(1,1),
    file=”pdf”,memo=”results”)
References
1. Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: Recent findings and new 
physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82-118.
2. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous 
chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology. 2008;115(1):169-
173.
3. van Dijk EHC, Schellevis RL, Breukink MB, et al. FAMILIAL CENTRAL SEROUS 
CHORIORETINOPATHY. Retina. 2017.
4. Weenink AC, Borsje RA, Oosterhuis JA. Familial chronic central serous chorioretinopathy. 
Ophthalmologica Journal international d’ophtalmologie International journal of ophthalmology 
Zeitschrift fur Augenheilkunde. 2001;215(3):183-187.
5. Miki A, Kondo N, Yanagisawa S, Bessho H, Honda S, Negi A. Common variants in the complement 
factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology. 
2014;121(5):1067-1072.
6. de Jong EK, Breukink MB, Schellevis RL, et al. Chronic central serous chorioretinopathy is 
associated with genetic variants implicated in age-related macular degeneration. Ophthalmology. 
2015;122(3):562-570.
7. Schubert C, Pryds A, Zeng S, et al. Cadherin 5 is regulated by corticosteroids and associated with 
central serous chorioretinopathy. Human mutation. 2014;35(7):859-867.
8. van Dijk EH, Schellevis RL, van Bergen MG, et al. Association of a Haplotype in the NR3C2 Gene, 
Encoding the Mineralocorticoid Receptor, With Chronic Central Serous Chorioretinopathy. 
JAMA ophthalmology. 2017.
9. Breukink MB, Schellevis RL, Boon CJ, et al. Genomic Copy Number Variations of the Complement 
Component C4B Gene Are Associated With Chronic Central Serous Chorioretinopathy. Invest 
Ophthalmol Vis Sci. 2015;56(9):5608-5613.
10. Schellevis RL, van Dijk EHC, Breukink MB, et al. Role of the Complement System in Chronic 
Central Serous Chorioretinopathy: A Genome-Wide Association Study. JAMA ophthalmology. 
2018.
11. Hosoda Y, Yoshikawa M, Miyake M, et al. CFH and VIPR2 as susceptibility loci in choroidal 
thickness and pachychoroid disease central serous chorioretinopathy. Proc Natl Acad Sci U S A. 
2018;115(24):6261-6266.
12. Lelieveld SH, Reijnders MR, Pfundt R, et al. Meta-analysis of 2,104 trios provides support for 10 
new genes for intellectual disability. Nat Neurosci. 2016;19(9):1194-1196.
13. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for 
analyzing next-generation DNA sequencing data. Genome research. 2010;20(9):1297-1303.
14. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship inference 
in genome-wide association studies. Bioinformatics. 2010;26(22):2867-2873.
15. Li H. Toward better understanding of artifacts in variant calling from high-coverage samples. 
Bioinformatics. 2014;30(20):2843-2851.
16. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental 
findings in clinical exome and genome sequencing. Genetics in medicine : official journal of the 
American College of Medical Genetics. 2013;15(7):565-574.
17. Lee S, Fuchsberger C, Kim S, Scott L. An efficient resampling method for calibrating single and 
gene-based rare variant association analysis in case-control studies. Biostatistics. 2016;17(1):1-
15.
18. Lee S, Emond MJ, Bamshad MJ, et al. Optimal unified approach for rare-variant association 
testing with application to small-sample case-control whole-exome sequencing studies. 
American journal of human genetics. 2012;91(2):224-237.
19. FIRTH D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80(1):27-38.
20. haplo.stats: statistical analysis of haplotypes with traits and covariates when linkage phase is 
ambiguous; R package version 1.7.7. https://CRAN.R-project.org/package=haplo.stats. Accessed 
June 22, 2018.
21. Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to 
human disease. Nat Rev Genet. 2011;12(10):683-691.
22. Ellegren H, Parsch J. The evolution of sex-biased genes and sex-biased gene expression. Nat Rev 
Genet. 2007;8(9):689-698.
169
3.2
23. Ober C, Loisel DA, Gilad Y. Sex-specific genetic architecture of human disease. Nat Rev Genet. 
2008;9(12):911-922.
24. Haasnoot AJW, Schilham MW, Kamphuis S, et al. Identification of an Amino Acid Motif in HLA-
DRbeta1 That Distinguishes Uveitis in Patients With Juvenile Idiopathic Arthritis. Arthritis 
Rheumatol. 2018;70(7):1155-1165.
25. Shifman S, Johannesson M, Bronstein M, et al. Genome-wide association identifies a common 
variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet. 
2008;4(2):e28.
26. Liu B, Deng T, Zhang J. RISK FACTORS FOR CENTRAL SEROUS CHORIORETINOPATHY: A 
Systematic Review and Meta-Analysis. Retina. 2016;36(1):9-19.
27. Zhao Y, Garcia J, Kolp L, Cheadle C, Rodriguez A, Vlahos NF. The impact of luteal phase support 
on gene expression of extracellular matrix protein and adhesion molecules in the human 
endometrium during the window of implantation following controlled ovarian stimulation with a 
GnRH antagonist protocol. Fertil Steril. 2010;94(6):2264-2271.
28. Ko E, Choi H, Kim B, et al. Testosterone stimulates Duox1 activity through GPRC6A in skin 
keratinocytes. J Biol Chem. 2014;289(42):28835-28845.
29. Bryan JM, Fufa TD, Bharti K, Brooks BP, Hufnagel RB, McGaughey DM. Identifying core biological 
processes distinguishing human eye tissues with precise systems-level gene expression analyses 
and weighted correlation networks. Human Molecular Genetics. 2018:ddy239.
30. Aisenbrey S, Zhang M, Bacher D, Yee J, Brunken WJ, Hunter DD. Retinal pigment epithelial 
cells synthesize laminins, including laminin 5, and adhere to them through alpha3- and alpha6-
containing integrins. Investigative ophthalmology & visual science. 2006;47(12):5537-5544.
31. Bhatt L, Groeger G, McDermott K, Cotter TG. Rod and cone photoreceptor cells produce ROS in 
response to stress in a live retinal explant system. Mol Vis. 2010;16:283-293.
32. Eisenhaber B, Sinha S, Wong WC, Eisenhaber F. Function of a membrane-embedded domain 
evolutionarily multiplied in the GPI lipid anchor pathway proteins PIG-B, PIG-M, PIG-U, PIG-W, 
PIG-V, and PIG-Z. Cell Cycle. 2018;17(7):874-880.
33. Haskamp V, Karrie S, Mingers T, et al. The radical SAM protein HemW is a heme chaperone. J Biol 
Chem. 2018;293(7):2558-2572.

171
4.1 Familial central serous chorioretinopathy
4.2 Exome sequencing in familial chronic central serous 
chorioretinopathy
4. Familial Central Serous
Chorioretinopathy
173
4.1 Familial central serous 
chorioretinopathy 
Elon H.C. van Dijk*, Rosa L. Schellevis*, Myrte B. Breukink, 
Danial Mohabati, Greet Dijkman, Jan E. E. Keunen, Suzanne 
Yzer, Anneke I. den Hollander, Carel B. Hoyng, Eiko K. de 
Jong, Camiel J.F. Boon
Retina. 2017 Nov 28.  
doi: 10.1097/IAE.0000000000001966. 
* These authors contributed equally to this study
175
4.1
Abstract
Purpose: To assess ophthalmological characteristics in patients and unaffected 
individuals in families with multiple members affected by central serous 
chorioretinopathy (CSC), both at presentation and long-term follow-up. 
Methods: In 103 subjects from 23 families, with at least 2 affected patients with 
CSC per family, prospective extensive ophthalmological examination was performed, 
including best-corrected visual acuity, indirect ophthalmoscopy, digital color 
fundus photography, optical coherence tomography, fundus autofluorescence, and 
fluorescein angiography imaging. From these, 24 individuals from 6 families had 
undergone extensive ophthalmological examination in either 1994 or 1995 and were 
followed up in this study.
Results: Subretinal fluid accumulation on optical coherence tomography and/or “hot 
spots” of leakage on fluorescein angiography indicative of CSC were detected in 45 of 
103 phenotyped subjects (44%). Findings suggestive of CSC, but without the presence 
of subretinal fluid on optical coherence tomography and/or “hot spots” of leakage on 
fluorescein angiography, were observed in an additional 27 family members (26%). In 
4 out of 17 previously non-affected subjects (24%) from the 24 individuals that were 
followed up after more than 20 years, we found more severe abnormalities.
Conclusion: Extensive ophthalmological phenotyping resulted in the detection of 
(suggestive) CSC in 52% of family members of patients with CSC. Genetic factors 
may play an important role in these specific CSC cases. Moreover, during follow-up 
progressive disease can occur in a noteworthy number of patients. 
Introduction
Central serous chorioretinopathy (CSC) is a chorioretinal disease characterized by a 
detachment of the neurosensory retina because of serous subretinal fluid (SRF). The 
disease is hypothesized to occur as a result of hyperpermeability and thickening of 
the choroid (pachychoroid), and subsequent damage to the retinal pigment epithelium 
(RPE).1-5 Exposure to exogenous corticoids is the most important risk factor for 
CSC, with odds ratios of up to 37.6-8 Genetic risk and protective factors have also 
been identified in chronic CSC, although the exact pathogenetic mechanism of 
the disease is still unclear.9-13 Single nucleotide polymorphisms (SNPs) in the age-
related maculopathy susceptibility 2 (ARMS2), complement factor H (CFH), cadherin 5 
(CDH5), and nuclear receptor subfamily 3 group C member 2 (NR3C2, mineralocorticoid 
receptor) genes, and the absence of the complement component 4B (C4B) gene have 
been associated with an increased risk for CSC in whites.10-13 The risk-conferring CFH 
association was also observed in an Asian cohort.9 In addition, the presence of three 
copies of the C4B gene and several other single nucleotide polymorphisms in the CFH 
gene were associated with a protective effect for CSC.11,13 
Familial occurrence of CSC has been described previously, but its occurrence appears 
to be rare.14-17 A recent study described a thickened choroid (>395 µm) in 50% of eyes 
from family members of patients with CSC, suggestive of an autosomal-dominant 
inheritance pattern for pachychoroid.18 A previous study in which ophthalmological 
imaging was performed in at least 2 members per family described multiple affected 
family members in 52% of 27 families and fundus lesions suggestive of CSC in 44% 
out of 80 screened unaffected relatives.15 That work, performed over 20 years ago, did 
not address whether any progression was observed in the unaffected family members 
that had suspected lesions. In our current study, through extensive ophthalmological 
imaging in newly recruited families with multiple members affected by CSC, we 
aimed to corroborate earlier observations on the occurrence of suspected lesions in 
unaffected family members. Moreover, we followed up a number of individuals with 
reported suspected lesions over 20 years ago to ascertain whether these individuals 
demonstrated any sign of progression of the disease. 
Methods
Subject selection
In this multicenter prospective cohort study, 103 subjects from 23 families including 
probands were phenotyped either at the Department of Ophthalmology of the 
Radboud university medical center ([Radboudumc] Nijmegen, the Netherlands), the 
Leiden University Medical Center ([LUMC] Leiden, the Netherlands), or the Rotterdam 
Eye Hospital (Rotterdam, the Netherlands). All patients were recruited at the outpatient 
clinic of the participating hospitals, after the proband had reported a history of having 
additional family members affected by CSC. Thirty subjects (from six families) out of 
103, were previously phenotyped at the Department of Ophthalmology of the LUMC, 
before the era of optical coherence tomography (OCT) and multimodal imaging, using 
only indirect ophthalmoscopy and fluorescein angiography (FA), and were invited for 
a long-term follow-up visit. At the previous visit, findings characteristic for CSC were 
seen in 9 subjects (30%) and a suspicion of CSC in 16 subjects (53%).15 To update and 
extend the available ophthalmological information for these patients, we were able 
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to include 24 of these 30 subjects for new imaging. Five additional new members of 
these families were also recruited and studied. Another 72 members from 17 other 
families, in which the proband reported either a possible or a confirmed CSC diagnosis 
in one or more additional family members were invited for phenotyping (Figure 1). 
In total, before ophthalmologic phenotyping for this study, in 39 subjects (30 male 
subjects and 9 female subjects) of the 23 families, the diagnosis of CSC had already 
been confirmed. Of these 39 patients, 37 patients could be phenotyped again for this 
study. Two patients with confirmed diagnosis of familial CSC could not be invited for 
new phenotyping, but were included in the analysis. Subjects were included from April 
2011 to August 2016. Written informed consent for the enrollment was obtained 
from all subjects. The study adhered to the tenets of the Declaration of Helsinki. 
Approval of the institutional review board and the ethics committee was obtained for 
all centers involved. 
Ophthalmological imaging
Subjects included in this study received an extensive ophthalmological examination. 
First, an Early Treatment of Diabetic Retinopathy Study (ETDRS) best-corrected visual 
acuity (BCVA) measurement was performed. A previously published method was used 
to convert Snellen BCVA to ETDRS BCVA, when this was not available.19 Next, pupils 
were dilated with 1% tropicamide and 5% phenylephrine. Subsequently, indirect 
ophthalmoscopy and digital color fundus photography (Topcon Corp., Tokyo, Japan) 
Families = 6
Subjects with old imaging = 30
Known families
Families = 6
Subjects with old and new imaging = 24
Subjects with only old imaging* = 6
Subjects without imaging* = 4
Newly included subjects = 5
Families = 17
Subjects with new imaging = 72
Families = 23
Subjects =103
New families
Previously diagnosed CSC: 
new imaging = 37
Family
members = 64
Newly diagnosed
CSC = 6
Suggestive
CSC = 27
Unaffected 
= 31
Previously diagnosed CSC: 
only old imaging = 2
Figure 1: Outline of selection of patients with CSC who underwent ophthalmologic phenotyping. *Family 
members who were excluded for ophthalmologic analysis, except for the two family members in whom CSC had 
been previously diagnosed.
were performed. Using the spectral-domain OCT device (SPECTRALIS HRA+OCT; 
Heidelberg Engineering, Dublin, CA), regular OCT, enhanced depth imaging (EDI) 
OCT, fundus autofluorescence (FAF), and FA images were obtained. Fluorescein 
angiography imaging was performed at 10, 15, 20, 25, and 30 minutes after oral 
administration of 10 ml of 20% fluorescein, after a subject had fasted for at least 
3 hours. When treatment or follow-up was necessary on the basis of the obtained 
images, subjects were invited for a regular visit to the outpatient clinic. An experienced 
retina specialist (C.J.F.B.) assessed the obtained images in a masked manner. 
Subjects were categorized as having CSC when serous SRF could be detected on OCT 
and when ≥1 “hot spot” of leakage or diffuse leakage in combination with irregular 
RPE window defects was present on FA. No signs of either polypoidal choroidal 
vasculopathy or age-related macular degeneration, or other atypical findings could be 
present. In subjects who could not be reinvited for phenotyping and for whom OCT 
images were not available, a description of a serous neurosensory detachment on 
ophthalmoscopy in combination with FA abnormalities was considered confirmative 
for the diagnosis of CSC. Based on multimodal imaging, a diagnosis of a clinical picture 
suggestive of a CSC background (suggestive CSC) could be established in subjects 
who did show RPE abnormalities either typical for CSC without SRF on OCT or typical 
for pachychoroid pigment epitheliopathy.5 
Choroidal thickness (CT) was defined as the distance from the outer part of the 
hyperreflective RPE layer to the hyperreflective line of the inner surface of the 
sclera, and was assessed manually using the caliper tool provided by the SPECTRALIS 
HRA+OCT machine in subjects for whom EDI-OCT was available. Subjects with a CT 
of >395 µm were considered to have pachychoroid.18 
Statistical analysis
Statistical analyses were performed in IBM SPSS Statistics, version 23.0 (IBM Corp., 
Armonk, NY) and GraphPad Prism, version 5.03 (GraphPad Software Inc., La Jolla, 
CA). The distribution of the ETDRS BCVA and CT values of affected and unaffected 
eyes, and eyes in which suggestive CSC was found at moment of diagnosis were 
analyzed with the D’Agostino-Pearson omnibus normality test. Non-parametric 
tests were used for further analysis, when at least 1 of the compared groups was 
Table 1. Clinical characteristics of different subgroups
 
Known CSC New CSC
Suspected 
CSC
Un-affected Total
No. of patients 39 6 27 31 103
% Males 77 50 44 42 56
Mean age ± SD (years) 49 ± 12 48 ± 15 53 ± 9 52 ± 11 51 ± 11
History of cardiovascular diseases, % 41 50 52 36 43
History of depression, % 8 0 0 0 3
Hypertension, % 36 33 44 23 34
Steroid use <1 year diagnosis (%) 4/39 (10) 0 5/27 (18) 7/31 (23) 16/103 (16)
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not normally distributed. The CT values of affected and unaffected eyes, and eyes 
with suggestive CSC at moment of diagnosis were compared using a Kruskal-Wallis 
test with Dunn’s post-hoc comparison adjustment. ETDRS BCVA of affected eyes at 
moment of diagnosis and at follow-up was compared using Wilcoxon’s matched-pairs 
signed-rank test. P values <0.05 were considered to be statistically significant.
Results
In total, 23 families with multiple individuals diagnosed with CSC were included 
in this study, resulting in the inclusion of 103 subjects (Figure 1). This included 39 
previously diagnosed CSC patients and 64 undiagnosed family members, who were 
extensively phenotyped. Families were of variable size, with a range of 2 to 10 family 
members participating in the study (Figure 2 and Supplementary Figure 1). In 6 
families (26%), CSC could be diagnosed in multiple generations, with a father-to-son 
transmission in three families. Reduced penetrance seemed to be present in 2 families 
(Supplementary Figure 1 P and W), and possible maternal transmission was found in 
one family (Supplementary Figure 1O).
Characteristics of previously diagnosed CSC patients
Thirty-nine patients (30 men and 9 women), who were previously diagnosed with 
CSC, were phenotyped in this study. The age at diagnosis of these patients was 49 
± 12 years (Table 1). The median ETDRS BCVA of the 63 affected eyes at diagnosis 
was 80 letters (Snellen equivalent: 20/25; Q1:70-Q3:85) and 85 (Snellen equivalent: 
20/20; Q1:81-Q3:89) in the 15 unaffected eyes. The median ETDRS BCVA of the 56 
affected eyes, for which new ophthalmological phenotyping could be performed after 
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Figure 2: Pedigrees of two CSC families (A and B) with multiple affected family members. All family members 
were phenotyped again for this study with the exception of the individuals indicated with NNI (no new images).
a median follow-up of 38 months (Q1:11-Q3:160), was 80 letters (Snellen equivalent: 
20/25; Q1:68-Q3:85) and 84 (Snellen equivalent: 20/21; Q1:78-Q3:89) in the 12 
unaffected eyes, which did not differ from the ETDRS BCVA at the moment of CSC 
diagnosis.
In 14 of the 39 patients (36%), a history of hypertension was present and in a total 
of 16 patients (41%), cardiovascular diseases had been previously diagnosed. Three 
patients were clinically diagnosed with depression. One patient was diagnosed with 
Cushing disease after she had presented with CSC and three patients were previously 
known with amblyopia. A total of four patients (10%) reported steroid use within 
a year before the first diagnosis of CSC, out of whom three patients had received 
a renal transplant, for which low-dose steroids were prescribed at the moment of 
ophthalmological phenotyping.
Of the 39 patients, 23 had previously received treatment in a total of 27 eyes: 18 
eyes received photodynamic therapy, 11 eyes underwent high-density subthreshold 
micropulse laser, and 6 eyes were treated with focal thermal laser. In eight other eyes of 
seven patients, intravitreal injections with either bevacizumab (7 eyes) or ranibizumab 
(1 eye) were performed because of either the suspicion or the presence of a choroidal 
neovascularization. Of these eight eyes, two eyes of two different patients exclusively 
received intravitreal anti-vascular endothelial growth factor injections, after which 
SRF disappeared in one eye. 
The remaining six eyes also received other types of treatment, after which SRF 
leakage disappeared in five eyes (83%). Thirteen eyes had received treatment with a 
single treatment modality, which lead to complete resolution of SRF in 8 eyes (62%), 
whereas 14 eyes were treated with multiple treatment modalities, leading to an
Table 2. Performed treatments for central serous chorioretinopathy and outcome of these treatments, in 23 
treated probands
Type of treatment(s) No. of patients No. of eyes
No SRF (leakage) 
at final follow-up
Treatment with one treatment modality 13 13 8/13 (62%)
Focal thermal laser 2 2 2/2 (100%)
HSML 4 4 2/4 (50%)
Intravitreal bevacizumab injections 2 2 1/2 (50%)
PDT 5 5 3/5 (60%)
Treatment with multiple treatment modalities 14 14 10/14 (71%)
Focal thermal laser + intravitreal bevacizumab 
injections + PDT
1 1 1/1 (100%)
Focal thermal laser + intravitreal bevacizumab 
injections
1 1 0/1 (0%)
Focal thermal laser + PDT 2 2 2/2 (100%)
HSML + PDT 6 6 4/6 (67%)
HSML + intravitreal ranibizumab injections + PDT 1 1 0/1 (0%)
Intravitreal bevazumab injections + PDT 2 3 3/3 (100%)
HSML, high-density subthreshold micropulse laser; PDT: photodynamic therapy
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Figure 3: Spectrum of observed phenotypes in previously diagnosed patients with central serous chorioretinop-
athy. A-D. Multimodal imaging of the right eye of a 40-year-old female patient with unilateral chronic CSC. 
On intravenous FA (A), some hyperfluorescent changes, but no clear “hot spot” of leakage could be detected. 
Indocyanine green angiography (B) showed areas of hyperfluorescent changes, which were larger compared to 
changes on FA. Fundus autofluorescence (C) imaging revealed hyperautofluorescent changes in the fovea. The 
EDI-OCT (D) scan showed a foveal accumulation of SRF, with the presence of debris within the SRF. Moreover, 
dilated Haller vessels (pachyvessels) were present, and the subfoveal CT was 513 µm. E-H. Multimodal imaging 
of the left eye of a 55-year old male patient with unilateral chronic CSC. Intravenous FA (E) revealed foveal 
hyperfluorescent changes with a “hot spot” of leakage. Indocyanine green angiography imaging (F) showed 
diffuse zones of hyperfluorescent changes, without signs of either polypoidal choroidal vasculopathy or a cho-
roidal neovascularisation. On FAF (G), mostly hypoautofluorescent changes were present foveally. On EDI-OCT 
(H), a foveal SRF accumulation and pachyvessels could be detected. Subfoveal CT was 420 µm.I-L. Multimodal 
imaging of the right eye of a 76-year-old male patient with bilateral chronic CSC. Oral FA (I) revealed multiple 
hyperfluorescent areas, with a possible “hot spot” of leakage nasally of the fovea (arrow). Fundus photography 
(J) showed multiple areas of alterations of the RPE. On FAF (K), both hyperautofluorescent and hypoautofluores-
cent changes were present. On EDI-OCT (L), SRF could be observed nasally of the fovea. A large pachyvessel 
could be found below the area of leakage on FA. Subfoveal CT was 245 µm, at that moment. 
absence of SRF in 10 eyes (71%). The performed treatments and outcome of these 
treatments have been summarized in Table 2.
A wide range of phenotypical characteristics typical for CSC could be detected on 
multimodal imaging of the 39 previously diagnosed CSC patients (Figure 3). Either 
bilateral SRF on OCT or bilateral “hot spots” of leakage on FA was detected in 24 
patients (62%). Until the moment of phenotyping for this study, a recurrence of 
SRF leakage had appeared in 15 patients (38%). On multimodal imaging, a unilateral 
epiretinal membrane could be observed in two patients, choroidal folds were found 
in both eyes of one patient, and cuticular drusen were observed bilaterally in another 
patient. Median CT in all 48 eyes of 25 patients, for whom EDI-OCT was available, 
was 323 µm (Q1: 275.5-Q3:365.5). Median CT in the 38 affected eyes was 325 
µm (Q1:279-Q3:361), whereas median CT in the 10 unaffected eyes was 287 µm 
(Q1:247-Q3:372). Pachychoroid could be detected in 6 eyes of 5 patients.
Phenotyping of family members
Sixty-four family members (28 men and 36 women), in whom no previous CSC was 
diagnosed, were phenotyped for this study. Medical history of these subjects revealed 
hypertension in 22 subjects (34%) and other cardiovascular diseases in 9 other 
subjects (14%; total 48%). One subject had received two panretinal laser treatments 
because of a central retinal artery occlusion with secondary ischemia. Twelve of these 
screened family members (19%) reported steroid use within a year before screening. 
No link of the outcome of phenotyping with either steroid use or medical history 
could be detected.
Based on serous SRF on OCT and corresponding abnormalities on multimodal 
imaging, six screened family members (9%) were diagnosed with CSC. Mean age at 
diagnosis of these 3 men and 3 women was 48 ± 15 years (Table 1) and median ETDRS 
BCVA was 84 letters (Snellen equivalent: 20/21; Q1:80-Q3:85) in the 7 affected eyes 
and 85 (Snellen equivalent: 20/20; Q1:71-Q3:89) in the 5 unaffected eyes (Table 
3). Moreover, multimodal imaging showed RPE changes suggestive of CSC in 27 
screened subjects (42%). The mean age at diagnosis was 53 ± 9 years for these 27 
suggestive CSC subjects, and 44% of these subjects were male (Table 1). 
The extent of RPE changes on fundus photography and corresponding either 
hyperfluorescent or hypofluorescent changes on FAF imaging in suggestive CSC 
patients were variable. Abnormalities on FA ranged from subtle hyperfluorescent 
RPE changes to diffuse areas of hyperfluorescence, but without the presence of SRF 
leakage (Figure 4). On OCT, either subtle or obvious RPE alterations were present, 
but without SRF (Figure 4). Choroidal thickness was variable among the suggestive 
patients with CSC, but in only one of these patients bilateral pachychoroid was 
present. 
Within the group of screened family members without a previous history of CSC, 
multimodal imaging revealed bilateral cuticular drusen in two subjects, bilateral 
choroidal folds in two subjects, a unilateral macular epiretinal membrane in three 
subjects, a macular cystoid lesion in one eye, a lamellar macular hole in one eye, and 
findings characteristic of a previous vascular occlusion in one eye.
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Choroidal thickness in affected and suspected patients and unaffected 
individuals
Choroidal thickness data of CSC affected, CSC suggestive, and unaffected eyes in the 
three subgroups were combined (Table 3). Choroidal thickness measurements on EDI-
OCT images of 44 affected eyes of patients in whom CSC had been diagnosed showed 
a median subfoveal CT of 325 µm (Q1:282-Q3:360), wheareas 41 eyes of suggestive 
CSC patients with both detected abnormalities and available EDI-OCTs, had a median 
CT of 272 µm (Q1:237-Q3:337), and the 84 unaffected eyes showed a CT of 280 
µm (Q1:240-Q3:335). There was a significant difference in CT between affected and 
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Figure 4: Spectrum of observed phenotypes in family members of patients with CSC. Various phenotypes resem-
bling CSC were observed in family members of patients with CSC. A-C. Multimodal imaging of the right eye 
of a 61-year-old female patient. On oral FA (A) and FAF (B) imaging, subtle hyper (auto) fluorescent changes 
suggestive of CSC could be detected inferior of the fovea. Moreover, OCT (C) showed subtle RPE abnormalities, 
and a subfoveal CT of 247 µm. Similar hyperfluorescent lesions on FA and FAF could be detected in the left eye 
of this patient. D-F. Multimodal imaging of the left eye of a 60-year-old female patient. On oral FA (D) diffuse 
areas of hyperfluorescence were found without an obvious “hot spot” of leakage, which was considered to be 
suggestive of CSC. Both hyperautofluorescent and hypoautofluorescent changes were present on FAF (E), with 
an area of likely prior SRF superiorly. On OCT (F), a detachment of the RPE could be detected temporally of 
the fovea, without the presence of serous SRF. Subfoveal CT was 400 µm in this eye, and dilated Haller layer 
(pachyvessels) and bilateral choroidal folds were also present in this patient. G-I. Multimodal imaging of the 
right eye of a 60-year-old female patient. On oral FA (G), a characteristic “hot spot” of leakage superonasally of 
the fovea could be detected, with a surrounding area of hyper (auto) fluorescence on FA and FAF (H). On OCT 
(I), unilateral SRF could be detected superonasally of the fovea. A pachyvessel was present below the SRF, and 
the subfoveal CT in this eye was 528 µm.
both the unaffected and suggestive CSC eyes (P < 0.05). No significant difference was 
found between unaffected and suggestive CSC eyes (Table 3). Pachychoroid could 
be detected in 18 eyes in 12 family members in both the affected (6 patients, eight 
eyes), suggestive CSC (2 patients, four eyes), and unaffected (4 family members, six 
eyes) subgroups.
Follow-up of individuals who received ophthalmological phenotyping in 1994-
1995
Out of the 30 patients who were previously phenotyped at the Department of 
Ophthalmology of the LUMC,15 24 patients could be included for new imaging, which 
was performed at a median follow-up of 20.8 years (Q1: 20.7-Q3:21.2) after the 
original phenotyping. In 7 out of these 24 patients, the CSC diagnosis had already 
been established at baseline. In 4 of the remaining 17 patients (24%), the outcome of 
new phenotyping led to a diagnosis of more severe abnormalities. Namely, 2 patients 
out of 13 patients (15%) in whom RPE alterations were previously observed proved 
to have active CSC at the moment of new imaging. Moreover, in one out of four 
previously non-affected subjects (25%), findings suggestive of CSC were found during 
our phenotyping, and in another nonaffected subject (25%), active CSC was found.
Discussion
Based on the results of this extensive phenotyping, occurrence of CSC and RPE 
abnormalities suggestive of CSC appears to be relatively common in families with 
CSC. Family members of patients with CSC could therefore be at risk to develop CSC. 
Within this study, SRF on OCT and/or “hot spots” of leakage on FA could be detected 
in 45 of the 103 included subjects (44%) and a CSC suspicion in 27 others (26%). 
In 31 subjects (30%), no signs of CSC were present. The 45 individuals affected by 
CSC included 6 previously undiagnosed family members of diagnosed CSC patients. 
Moreover, in 24% of patients who were invited for a long-term follow-up visit after 
phenotyping more than 2 decades ago, either progression or new occurrence of CSC 
could be detected.
Active CSC was found only in a minority of patients in whom findings characteristic 
for CSC could be detected during ophthalmological screening. Based on the outcome 
of current ophthalmological screening, none of the screened patients in whom 
CSC was newly diagnosed required treatment for active CSC. In this study, the 
range of ophthalmological abnormalities in subjects who were diagnosed as having 
suggestive CSC was wide (Figure 4) and the clinical relevance of RPE abnormalities 
suggestive of CSC remains to be elucidated because similar findings have been 
described not to be present in healthy controls.20 Therefore, the exact relevance of 
the suggestive CSC diagnosis is unclear, as is the exact overlap between suggestive 
CSC and CSC.5 The diagnosis of suggestive CSC has features similar to the previously 
describedpachychoroid pigment epitheliopathy, for which either unilateral or 
bilateral reduced fundus tessellation with overlying RPE changes on fundoscopy and 
abnormalities on FAF have been described.5 However, in contrast with pachychoroid 
pigment epitheliopathy, an increased subfoveal CT was not seen in all patients with 
suggestive CSC.5 In this study, either unilateral or bilateral pachychoroid could be 
detected in only 6 of the 61 screened family members (10%), for whom EDI-OCT 
imaging was available. Pachychoroid, using a CT cut-off point of 395 µm, occurred 
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Table 3. Ophthalmologic characteristics of different subgroups
 Known CSC New CSC
Suggestive 
CSC
Unaffected Total
Affected subjects 39 6 27 31 103
Amblyopia 3 - 1 1 5
Bilateral choroidal folds 1 1 1 - 3
Bilateral cuticular drusen 1 - 2 - 3
Central retinal artery occlusion - - 1 - 1
Glaucoma 1 - - - 1
Ocular hypertension 1 1 - - 2
Unilateral epiretinal membrane 2 1 2 - 5
Unaffected eyes
No. of eyes with available 
BCVA/CT
15/10 5/4 10/10x 62/60 92/84
Median BCVA (ETDRS) (Q1-
Q3)
85 (81-89) 85 (71-89) 87 (73-90) 89 (82-91) 88 (81-90)
Median BCVA (Snellen equi-
valent)
20/20 20/20 20/18 20/17 20/17
Median CT in µm (Q1-Q3)
287
(247-372)
339
(268-386)
270
(252-332)
277
(227-334)
280
(240-335)
Suspected eyes
No. of eyes with available 
BCVA/CT
- - 43/41 - 43/41
Median BCVA (ETDRS) (Q1-
Q3)
- - 89 (85-91) -
89
(85-91)ns
Median BCVA (Snellen equi-
valent)
- - 20/17 - 20/17
Median CT in µm (Q1-Q3) - -
272
(237-337)
-
272
(237-337)ns
Affected eyes
No. of eyes with available 
BCVA/CT
63/38 7/6 - - 70/44
Median BCVA (ETDRS) (Q1-
Q3)
80 (70-85) 84 (80-85) - -
80
(70-85)**
Median BCVA (Snellen equi-
valent)
20/25 20/21 - - 20/25
Median CT in µm (Q1-Q3)
325
(279-361)
320
(296-376)
- -
325
(282-360)*
ns: non-significant compared to unaffected eyes
x: one eye was excluded due to poor visual acuity after a central retinal artery occlusion 
**P value compared with unaffected eyes: < 0.001
* P value compared with unaffected eyes: < 0.05
both in CSC affected, CSC suggestive, and unaffected screened family members.18 
Nevertheless, the CT of affected eyes of patients with CSC was significantly higher 
compared to all eyes of unaffected individuals (Supplementary Figure 2). More recently, 
both the maximal CT and pathologically dilated outer choroidal vessels (in the Haller 
layer) have been described to be even more typical than CT for various diseases within 
the pachychoroid spectrum including pachychoroid pigment epitheliopathy, CSC, and 
pachychoroid neovasculopathy.21,22 These abnormalities in the choroid, together with 
a loss in choriocapillary volume, could also be found in our patients (Figures 3 and 4), 
addressing the importance of the previously reported pachychoroid spectrum.5,21,22
The underlying pathogenesis of familial clustering of CSC and CSC-like RPE 
abnormalities remains obscure. Age at CSC diagnosis, sex, steroid use, response to 
different CSC treatments, medical history, and presence of choroidal neovascularisation 
do not differ when comparing the current familial CSC cohort with the occurrence 
of these factors in previously described nonfamilial CSC patient cohorts.1-3,23-26 This 
leads to a challenge in recognizing family members who may be at risk for developing 
active CSC because we did not find phenotypic characteristics in the probands that 
could be indicative of a familial occurrence of CSC. However, both the percentage of 
recurrent and/or bilateral CSC among the probands in the CSC families in our study 
was relatively high, compared with sporadic CSC patients in available literature.27 The 
presence of these signs of a relatively severe CSC could lead to a higher risk for family 
members to develop CSC.
Central serous chorioretinopathy is believed to be a complex, multifactorial disease, 
in which both environmental and genetic factors play a role, and its inheritance 
pattern is currently unknown. In the current study, most of the affected family 
members involved sibships, but in some families, CSC could be detected in several 
generations. In most families, the mode of inheritance appears to be autosomal 
dominant (Supplementary Figure 1). The possible autosomal-dominant inheritance 
pattern is in line with a recent study on the familial occurrence of pachychoroid, in 
which this pattern has been suggested.18 However, the lack of large families with data 
from multiple generations could lead to an unreliable determination of the inheritance 
pattern. Ophthalmologic phenotyping in multiple generations was only performed 
when members of the younger generation reported a possible history of CSC or were 
within the expected age range to develop CSC. Our findings could, therefore, be an 
underestimation of the actual occurrence of clinical findings characteristic for CSC in 
multiple generations. 
Based on the familial occurrence of CSC, it has already been suggested that genetic 
factors might play an important role in CSC. This hypothesis is supported by studies 
on common genetic variants (single nucleotide polymorphisms) that have previously 
been associated with sporadic CSC.9-11 Single nucleotide polymorphisms in the 
ARMS2, CDH5, and CFH genes and copy number variations in the C4B gene involved 
in extracellular matrix, cell adhesion, and complement system, respectively, have 
already been associated with CSC.9-11 The detection of (suggestive) CSC in 52% of 
family members of CSC patients reported in this study may indicate that there is also 
a role for more severe rare genetic variants in CSC. This has already been described 
in families with age-related macular degeneration, a disease that shows overlapping 
features with CSC.28 
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In conclusion, CSC and lesions that could be predisposing to CSC can cluster in 
families, which may indicate that family members of CSC patients are at risk to 
develop the disease. However, many of these individuals may remain asymptomatic. 
During a follow-up at which multimodal imaging is performed, progression of disease 
can occur in a noteworthy number of patients. Comparing next generation genetic 
sequencing data of both affected and unaffected family members, ideally from multiple 
generations, may shed a light on which genetic factors are involved in familial CSC. In 
future studies, a combination of extensive phenotyping and in-depth genotyping can 
provide new clues on the etiology of CSC.
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Brief summary statement: In a noteworthy percentage of family members of patients 
with central serous chorioretinopathy findings characteristics for this disease can 
be detected. During follow-up central serous chorioretinopathy developed in some 
individuals that were previously unaffected, suggesting a higher risk for this disease 
for family members of an affected proband.
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Supplementary Files
Supplementary Figure 1. Pedigrees of the families who have been invited for ophthalmological phenotyping
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Supplementary Figure 2: Measurement of choroidal thickness in unaffected, central serous chorioretinopathy 
suggestive, and affected eyes. Medians with interquartile range are depicted in red.
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Abstract
Central serous chorioretinopathy (CSC) is a chorioretinal disease characterized by 
fluid accumulation between the neuroretina and retinal pigment epithelium with 
unknown etiology. Family studies have suggested that CSC might be an inherited 
disease with an autosomal dominant inheritance pattern. We therefore performed 
exome sequencing on 72 individuals of 18 families with CSC, and determined whether 
rare genetic variants (minor allele frequency <1%) segregated in two or more families 
with CSC. In addition, familial gene-burden analysis was performed and compared 
to gene-based results of an exome sequencing study on a large sporadic CSC case-
control cohort. In total, 11 variants were found to segregate in two out of 18 families. 
One of these variants, c.4145C>T; p.T1382I (rs61758735) in the PTPRB gene, was 
also associated with CSC in the case-control cohort (P=0.008965). Additionally, in 28 
genes two or more different heterozygous variants were found to segregate in two 
or more families, but none of these genes showed consistent associations in both the 
family gene-burden results and gene-burden analysis in the case-control cohort. In this 
study, we identified possible candidate genes for familial CSC. However, Mendelian 
inheritance of variants in one or a limited number of genes can be excluded based on 
this study. Instead, familial CSC may be a heterogeneous Mendelian disease caused 
by variants in many different genes, or alternatively CSC may represent a complex 
disease to which both environmental factors and genetics contribute.
Introduction
In central serous chorioretinopathy (CSC), choroidal congestion, thickening, and 
hyperpermeability have been suggested to cause leakage through the retinal pigment 
epithelium (RPE). Subsequently, a neuroretinal detachment occurs due to the 
accumulation of serous subretinal fluid.1-5 The exact etiology of CSC is still unclear, 
but male gender, administration of exogenous corticoids have been described to be 
the most pronounced risk factors for CSC.6-8 Other risk factors include endogenous 
hypercortisolism, stress and pregnancy.2,9,10 Moreover, genetic variants that confer 
risk or are protective for CSC have been identified by genetic association studies in 
case-control cohorts.11-16
Although familial occurrence of CSC appears to be rare, several reports on familial 
CSC and the occurrence of CSC in multiple generations within a single family have 
been published, pointing to a potential role for genetic factors in familial CSC.17-20 A 
Mendelian inheritance of CSC has been proposed previously based on observations 
that at least two family members proved to have findings characteristic for CSC in 
52% of 27 families.18 In some families affected individuals were present in multiple 
generations, suggesting an autosomal dominant mode of inheritance of familial 
CSC.20 Additionally, in 50% of eyes from screened family members of CSC patients a 
thickened choroid (pachychoroid) of more than 395µm was detected, which has been 
described to be the underlying choroidal abnormality in various diseases that are part 
of the pachychoroid spectrum.21 However, thus far no genetic studies on familial CSC 
have been conducted. 
Whole exome sequencing has proven to be a powerful tool to identify novel disease-
associated genes and gene variants in many disorders.22,23 Exons are presumed to 
harbor about 85% of disease-causing mutations, making them a primary target to 
search for disease-associated variants in CSC families.24 Therefore in this study, we 
performed exome sequencing on 72 individuals of 18 families in which multiple 
members were found to have CSC, in order to determine whether Mendelian 
inheritance of rare genetic variants causes familial CSC. 
Materials and methods
Editorial Policies and Ethical Considerations
Written informed consent for the enrollment was obtained from all subjects. The study 
adhered to the tenets of the Declaration of Helsinki. Approval of the institutional 
review board and the ethics committee was obtained for all centers involved. 
Subject selection
In this multicenter study, 72 subjects from 18 families, including patients with CSC and 
unaffected family members, visited either the Department of Ophthalmology of the 
Radboud university medical center ([Radboudumc] Nijmegen, the Netherlands) or the 
Leiden University Medical Center ([LUMC] Leiden, the Netherlands). The participants 
were recruited at the outpatient clinic of the participating hospitals, after the proband 
had reported a family history of CSC. The majority of the individuals were included in 
our previously published study on the phenotypic characteristics of familial CSC and 
were divided in the following groups: “Affected with CSC”, “Suggestive of CSC” or 
“Unaffected”, using the criteria described before.20 
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Briefly, subjects were categorized as having CSC when serous fluid was detected on 
OCT and when one or more ‘hot spots’ of leakage or diffuse leakage was present in 
combination with irregular RPE window defects on fluorescein angiography. Patients 
were excluded if signs of either polypoidal choroidal vasculopathy or age-related 
macular degeneration (AMD), or other atypical findings were present. Suggestive 
CSC was characterized by RPE alterations typical for CSC, but without the presence 
of either subretinal fluid or ’hot spots’ of leakage on fluorescein angiography.20 
Unaffected individuals showed no abnormalities on any of the modalities using 
multimodal imaging. 
Exome sequencing
Library preparation of the 52 family members of 12 families collected at the 
Radboudumc, Nijmegen, was performed with the SureSelectXT target enrichment 
system for Illumina paired-end multiplex sequencing according to manufacturer’s 
instructions (Version B4, August 2015, Agilent Technologies). Finished libraries 
were sent to the Department of Genetics of Maastricht University Medical Center+, 
Maastricht, the Netherlands, where sequencing was performed with 8 samples per 
lane using an Illumina HiSeq2000 with 2*100bp chemistry, together with a large 
cohort of 269 sporadic CSC patients (Schellevis et al. 2018 submitted).
The 20 samples of the 6 families collected in Leiden University Medical Center, 
Leiden, the Netherlands were sent to GenomeScan BV, Leiden, for sequencing. For 
these samples the Agilent SureSelect V5 enrichment kit was used and sequencing 
was performed with 2*125bp chemistry on the HiSeq2500. 
Variant calling and recalibration
Data of all individuals were processed according to the Genome-Analysis-Toolkit 
(GATK) best practices (v3.8) together with the case-control cohort consisting of 269 
sporadic cCSC patients and 1586 population controls (Schellevis et al. 2018 submitted) 
to improve variant calling. Briefly, BAM to FastQC extraction was performed with 
Picard-tools (v 1.90), duplicate reads were marked with Picard-tools, and reads were 
aligned to the reference genome (GRCh37.p5 with alternate haplotypes excluded) 
using BWA-MEM (version v.0.7.12), as described before (Schellevis et al. 2018 
submitted). Base recalibration was performed and subsequent variant calling was 
performed with the HaplotypeCaller algorithm. All GVCFs were merged together, and 
joint genotyping was performed on the dataset together. 
Variant recalibration was performed on the entire dataset with GATK using the 
recommended settings,25 as described before. Genetic variants located in low complexity 
regions of the genome were removed.26 Multiallelic variants were extracted with 
VCFtools (v0.1.13) and split using the splitMultiallelic and LeftAlignandTrimVariants 
option in GATK (v3.8). Remaining variants were tested for Hardy-Weinberg equilibrium 
(P=1x10-8). Variants from the adult-onset genes captured in the American College of 
Medical Genetics and Genomics recommendations for incidental findings (BRCA1, 
BRCA2, MLH1, MSH2, MSH6, PMS2, MUTYH) were removed to reduce the risk of 
secondary findings.27,28 Finally, family members were extracted from the dataset and 
only variants with a minor allele count ≥ 1 in the combined family file were retained. 
Data was annotated with Tabanno (https://github.com/zhanxw/anno) and Annovar.29
Variant filtering
Variants were filtered based on a minor allele frequency (MAF) of ≤1% or ≥99% in 
the following populations: 1000Genomes_all, 1000Genomes_European, Exac_All, 
Exac_NFE, Exac_FIN, and esp6500siv2_all. Additionally, variants with MAF ≥1% in 
the 1586 controls of the sporadic CSC case-control cohort were removed. Variants 
that were annotated by Annovar to be present in the exonic or splice site regions 
were retained and synonymous variants were excluded. Remaining variants included: 
frameshift insertions and deletions (INDELs), nonframeshift INDELs, nonsynonymous 
variants, stop gain or loss variants, and variants with unknown effects. All variants 
present in one or more unaffected individuals in any of the families were removed, 
with the exception of the unaffected individual of Family 14, because based on the 
pedigree structure (Supplementary Figure 1) reduced penetrance appeared to be 
present in this family. Only variants with a CADD score above 20, corresponding to 
the 1% most deleterious variants of the human genome, or with an unknown CADD 
score in case of INDELs, were retained. 
Next, for each family segregation analysis of variants was performed, where variants 
were retained if they were present in all affected individuals of the family and not 
present in unaffected individuals. No filtering was performed for individuals with 
suggestive CSC. Variants that segregated in two or more families, or genes that 
contained multiple variants that segregated in two or more families were retained for 
further evaluation. Familial gene-burden associations were calculated with RareIBD 
Figure 1: Segregation analysis of rs61758735G>A in PTPRB for Family 1 and Family 2. Genotypes for 
rs61758735 are depicted below each individual in the pedigree. Individuals whom were sent in for exome 
sequencing are indicated with a blue arrow, while other individuals for which DNA was available were sent 
in for Sanger sequencing. Individual BIIB did not want to participate in the study, and therefore could not be 
sequenced.
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for those genes that carried multiple segregating variants in two or more families.30 
The region encompassing the c.4145C>T; p.T1382I (rs61758735) variant in the 
PTPRB gene was amplified in additional family members of Family 1 using AmpliTaq 
DNA polymerase with the following PCR program: 5 min. at 95°C, 10 cycles of 
touchdown starting at 62°C for 45 sec. and lowering the annealing temperature 
0.5°C each cycle, followed by 25 cycles of an annealing temperature of 57°C, all 
these cycles started with 30 sec. at 95°C and ended 45 sec. at 72°C. The PCR was 
concluded with 5 min. at 72°C and the following primers were used forward primer: 
AGCCTTTGAGCAGCTTTTTC and reverse primer: TGATGCTAGTGCCCCATAAG. The 
PCR product was analyzed by Sanger sequencing by the core sequencing facility at 
the Department of Human Genetics of the Radboudumc.
Results 
In this exome sequencing study on familial CSC we included 72 individuals from 18 
different families. Out of these 72 individuals, 33 subjects were affected with CSC, 18 
had characteristics suggestive of CSC, and 21 were unaffected (Table 1, Figure 1 and 
Supplementary Figure 1 for pedigrees). After variant filtering based on MAF (≤1%), 
CADD score (≥20), absence in unaffected individuals, and protein-altering function 
(frameshift INDELs, nonframeshift INDELs, nonsynonymous, stop gain/loss variants 
and variants with unknown effects), the dataset contained 2806 variants present in 
2368 genes. 
Segregation analysis was performed for all 18 families, retaining only variants that 
were present in the affected individuals and absent in unaffected individuals. The 
average number of segregating variants in each family was 44 and ranged from three 
to 124 (Table 1). In four families two segregating heterozygous rare variants in the 
same gene were observed. Family 12 carried two variants in KCNMA1, Family 7 in 
RBPJL, Family 8 in SLC26A10, and Family 1 in SP9 (Supplementary Table 1). The entire 
list of segregating variants for each family is available in Supplementary Table 2. 
Variants that segregated in two or more families were retained for further evaluation. 
In total, 11 rare variants were found to segregate in two families, of which one variant 
in the PTPRB gene was found homozygous in one individual, while the remaining 
variants in the SETD2, PWP1, ABCA9, AT2B2, ZFAND4, MROH5, ZAN, SHISA6, DCP1A, 
and PPM1E genes were heterozygous (Table 2). Expression of these genes in the 
retina and RPE was evaluated using the Eye Integration Database (Supplementary 
Figure 1).31 The single variant association results of these variants were extracted 
from the sporadic CSC case-control dataset (Schellevis et al. 2018 submitted), and 
the variant in the PTPRB gene (c.4145C>T; p.T1382I, rs61758735) was significantly 
associated with CSC in the case-control cohort (P=0.008965, Odds Ratio=2.83, 95% 
Confidence Interval=1.34-5.97). Extended segregating analysis of the PTPRB variant 
in additional available family members of Family 1 revealed that two individuals carried 
the variant homozygously (one individual is an affected subject and one is a subject 
with findings suggestive of CSC), six individuals carried the variant heterozygously 
(two affected individuals, two individuals with findings suggestive of CSC, and two 
unaffected individuals) and one individual did not carry the variant (this individual had 
characteristics suggestive of CSC) (Figure 1A). Since two unaffected individuals (of 
which one individual was 74 years at examination) carried the variant heterozygously, 
complete segregation of this variant with the disease in this family was not observed. 
For Family 2 no additional individuals were available for extended segregation analysis 
(Figure 1B). 
As a next step, genes that contained multiple variants segregating in two or more 
families were evaluated. In 28 genes, we observed two or more different heterozygous 
variants that segregated in two or more families, including in two genes known to cause 
a retinal phenotype (ABCA4 and VCAN, full list of variants in Table 3). Expression of 
these genes in the retina and RPE was evaluated using the Eye Integration Database, 
and all genes with the exception of CDMD2 and TCF25 showed moderate to high 
expression in the RPE or retina (Supplementary Figure 2).31 For all 28 genes the results 
of the gene-based analysis (Burden, SKAT, and SKAT-O) were extracted from the 
case-control analysis (Schellevis et al. 2018 submitted). Also, a family gene-burden 
analysis was performed with RareIBD including all rare variants found in all families in 
the 28 genes. Multiple genes were nominally associated with CSC, but no significant 
associations were observed in either of the tests after correction for multiple testing 
for 28 genes (Table 4). Additionally, no genes showed consistent associations in both 
the case-control cohort and the family cohort.
Table 1. Results of per family segregation
Family No. Affected 
individuals
No. Suggestive 
individuals
No. Unaffected 
individuals
No. Variants left 
after segregation
Family 1 2 3 - 75
Family 2 2 - - 69
Family 3 1 3 2 36
Family 4 1 1 4 14
Family 5 1 2 4 3
Family 6 2 2 1 37
Family 7 1 2 3 17
Family 8 3 - 1 17
Family 9 2 - 2 12
Family 10 2 1 - 58
Family 11 2 1 - 79
Family 12 3 - - 29
Family 13 2 - - 71
Family 14* 2 - 1 37
Family 15 2 - - 60
Family 16 2 1 1 21
Family 17 1 1 - 124
Family 18 2 1 2 29
* Possibly reduced penetrance in this family
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Table 4. Gene-based analysis results of the genes with multiple segregating variants in two or more families.
Case-control analysis Family analysis
Gene Burden SKAT SKAT-O RareIBD
ABCA4 0.074 0.295 0.129 0.051
ABCF3 0.386 1.000 0.523 0.047
AGXT 0.374 0.367 0.517 0.301
ARFGEF3 0.126 0.166 0.198 0.085
BAIAP3 0.076 0.663 0.132 0.143
COL22A1 0.564 0.506 0.684 0.020
CSMD2 0.460 0.266 0.471 0.328
DPH1 0.039 0.220 0.061 0.086
KIAA1324 0.074 0.035 0.051 0.097
KIF13B 0.053 0.026 0.044 0.288
KRIT1 0.345 0.821 0.446 0.021
LOXHD1 0.567 0.960 0.761 0.049
LTBP2 0.378 0.827 0.553 0.177
MARF1 0.710 1.000 0.878 0.094
MYH2 0.858 0.452 0.655 0.037
MYOF 0.016 0.128 0.025 0.144
NOTCH4 0.544 0.939 0.740 0.018
PREX1 0.044 0.165 0.073 0.061
RBPJL 0.131 0.262 0.195 0.014
RECQL4 0.234 0.538 0.391 0.144
RFT1 0.073 0.341 0.130 0.019
SETX 0.587 0.494 0.667 0.169
TCF25 0.782 0.594 0.829 0.191
TTN 0.577 0.435 0.596 0.072
USP20 0.226 0.948 0.354 0.215
VCAN 0.271 1.000 0.414 0.144
YLPM1 0.524 0.871 0.715 0.047
Burden, SKAT and SKAT-O results were obtained from our study and was performed with 263 sporadic CSC 
patients and 1352 population controls (Schellevis et al. 2018 submitted).
Discussion 
In this exome sequencing study on familial CSC we included 72 individuals from 
18 different families and focused on rare genetic variants that segregated with the 
disease in these families. We observed 11 variants that segregated in two families, 
of which one was also associated with CSC in a recent case-control study (Schellevis 
et al. 2018 submitted). In addition in 28 genes two different  variants were found to 
segregate in two families, and 26 of these genes showed expression in the retina or 
RPE according to the Eye Integration Database.31
For AMD, a well-studied multifactorial eye disease with phenotypic overlap with CSC, 
exome sequencing studies in families have been successful in identifying rare variants 
that fully or partially segregate with the disease.32-37 Most variants in these AMD 
families were identified in genes of the complement system, in which common and 
rare variants were previously identified to be associated with AMD in case-control 
cohorts.38  So far the only well-established genetic association for CSC has been 
found in common variants in the complement factor H (CFH) gene.11,13-15 However, in 
this study we did not observe any segregating rare variants in CFH in our families. 
In this first unbiased exome sequencing study in familial CSC, we did not identify 
either a single variant nor multiple variants in a single gene that segregated with the 
CSC phenotype. This excludes that familial CSC is a Mendelian disease caused by 
mutations in a single gene. Analysis of exome sequencing data identified numerous 
variants that segregate with the disease in each individual family. However with the 
current study setting it is impossible to identify which of these variants might have an 
effect on the phenotype. Therefore, we focused on variants that segregated with CSC 
in at least two families, and on genes that carried multiple variants that segregated 
with CSC in at least two families.  
In total, 11 segregating variants were observed in two families, of which the 
c.4145C>T; p.T1382I (rs61758735) variant in the PTPRB gene showed an association 
in the sporadic CSC case-control cohort (Schellevis et al. 2018 submitted). However, 
extended segregation analysis in additional family members excluded complete 
segregation of the PTPRB variant with the disease in one of two families. This is in 
line with results obtained in AMD families in which rare variants did not always fully 
segregate with the disease.32,34,39 Nevertheless, these variants are likely to contribute 
to the disease in these families, since several rare variants significantly associated 
with AMD in case-control studies often also show partial segregation in families.32,37
The PTPRB gene encodes the vascular endothelial protein tyrosine phosphatase 
(VEPTP) protein. VEPTP is an important modulator of vascular endothelium 
morphogenesis and is involved promoting angiogenesis and regulates endothelial 
barrier functions by interacting with cadherin.40,41 Additionally, intra-ocular 
injectionsof anti-VEPTP suppress neovascularization in mice.42 As it is hypothesized 
that choroidal hyperpermeability and dysfunction is one of the underlying problems 
in CSC,2 the PTPRB gene is an interesting candidate gene for CSC and should be 
investigated in future studies. The remaining 11 variants were extremely rare in the 
case-control cohort, and we can neither rule out nor confirm their possible role in the 
CSC disease mechanism at this time. 
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In 28 genes, multiple different segregating variants were observed in at least two 
families. For these genes gene-based associations in the case-control cohort (using 
SKAT, SKAT-O, and Burden test) and gene-based associations in the CSC families 
(using RareIBD) were evaluated. Five genes were nominally associated in the gene-
burden analyses of the case-control cohort and 9 genes were nominally associated 
in the family dataset. However, none of the genes showed consistent associations 
in both the gene-burden analysis in the case-control cohort and in the family gene-
burden analysis. Of the 5 genes associated in the case-control cohort, the DPH1, 
KIAA1324, and PREX1 genes were close to significance in our families and might be 
interesting genes for replication in a larger family dataset.  
In summary, we aimed to identify rare variants associated with familial CSC. In 
each family many variants segregated with the disease, but only few were found to 
segregate in at least two families. One variant was also associated with CSC in a 
recent  case-control cohort (Schellevis et al. 2018 submitted), and this gene, PTPRB, 
has a function that could be of importance in the etiology of CSC. Therefore, PTPRB 
might be an interesting candidate gene for future studies on CSC. Future analyses 
should include more families with more individuals to increase the chance of finding 
segregating variants in multiple families, and to increase the power of the RareIBD 
analysis. Additionally, future studies may focus on the possible role for genetic 
variants in non-coding genetic regions, such as introns and promoter regions or large 
structural alterations that cannot be detected with exome sequencing, such as copy 
number variations. 
In general, in familial CSC a Mendelian inheritance pattern of variants in one or a 
limited number of genes can be excluded based on this study. Instead, familial CSC 
may be a heterogeneous Mendelian disease caused by variants in many different 
genes, or alternatively CSC may represent a complex disease to which both genetic 
and environmental factors contribute. 
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Supplementary Figure 2. Expression according to the Eye integration database31 for the 11 genes with the same 
variant in two families. Adult retina is depicted in red, whereas RPE is blue.
 Supplementary Figure 3. Expression according to the Eye integration database31 for the 28 genes with multiple 
different variant in two families. Adult retina is depicted in red, whereas RPE is blue.
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Abstract
Importance: Chronic central serous chorioretinopathy (cCSC) is a vision-threatening 
eye disease characterized by fluid accumulation between the photoreceptors and the 
retinal pigment epithelium. The etiology of cCSC is currently unknown, but reported 
associations with the use of steroids, stress, pregnancy and the male gender suggest 
an important role for the steroid hormone system in the disease. 
Objective: To perform a comprehensive analysis of the steroid hormone system in 
cCSC by measuring levels of 17 different steroid hormones simultaneously. 
Design: Case-control study
Setting: Two referral university medical centers for outpatient care
Participants: 46 male patients with active cCSC and 46 male age-matched controls.
Main outcome measurements: Serum hormone levels of 17 steroid hormones and 
Spearman’s correlations between steroid hormones. The AbsoluteIDQ stero17 kit was 
used, measuring cortisol, cortisone, 11-deoxycortisol, aldosterone, corticosterone, 
deoxycorticosterone [DOC], 17α-hydroxyprogesterone [17-OHP], progesterone, 
estrone [E1], estradiol [E2], androstenedione, androsterone, dehydroepiandrosterone 
[DHEA], dehydroepiandrosterone sulfate [DHEAS], dihydrotestosterone [DHT], 
etiocholanolone and testosterone. 
Results: Elevated levels of androsterone, estrone, etiocholanolone and androstenedione 
were observed in 46 male cCSC patients (mean age: 50 [range: 28-72] years) compared 
to 46 male controls (mean age: 50 [range: 22-72]). Median hormone levels in cCSC 
patients vs. controls, respectively, were: androsterone: 0.84 ng/ml (Inter quartile 
range [IQR]=0.61-1.06) vs. 0.69 ng/ml (IQR=0.48-0.96, P=0.031), estrone: 0.12 ng/
ml (IQR=0.10-0.15) vs. 0.10 ng/ml (IQR=0.08-0.11, P=0.0048) and etiocholanolone: 
0.19 ng/ml (IQR=0.15-0.29) vs. 0.13 ng/ml (IQR=0.099-0.20, P=0.0061). Mean levels 
of androstenedione, which were normally distributed, were 3.10 ng/ml (SD=1.03) 
vs. 2.55 ng/ml (SD=0.95), in cCSC patients vs. controls, respectively. Additionally, 
Spearman’s correlations between aldosterone and 11-deoxycortisol, androsterone, 
DHEA, DHEAS and E1 differed between cCSC patients and controls, as well as 
between andosterone and E1, and between DHT and 17OHP. 
Conclusions and relevance: In this study, by simultaneously measuring levels of 17 
steroid hormones, a comprehensice overview of the status of the steroid hormone 
system in active cCSC was obtained. Levels of four hormones were significantly 
elevated in cCSC patients compared to controls. Also, the relationships between 
steroid hormones differed between cases and controls, suggesting that the balance 
in the steroid hormone system is altered in cCSC patients. This study suggests that 
steroid hormones might be useful for predicting active phases of cCSC, and that 
restoring steroid hormone homeostasis might be a target for treatment of cCSC. 
Introduction
Central serous chorioretinopathy (CSC) is a multifactorial retinal disease characterized 
by fluid accumulation between the photoreceptors and the retinal pigment epithelial 
(RPE) leading to vision impairment.1-3 The etiology of CSC is currently unknown 
and treatment options are limited. Two forms of CSC are described: acute CSC and 
chronic CSC (cCSC). Acute CSC usually spontaneously resolves, while patients with 
chronic CSC (cCSC) have persisting complaints or multiple separate episodes of fluid 
accumulation accompanied with permanent loss of visual acuity and RPE alterations.1,4 
CSC is more frequent in males (~80% of patients) and has been associated with stress, 
the use of steroids, type A personality and pregnancy,1-3 suggesting an important role 
for the steroid hormone system in the disease.
Steroid hormones regulate a large number of physiological processes, such as sex 
differentiation, metabolism and immune responses.5 To date, only a limited number of 
studies have investigated hormone levels in CSC patients. The most widely studied 
hormone is cortisol with over 11 studies,6-16 aldosterone was measured in 2 studies,8,17 
testosterone levels were measured in 4 studies,7,8,10,12 dehydroepiandrosterone 
(DHEA) and dehydroepiandrosterone  sulfate (DHEAS) were both described in 
only one study.8,18 However, results between studies were not consistent, showing 
associations with CSC and cortisol or testosterone levels in some studies, but not 
in others.6-16 Notably, these studies focused only on a limited number of hormones, 
while it is known that many complex interactions exist between steroid hormones 
and that they are highly correlated.5 A comprehensive analysis of the steroid hormone 
system would not only provide information on differences in levels on individual 
steroid hormones, but would also allow for the assessments of interactions between 
hormones. 
Therefore, in order to better understand the role of the hormone system and to 
observe possible disbalances in this system in cCSC, we simultaneously measured 17 
different steroid hormones in serum samples of 46 patients with active cCSC and 46 
age- and sex-matched controls. With this study we aimed to increase our knowledge 
on the status of the steroid hormone system in cCSC patients, in order to gain more 
insight into the mechanisms underlying the disease.
Key Points
Question: Which steroid hormones are associated with active chronic central serous 
chorioretinopathy (cCSC)?
Findings: By measuring 17 steroid hormones simultaneously in patients with 
cCSC compared to age- and sex-matched controls, we observed elevated levels of 
androsterone, estrone, etiocholanolone and androstenedione in cCSC patients. 
Additionally, correlations between steroid hormones, in particular of the aldosterone 
hormone, were altered in cCSC patients.
Meaning: This study indicates involvement of sex-hormones in cCSC and suggests an 
altered balance of the hormone system in patients with active cCSC. 
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Methods
Study participants 
In this multicenter study, we included 46 patients with cCSC from 2 different university 
hospitals. As controls 46 age- and sex-matched individuals from the EUGENDA 
database were used (www.eugenda.org). In total, 16 cCSC patients and 36 controls 
were collected at the Radboud university medical center (Nijmegen, The Netherlands) 
and 30 cCSC patients and 10 controls were collected at the University Hospital of 
Cologne (Cologne, Germany). The diagnosis of cCSC was based on multimodal 
grading of images obtained via color fundus photographs, optical coherence 
tomography, fluorescein angiography (FA) and indocyanine green angiography (ICGA) 
by two independent graders (LA, VS). Included were patients with active chronic 
cCSC, defined as focal or diffuse leakage in FA/ICGA with retinal pigment epithelium 
(RPE) alterations and visible subretinal fluid on spectral domain optical coherence 
tomography (SD-OCT). Patients with extensive RPE alterations (>=5 disc areas) were 
excluded. None of the controls and cCSC patients showed signs of other retinal 
diseases (drusen, age-related macular degeneration, former or present choroidal 
neovascularization, myopic degeneration, dome-shaped maculopathy, hemangioma, 
vitreomacular traction, diabetic macular edema etc.) on OCT, fundus photography or 
on FA/ICGA. Individuals who reported steroid or eplerenon/spirinolacton use within 
last 6 months at the moment of blood withdrawal were excluded from the study.
Informed consents were obtained for all individuals participating in this study. This 
study was performed according to the guidelines of the Declaration of Helsinki and 
the local ethic committees of the participating hospitals approved the study. 
Steroid measurements 
Serum samples were collected using a standardized coagulation and centrifugation 
protocol, and samples were stored at -80 °C within 1 hour after collection. Time of 
blood withdrawal was recorded for the cCSC patients as they were collected specifically 
for this study, but was not known for the EUGENDA control samples which were 
collected previously for the EUGENDA database. For each participant an aliquot of 
frozen serum (500µl) was shipped to Biocrates Life Sciences (Innsbruck, Austria) and 
17 different steroid hormones were measured using the AbsoluteIDQ® stero17 assay. 
The 17 steroids include glucocorticoids (cortisol, cortisone and 11-deoxycortisol), 
mineralocorticoids (aldosterone, corticosterone and deoxycorticosterone [DOC]), 
progestogens (17α-hydroxyprogesterone [17-OHP] and progesterone), estrogens 
(estrone [E1] and estradiol [E2]), and androgens (androstenedione, androsterone, 
dehydroepiandrosterone [DHEA], dehydroepiandrosterone sulfate [DHEAS], 
dihydrotestosterone [DHT], etiocholanolone and testosterone). Measurements 
of the 17 hormones were obtained from Biocrates in an Excel sheet along with a 
corresponding data report.
Statistical Analysis. 
All statistical analyses were conducted using SPSS (IBM, version 25). Hormone levels 
in cCSC patients and controls were tested for normality with the Shapiro-Wilk test. 
Levels of normally distributed hormones were compared between cCSC patients 
and controls with an independent sample t-test, whereas non-normally distributed 
hormones were tested with a Mann-Whitney U test. The levels of associated steroids 
(P-values <0.05) were compared between collection sites (Cologne and Nijmegen) 
with the same tests, depending on the normality of the distribution of the individual 
hormones. Additionally, levels of the associated steroids were compared between 
time of blood withdrawal with a Kruskal-Wallis test with the following hourly bins: 
8.00-9.00, 9.00-10.00, 10.00-12.00, 12.00-13.00, and 14.00-15.00. 
Because all steroid hormones are derived from cholesterol, and are thus highly 
correlated, the Spearman’s rho rank correlation between the different steroid 
hormones was calculated. The correlation coefficients of cCSC patients and the 
control individuals were compared using the “r.test” function of the “psych” package. 
The r.tests first transforms the rho correlations into Z-scores using the Fisher Z 
transformation, and compares the differences divided by the standard error of the 
differences to obtain a p-value as proposed by Cohen and Cohen.19 
Results
This study included 46 male patients with an active episode of cCSC and 46 unaffected 
male controls collected at two university hospitals. The mean age of the included 
patients was 50 (range: 28-72) years, and the mean age of the age-matched-controls 
was 50 (range: 22-72) years. Fourteen of the 17 steroid hormones were successfully 
measured, whereas 3 steroids had measurements outside of the limit of detection 
(LOD) in some samples [aldosterone (10 samples; 10.8%), estradiol (E2) (1 sample; 
1.1%), etiocholanolone (11 samples; 12.0%)]. The distribution of samples that ranged 
outside of the LOD was similar between cCSC patients and controls. All hormone 
levels, except for androstenedione, cortisone and DHEAS, showed deviation from 
normality in either cCSC patients or controls, therefore nonparametric tests were used 
for these hormones and median levels with inter quartile ranges (IQR) are described. 
Higher levels of androsterone, androstenedione, E1 and etiocholanolone were 
observed in cCSC patients compared to controls (Figure 1, Table 1). Median levels 
for androsterone were 0.84 ng/ml (IQR=0.61-1.06) in cCSC patients and 0.69 ng/
ml (IQR=0.48-0.96) in controls (P=0.031). The median levels of E1 in cCSC patients 
were 0.12 ng/ml (IQR=0.10-0.15) and 0.10 ng/ml (IQR=0.08-0.11) in controls 
(P=0.0048). Median concentration of etiocholanolone was 0.19 ng/ml (IQR=0.15-
0.29) in cCSC patients and 0.13 ng/ml (IQR=0.099-0.20) in controls (P=0.0061). 
Finally, mean androstenedione levels were 3.10 ng/ml (Standard deviation [SD]=1.03) 
in cCSC patients and 2.55 ng/ml (SD=0.95) in controls (P=0.0094). No difference was 
observed between samples collected from Nijmegen or Cologne for the associated 
steroids (Supplementary Table 1) and no association was observed between levels of 
these four steroids and the time of blood withdrawal (Supplementary Table 2). 
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Figure 1: Hormone levels associated with cCSC. Different panels indicate the absolute hormone levels measu-
red in cCSC patients (case) in red and controls in green. For Androstenedione error bars indicate mean and 
standard deviation, while for the other hormones the median and inter quartile ranges  are depicted. Values 
for mean and medians can be found in Table 1.
Next, the relationship between steroids was investigated in cCSC patients and 
controls by calculating Spearman’s rho correlations between all measured steroids. 
Numerous steroid hormones were highly correlated in both the cCSC patients and 
controls (Figure 2). Comparison of the Spearman’s correlation coefficients between 
cCSC patients and controls identified a difference in correlations for aldosterone 
with androsterone (0.316 vs. -0.379, P-value=0.00076), DHEA (0.029 vs. -0.445, 
P-value=0.019), DHEAS (0.117 vs. -0.333, P-value=0.031), E1 (0.381 vs. -0.085, 
P-value=0.024) and 11-deoxycortisol (0.208 vs. -0.255, P-value=0.029) in controls 
and cCSC patients, respectively. Additionally, a difference in the correlation of 
androsterone with E1 (0.613 vs. -0.182, P-value=0.014) and DHT with 17-OHP 
(-0.100 vs. 0.538, P-value=0.0011) was observed between controls and cCSC patients, 
Table 1. Association results of steroids in 46 cCSC patients compared to 46 controls
Concentration in ng/ml
Controls cCSC patients
Non-normally distributed 
hormones
Median ng/
ml
IQR
Median 
ng/ml
IQR
Mann Whitney U 
2-sided P-value
11-Deoxy-corticosterone 0.070 (0.053-0.11) 0.088 (0.052-0.13) 0.323
11-Deoxycortisol 0.55 (0.35-0.9) 0.59 (0.41-1.26) 0.492
17α-Hydroxyprogesterone 
(17-OHP)
2.11 (1.6-2.64) 2.14 (1.63-2.63) 0.854
Aldosterone 0.14 (0.085-0.21) 0.16 (0.13-0.23) 0.303
Androsterone 0.69 (0.48-0.96) 0.84 (0.61-1.06) 0.031
Corticosterone 5.12 (3.048-8.49) 4.96 (2.65-9.82) 0.975
Cortisol 259.35
(209.65-
360.13)
275.60
(232.05-
357.35)
0.331
Dehydroepiandrosterone 
(DHEA)
10.05 (5.15-15) 11.25 (7.63-16.35) 0.414
Dihydrotestosterone (DHT) 1.28 (1.04-1.73) 1.24 (0.90-1.81) 0.468
Estrone (E1) 0.10 (0.080-0.11) 0.12 (0.10-0.15) 0.0048
Estradiol (E2) 0.067
(0.052-
0.081)
0.060
(0.052-
0.083)
0.654
Etiocholanolone 0.13 (0.099-0.20) 0.19 (0.15-0.29) 0.0061
Progesterone 0.17 (0.13-0.26) 0.16 (0.12-0.25) 0.797
Testosterone 14.75
(10.40-
18.40)
14.50 (10.8-17.45) 0.587
Normally distributed 
hormones
Mean ng/ml SD
Mean 
ng/ml
SD
Independent T-Test 
P-value
Androstenedione 2.55 0.95 3.10 1.029 0.0094
Cortisone 61.78 16.56 68.01 13.62 0.052
Dehydroepiandrosterone 
sulphate (DHEAS)
5064.82 3030.96 5759.03 2638.17 0.244
cCSC: chronic central serous chorioretinopathy, IQR: Inter quartile range depicting the 25 and 75 
percentile, SD: Standard deviation
respectively (Table 2, Figure 2, red bordered squares). The four steroids associated 
with cCSC were positively correlated in all groups (Supplementary Figure 1). 
Discussion
In order to obtain an overview of the steroid hormone system in cCSC we studied 17 
steroids in 46 patients with active cCSC and 46 age-matched controls. We measured 
elevated levels of androsterone, androstenedione, estrone and etiocholanolone 
in patients with active cCSC compared to controls. Additionally, alterations in the 
balance of the steroid hormone system were observed in cCSC patients, mainly 
involving relationships of aldosterone with other steroids.
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Several steps were performed in order to prevent confounding by factors that are 
known to influence steroid levels. First, to homogenize the dataset we include only 
males in this study, because the disease is most prevalent in this group (9.9:100,000 
vs. 1.7:100,000 in women).20 Secondly, the controls used in this study were age-
matched with the cCSC patients. Also, all individuals that reported steroid use at 
blood withdrawal were excluded. Finally, for the cCSC-associated hormones we 
confirmed that levels were not dependent on time at blood withdrawal and did not 
differ between recruitment sites.
A limited number of studies have been performed on steroid hormone imbalances in 
cCSC patients till date, and these studies focused on either single measurements or 
at most on four steroids simultaneously. Association results were variable between 
studies and reported hormone levels also varied greatly between studies. Some 
associations with testosterone or morning, evening or 24h cortisol levels have been 
reported,6,8-10,13,15 but other studies did not confirm these results.10,11,14 Aldosterone, 
DHEA and DHEAS were measured, but no association with cCSC were observed in 
the studies investigating these hormones.8,18
To our knowledge, no studies have been published that have reported higher levels 
of androsterone, androstenedione, E1 and etiocholanolone in cCSC patients as 
observed in the current study. Androsterone, androstenedione, etiocholanolone and 
estrone are important products of the sex-hormone branch of the steroid hormone 
system. Androstenedione, androsterone and etiocholanolone are weak androgens and 
mainly function as precursors or metabolites for testosterone (Figure 3).5 However, 
androsterone and etiocholanolone have additional neurosteroid properties acting 
on the GABAA receptor and are able to cross to the blood-brain barrier to prevent 
seizures.21,22 Androstenedione is the main precursor of testosterone and estrone.5 
Table 2. Difference in correlations of steroid hormones between cCSC patients and controls
Controls cCSC Patients
Correlation
Spearman 
Rho
Correlation 
P-value
Spearman 
Rho
Correlation 
P-value
Delta Rho Delta Z P-value
Aldosterone - 
11-Deoxycortisol
0.208 0.198 -0.255 0.103 0.463 2.188 0.029
Aldosterone - 
Androsterone
0.316 0.047 -0.379 0.013 0.695 3.367 0.00076
Aldosterone - 
DHEA
0.029 0.859 -0.445 0.0031 0.474 2.354 0.019
Aldosterone - 
DHEAS
0.117 0.473 -0.333 0.031 0.450 2.152 0.031
Aldosterone - 
Estrone (E1)
0.381 0.0153 -0.085 0.592 0.466 2.255 0.024
Estrone (E1) - 
Androsterone
0.613 6.00E-06 0.182 0.227 0.431 2.456 0.014
DHT - 17OHP -0.100 0.510 0.538 1.13E-04 -0.638 3.255 0.0011
17-OHP: 17α-Hydroxyprogesterone, DHEA: Dehydroepiandrosterone, DHEAS: Dehydroepiandrosterone 
sulphate, DHT: Dihydrotestosterone. cCSC: chronic central serous chorioretinopathy
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Estrone is a weak estrogen hormone that can readily be converted to estradiol, has 
binding affinity to the estrogen receptors ERα and ERβ and its levels are known to 
be increased in the blood of postmenopausal women.23 Currently, the role of these 
hormones in the etiology of cCSC is still unknown. Future studies might focus on 
determining the influence of elevated levels of these hormones on the RPE and 
choroid using for example cell models. 
We assessed the steroid hormone system as a whole by investigating relationships 
between the different hormones because steroid hormones are highly correlated, and 
multiple testing correction with Bonferroni would be too conservative. Interestingly, 
we observed several altered correlations between the measured hormones when 
comparing controls and cCSC patients. In controls, a triangular positive correlation 
was observed between aldosterone, androsterone and estrone. In the cCSC 
patients, a negative correlation for aldosterone with androsterone was observed 
and the correlation with estrone with both aldosterone and androsterone was lost. 
Additionally, in cCSC patients DHEA, DHEAS and 11-deoxycortisol were negatively 
correlated with aldosterone, and DHT was negatively correlated with 17-OHP, while 
these correlations were not observed in controls. Although aldosterone itself was not 
associated with cCSC in this study, its altered relationship with multiple other hormones 
suggests an altered balance in the steroid hormone system in cCSC patients. In light 
of the current clinical trials targeting the mineralocorticoid receptor (the binding site 
of aldosterone), this observation might be clinically relevant. In future studies, follow-
up measurements of patients with active cCSC when they either have spontaneously 
resolved, have responded to treatment (micropulse laser, photodynamic therapy or 
eplerenone) or have persisting complaints might be informative to determine whether 
alterations in the hormone level balance might be used as predictor of disease status 
or treatment response, or might in itself be a target for treatment. 
Here, by simultaneously measuring 17 components of the steroid hormone system in a 
group of active cCSC patients the status of the hormone system could be investigated. 
This approach allowed us to describe elevated single hormone levels in addition 
to altered relationships between various hormones in cCSC patients compared to 
controls. Even though this is one of the larger studies on steroid measurements in 
cCSC patients to date, the current sample size is still limited and future studies should 
focus on replication of the current study in an independent cCSC cohort. Additionally, 
as only male cCSC patients were included in this study, measurements of the 17 
steroids and the hormone system balance in female cCSC patients could provide new 
insights on sex-specific differences in the disease. 
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Conclusions
In this study, we measured elevated levels of androsterone, androstenedione, 
E1 and etiocholanolone in patients with an active episode of cCSC compared to 
controls. Additionally, we observed altered correlations between hormones in cCSC 
patients, mainly with aldosterone, indicative of an altered hormone system balance in 
individuals with cCSC. This study provides new insights into the status of the steroid 
hormone system in active cCSC and suggests new leads for future studies into the role 
of steroid hormones in cCSC. These studies might focus on the potential predictive 
value of the hormone system balance for active phase cCSC and on whether restoring 
steroid hormone balance might be an avenue for treatment of cCSC. 
Footnotes and Financial Disclosures
Financial Support: This study was funded by the Bayer Ophthalmology Research 
Award 2018 (BORA) awarded to R.L. Schellevis and the Radboud Institute for 
Molecular Life Sciences. 
Role of funding organizations: The funding organizations had no role in the design or 
conduct of the study and were not involved in interpretation of the data or writing of 
the manuscript.  
Conflict of interest: No conflicting relationship exists for any author
Rosa L. Schellevis had full access to all the data in the study and takes responsibility 
for the integrity of the data and the accuracy of the data analysis.
241
5
Supplementary Figure 1: Correlations between the four associated steroids. Colors indicate positive (blue) and 
negative (red) correlations between the different hormones, and significant correlations are indicated with an 
asterix (*). Red bordered squares are those correlations that were significantly different between cCSC patients 
and controls (Table 2).
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Although the familial occurrence of CSC already hinted towards a genetic component 
for CSC in 1960, the first publications linking genetic variants to the occurrence 
of cCSC only appeared in 2014 just before the start of this thesis. To date, various 
candidate gene studies and one unbiased genome-wide association study focusing 
on CSC have been performed. Additionally, exome sequencing in both sporadic and 
familial CSC patients was performed as part of this thesis. In this general discussion, 
we present the published studies on the genetics of CSC specified per gene in order 
of publication date, discuss the robust association between the CFH gene and cCSC, 
and suggest future studies to be conducted.
Candidate gene studies
CFH
Involvement of the complement factor H (CFH) gene in CSC was initially investigated 
because the factor H protein is able to bind adrenomedullin. This molecule is a 
vasodilator in the choroid important for regulation of choroidal flow, which was 
previously suggested to be the cause of CSC.1 
The first publication on genetic associations of CFH with CSC was reported in a 
Japanese CSC cohort (n=140) indicating that four variants in the CFH gene conferred 
increased risk for cCSC (rs3753394, rs800292 [I62V], rs2284664 and rs1329428), 
whereas one (rs106548) was protective for CSC (Table 1).2 These associations were 
confirmed with the same direction of effect in a Dutch cCSC cohort (n=197), although 
the minor allele frequencies greatly differed and not all variants reached significance 
after correction for multiple testing (Table 1 and Chapter 2.1).3 In addition, two 
different CFH SNPs (rs12144939 and rs1061170 [Y402H]) were also tested in this 
cohort, but both were not associated with CSC after correction for multiple testing.3 
Associations of the same CFH variants in a small Greek CSC cohort (n=41) showed 
an opposite effect for the rs3753394 and rs1065489 variants,4 as the respective C 
and G alleles were protective instead of risk-conferring compared to the Japanese 
and Dutch populations.2,3 In this study, the rs800292 and rs2284664 variants were 
not associated, while the rs1329428 variant was risk-conferring as observed in both 
other studies (Table 1).4 
In the Dutch study, different phenotypes of CSC were also compared, ranging from 
a very typical group with bilateral CSC (n=197), towards a unilateral CSC-affected 
group (n=52), and finally a group with a more mixed phenotype (n=43), including signs 
of neovascularisation and/or drusen on top of the subretinal fluid accumulation.3 
Comparison of the CFH variants between these groups, indicated that the typical CSC 
group was genetically distinct from the more admixed group, stressing the importance 
for extensive and thorough phenotyping of CSC.3
Haplotype analysis of the CFH gene was performed in both the Japanese and the 
Dutch study (Figure 1). In the Japanese study, two different haploblocks were 
constructed (J1: rs3753394|rs800929 and J2: rs2284664|rs1329428|rs1065489), 
while in the Dutch study the two blocks were combined and rs1061170 was also 
included (D: rs3753394|rs800929|rs1061170|rs2284664|rs1329428|rs1065489). 
The protective J1-H1:TG (OR=0.69) and J2-H1:CCT (OR=0.55) and the risk-carrying 
J1-H2:CA (OR=1.63), and J2-H2:TTG (OR=1.66) haplotypes were associated with 
CSC after correction for multiple testing.2 In the Dutch cohort, only the protective 
D-H3:TGTCCT (OR=0.54) haplotype was associated after correction for multiple 
testing, whereas the D-H2:CATTTG (OR=1.33) haplotype showed a trend towards 
association.3 Thus, although minor allele frequency differences exist between the 
Japanese and European population, similar haplotypes were risk-conferring or 
protective for CSC. 
CDH5
In a candidate gene study containing patients from the USA (n=145) and Denmark 
(n=254), the relationship between CSC and 82 SNPs in 44 genes was tested based 
on their role in three pathways: stress response, steroid metabolism, and choroidal/
epithelial permeability.6 Variants with suggestive associations in the American cohort 
(the p-value cutoff was not defined in this study) in the cadherin 5 (CDH5), heat shock 
protein 90 (HSP90), Mitogen-Activated Protein Kinase 1 (MAPK1) and CFH genes were 
replicated in the Danish cohort. Of these selected variants, three SNPs in CDH5 were 
independently associated to cCSC in both the initial USA and the Danish replication 
cohorts, with two variants carrying a protective effect (Table 2, rs1130844 [OR=0.78] 
and rs1073584 [OR=0.77]), and one risk-conferring variant (rs7499886 [OR=1.30]). 
These associations were reported to be mainly driven by the male subgroup of the 
Figure 1: Haplotypes of the CFH gene in the Japanese (J1-J2) and Dutch (D) candidate gene studies and the 
genome-wide association study (GWAS).2,3,5 Protective haplotypes are shaded in green, whereas red shaded 
haplotypes indicate a risk-carrying effect. Nucleotides A/C/T/G are colored for better distinction, and missing 
genotype information is indicated with a point. OR: Odds ratio, CI: confidence interval.
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cohort.6 It must be noted that the number of SNPs selected for replication was 
not reported, therefore it is uncertain if these associations remain significant after 
correction for multiple testing.
Haplotype analysis of the CDH5 gene was performed with two haploblocks 
(Figure 2, C1: rs1130844|rs2304527|rs1073584 and C2:rs10852432|rs7499886| 
rs1073584). The protective C1-H1: CTT (OR=0.61) and C2-H4: TGT (OR=0.66) 
haplotypes and the risk carrying C2-H3: CAC (OR=1.57) haplotypes were significantly 
associated to cCSC after correction for multiple testing (5 haplotypes: P<0.01). 
The authors suggest that the CDH5 protein might be involved in the CSC disease 
mechanism due to its function in endothelial cell-cell junctions, and its localization in 
the choriocapillaris. However, the genetic associations presented in this study have 
not been reported in other CSC cohorts, and therefore the involvement of the CDH5 
gene in the disease remains uncertain. 
PAI-1 
One small study using plasma of 17 CSC patients, showed that levels of the 
plasminogen activator inhibitor 1 (PAI-1) were elevated in CSC patients.7 PAI-1 is an 
important factor in inhibiting fibrin degradation, but also has been indicated in other 
processes such as inflammation.8 
Previous studies have indicated that a G-insertion/deletion polymorphism in the 
promoter of PAI-1 (4G/5G) directly influences the plasma PAI-1 levels. Therefore, in 
order to potentially explain the increased levels of PAI-1 in CSC, this polymorphism was 
investigated in a Turkish CSC cohort (n=60).9 Although the CSC patients group again 
showed significantly higher serum PAI-1 levels, no significant differences were found 
in the frequency of the 4G/5G polymorphism between CSC patients and controls 
(Table 2).9 To date, it remains unclear what might cause this PAI-1 elevation, and larger 
studies investigating a potential role for the PAI-1 gene in CSC are warranted.
ARMS2 and other AMD-associated genes
After the association of CFH with CSC was identified, the question arose whether 
other age-related macular degeneration (AMD)-associated variants are associated 
with CSC. Therefore, a total of 18 variants previously described to be associated 
with AMD10 were investigated in the same Dutch cCSC cohort that replicated the 
CFH association (n=197, Table 2 and Chapter 2.1).3 Variants in age related macular 
susceptibility 2 (ARMS2), TNF Receptor Superfamily Member 10A (TNFRSF10A) and 
A disintegrin and metalloproteinase with thrombospondin motifs 9 (ADAMTS9) were 
associated with CSC. However only the association with rs10490924 (A69S) in ARMS2 
remained significant after correction for multiple testing, conferring a protective effect 
for the minor T-allele (OR=0.64).3 The association of CSC with ARMS2 has not been 
reported in other cohorts, however the rs10490924 variant has been associated with 
polypoidal choroidal vasculopathy, one of the endophenotypes of CSC (see section: 
The genetics of CSC endophenotypes).
SGK-1
The protein encoded by the serum glucocorticoid kinase gene-1 (SGK-1) is able to 
regulate several channels and transporters in epithelial cells, including EnaC, SCN5A, 
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6
ROMK1, KCNE1/KCNQ1, Kv1.3, NHE3 and the Na+/K+-ATPase.11 Because of this 
ability to activate channels and because of its glucocorticoid responsive activation, 
the involvement of SGK-1 was investigated in a small Turkish cCSC cohort (n=32). The 
coding region of the SGK-1 gene was sequenced, and three variants were identified 
(Table 2, rs1057293, rs1743966 and rs147657480). Although the rs147657480 
variant was only observed in CSC patients and not in controls, none of the identified 
variants was significantly associated with CSC, potentially due to the small sample 
size and consequent lack of power. 
C4B 
Complement factor 4 (C4) is encoded by two nearly identical genes, C4A and C4B, 
and plays a role in the classical and lectin pathway of the complement system.12 Copy 
numbers of the C4A and C4B genes have occurred in the genome due to the process 
of recombination (Box 1 in Chapter 1), leading to a large variation in the amount of 
copies of these genes in individuals. The amount of C4A and C4B copies an individual 
carries has a direct influence on the expression of C4.13 Also, the regulation of stress 
through cortisol release after adrenocorticotropic hormone (ACTH) stimulation, has 
been indicated to vary based on the amount of C4 copies.13 Therefore, because of 
the involvement of C4 in both the complement system and the stress pathway, the 
influence of copy numbers of the C4 gene were studied in relation to cCSC (Chapter 
2.2).3 
Copy numbers of both the C4A and C4B gene and the combination of those two were 
studied. A significant difference in copy numbers of the C4B gene was observed in 
cCSC patients (n=197) compared to controls. A complete absence of C4B (C4B*Q0) 
conferred risk for CSC, with the largest OR reported for a genetic variant in CSC 
so far (OR=2.61), while carrying three copies of the gene was protective for cCSC 
(OR=0.45).3 The association of the C4B gene with cCSC has so far not been reported 
in other cohorts.
GTSM1
Because of its role in oxidative stress, and potential role in choroidal vasoconstriction, 
variants in the Glutathione-S-Transferase M1 (GTSM1) gene were studied in a Greek 
CSC cohort (n=41).4 However, in this small cohort the frequencies of the normal and 
null alleles of the GSTM1 polymorphism were not significantly different between CSC 
patients and controls (Table 2).4 
Figure 2: Haplotypes of the CDH5 gene in the candidate gene study.6 Protective haplotypes are shaded in green, 
whereas red shaded haplotypes indicate a risk-carrying effect. Nucleotides A/C/T/G are colored for better 
distinction, and missing genotype information is indicated with a point. OR: Odds ratio, CI: confidence interval.
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NR3C1 and NR3C2
The NR3C1 and NR3C2 genes encode the glucocorticoid and mineralocorticoid 
receptors, respectively. Because of the known association of stress and use of 
corticosteroids with CSC, genetic variants that influence the function of these 
receptors were tested in a Dutch cCSC cohort (Table 2, n=336, Chapter 2.3).14 Three 
variants in NR3C1 (rs56149945, rs41423247,and rs6198) and one variant in NR3C2 
(rs5522) were not associated with cCSC. However, the rs2070951 variant in NR3C2 
was associated with an increased risk for cCSC (OR=1.29). Haplotype analysis of the 
two studied variants (Figure 3, N: rs2070951|rs5522) identified a protective effect for 
the N-H1: CA haplotype (OR=0.72), while N-H3: GA conferred risk for CSC (OR=1.39). 
The association of the rs2070951 variant and NR3C2 haplotypes have not been 
confirmed in other CSC cohorts, however, a GWAS on choroidal thickness indicated 
a nominal significant association for another variant in NR3C2 (rs10519952, P = 0.03) 
with this CSC endophentoype.15 
Unbiased studies
Genome-wide association analysis
Most studies published so far have used a candidate gene approach, however recently 
the first genome-wide association study for cCSC has been performed (Chapter 3.1).5 
In this study, the allele frequencies of ~11 million SNPs were compared between 521 
European cCSC patients and 3577 population controls. A genome-wide significant 
association with variants at the CFH gene was identified, and 6 variants with suggestive 
association (P<1x10-6) were observed.5 
Haplotypes of CFH were extended compared to the previous publication of 
the same group (Figure 1, GWAS:rs3753394|rs529825|rs800929|rs3766404| 
rs1061170|rs203674|rs3753396|rs2284664|rs1329428|rs1065489).3 The GWAS-
H2:CAATTTATTG, GWAS-H4:CGGCTTACTG, GWAS-H5:TGGTTTACTG, all 
containing the minor allele of the top-GWAS variant (bold) were risk carrying for cCSC 
(OR=1.57, 1.43 and 1.80, respectively), whereas the GWAS-H1: CGGTCGACCG and 
GWAS-H3: TGGTTTGCCT containing the wild-type allele were protective (OR=0.64 
and 0.54, respectively).5
In the same publication, gene expression in the cCSC patients and controls was 
predicted using expression quantitative trait loci (eQTLs) data of the Genotype-Tissue 
Expression (GTEx) database. Significant differences of predicted expression were 
found for genes in the CFH locus, namely, CFH itself, but also CFH related 1 and 4 
(CFHR1/4), and the nearby Potassium Sodium-Activated Channel Subfamily T Member 2 
(KCNT2) gene.5 Additionally, the cluster of differentiation 46 (CD46) and tumor necrosis 
factor receptor superfamily member 10a (TNFRSF10A) genes located elsewhere in 
the genome were predicted to be differentially expressed. The predicted altered 
expression makes CFHR1, CFHR4, CD46 and TNFRSF10A interesting candidate 
genes for future studies on cCSC. Finally, pathway analyses of the data indicated the 
involvement of the complement cascade in cCSC.5
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Exome sequencing analyses
For this thesis the first exome sequencing studies on cCSC were performed on both 
a case-control cohort and in a family-based study (Section 4). So far, no other studies 
have been performed using exome sequencing on cCSC patients.
The analysis of exome sequencing data of the cCSC case-control cohort was 
performed on 263 European cCSC patients and 1352 population controls and mainly 
consisted of gene-based analyses of the data (Chapter 4.1). A significant association 
was observed with cCSC in females for the PIGZ, DUOX1, LAMB3 and RSAD1 genes. 
Almost half of the female cCSC patients (45.5%) carried at least 1 rare variant in 
one of these genes compared to a carrier rate of 18.5% in female controls. In this 
study, we did not observe any significant associations with cCSC in the entire cohort 
nor in the males only after correction for multiple testing. Additionally, no gene-
burden associations were observed in the previously associated cCSC genes and loci 
described in the Candidate gene studies section of this discussion. The sex-specific 
association of rare variants in the PIGZ, DUOX1, LAMB3 and RSAD1 genes suggest 
that a different disease mechanism might underlie CSC in females compared to males, 
but replication of these results in other cohorts with cCSC is warranted. 
For the family-based data analysis, 72 individuals of 18 families in which CSC was 
present were analyzed by exome sequencing (Chapter 4.2). In total, 12 different 
segregating variants were present in 2 families. Of these, a variant (rs61758735) in 
the PTPRB gene was also significantly associated with CSC in the case-control exome 
sequencing study. Segregation of rs61758735 in additional family members of one 
of the families showed partial segregation with the phenotype, as also previously 
observed for rare variants associated with familial AMD.16,17 The function of the 
VEPTP protein encoded by PTPRB in angiogenesis and endothelial barrier functioning 
makes it an interesting candidate gene for CSC. Gene burden analysis of the family 
data did not identify the genes as in the case-control cohort. In this study, our analysis 
of familial CSC did not confirm the proposed Mendelian inheritance for CSC, but 
suggests an interaction between genetics and the environment, which would rather 
be in line with a complex disease. Extension of genetic studies on familial CSC might 
confirm the complex inheritance, or might increase the chance of finding multiple 
families carrying segregating variants in the same gene that could support a Mendelian 
inheritance instead.
Figure 3: Haplotypes of the NR3C2 gene in the candidate gene study.14 Protective haplotypes are shaded in 
green, whereas red shaded haplotypes indicate a risk-carrying effect. Nucleotides A/C/T/G are colored for 
better distinction. OR: Odds ratio, CI: confidence interval.
The genetics of CSC endophenotypes 
A disease generally is a composite of several features, or traits, that can be evaluated 
independently from the disease itself. These traits, or endophenotypes of a disease, 
can be tested for genetic associations, revealing potential susceptibility loci for the 
disease as a whole. This approach has been successful in other eye diseases such as 
myopia, where large-scale genetic association studies on several endophenotypes of 
myopia including axial length,18 refractive error,19 and corneal curvature,20 discovered 
several loci of interest for myopia. 
One of the main endophenotypes for cCSC is choroidal thickness. Although it is not 
apparent in all CSC cases, thickening of the choroid in particular has been reported to 
be a hallmark of the disease. Because of this connection, CSC has been regarded as 
part of the pachychoroid spectrum of diseases.21 Pachychoroid is a feature that can 
be measured in OCT images, with enhanced depth imaging and several studies have 
been published that have measured choroidal thickness in normal individuals.22 
So far only two groups have investigated whether pachychoroid itself, independent 
of diagnosed CSC, is a heritable trait. In one prospective observational study relatives 
(n=16) of CSC patients (n=5) were given an extensive eye exam, including detailed 
retinal imaging.22 In 50% of the eyes of relatives of CSC patients, pachychoroid could 
be observed and this feature seemed to be dominantly inherited, independent of a 
clinical diagnosis of CSC.22 A second study sought to quantify the level of heritability 
of the pachychoroid feature and did so using extended Amish families with early/
intermediate AMD. Choroidal thickness was measured in almost 700 individuals of 
these families and was shown to be transmitted across generations independent 
of AMD status. The authors concluded that choroidal thickness was moderately 
heritable with a heritability score of 0.40, but did not evaluate genetic associations 
with thick choroid.23 
Candidate gene studies
Because of the tight links between choroidal thickness in AMD, CSC and polypoidal 
choroidal vasculopathy (PCV), and the respective genetic associations to CFH and 
ARMS2 in those diseases, most genetic studies exploring associations to choroidal 
features used variants in CFH or ARMS2 as the starting point. The first of these studies 
investigated the link between choroidal thickness and vascular hyperpermeability and 
polymorphisms in CFH and ARMS2 in patients with PCV (n=63) and AMD (n=58).24 
This study reported an association between an increased choroidal thickness and the 
minor-A allele of the variant rs800292 (I62V) in CFH in PCV patients. The rs10490924 
(A69S) variant in ARMS2 and rs1061170 (Y402H) in CFH were not associated to 
choroidal thickness in this study.24 
A similar study also investigated associations with choroidal vascular hyperpermeability 
and choroidal thickness, testing ARMS2 and CFH variants in 149 patients with PCV.25 
Increased choroidal thickness and vascular permeability in these PCV patients was 
associated with the major-G allele of the rs10490924 (A69S) variant in ARMS2 
and the minor-T allele of rs1329428 in CFH. The rs800929 (I62V) in CFH was not 
associated to any of the traits.25 
One study investigated choroidal blood flow regulation in young healthy subjects 
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(n=96).26 This study showed that homozygous carriers of the AMD-risk genotype (CC) 
of the rs1061170 (Y402H) variant in CFH demonstrated impaired choroidal blood 
flow after squatting exercises. The authors argue that dysregulation of the choroidal 
blood stream, in part related to a person’s genotype, could predispose them, from an 
early age, to precipitating events leading to ocular disease.26 However, due to absence 
of overlap between associations in the above mentioned studies, no solid conclusions 
can be drawn about the involvement of the CFH and ARMS2 variants in choroidal 
thickness based on these candidate studies. 
Genome-wide association study
Only one large study investigated the genetic underpinnings of choroidal thickness in 
an unbiased, hypothesis-free manner by performing a GWAS on choroidal thickness 
in 3418 individuals.15 This work made use of the Japanese Nagahama Study in which, 
among others, detailed ophthalmic examinations including measures of choroidal 
thickness were coupled to available genome-wide genotyping information. One 
locus in CFH (top-associated variant: rs3753394) was discovered to be associated to 
choroidal thickness, while another novel locus in the VIPR2 (top-associated variant: 
rs7782658) gene showed a suggestive association. SNPs that showed moderate 
linkage disequilibrium with the top-associated variants (CFH [rs800292] & VIPR2 
[rs3793217]) were replicated in 2692 independent individuals from the same 
Nagahama study. In the meta-analysis both loci reached genome-wide significance. 
Additionally, these SNPs were tested for association in a Japanese (n=539/701) and 
Korean (n=425) CSC group including both acute and chronic patients. Both rs800292 
and rs3793217 were associated with CSC, although these associations did not reach 
genome-wide significance.15 Since the CFH association was recently identified in a 
GWAS for CSC and has been shown in multiple candidate studies,2-5, this finding can 
be considered robust. However, the VIPR2 association to CSC warrants replication 
in other independent cohorts, especially since the odds ratio of this variant in the 
Japanese study is relatively small (OR=1.24) and the allele frequency varies greatly 
among different populations (range minor allele frequency: 0.04-0.18).27 
Discussion 
Although the field of CSC-genetics is still emerging, we have observed a growth in 
studies on the genetics of CSC during the last 5 years. The studies described in this 
thesis confirm the genetic component contributing to the disease, and pave the way 
for future studies to understand the etiology of CSC. 
Although various candidate genes for CSC have been identified, the associations 
with variants in CDH5, ARMS2, C4B, NR3C2, VIPR2, CD46, KCNT2, TNRSF10A, 
CFHR1/4,3,5,6,14,15 LAMB3, DUOX1, RSAD1, PIGZ and PTPRB need to be tested in 
independent cohorts in order to be confirmed. Therefore, the implications of these 
associations are not discussed in detail here. 
In this section of this general discussion we focus on the robust genetic association 
of CFH with CSC in light of current literature. We elaborate on questions that still 
need to be answered regarding the etiology of CSC and propose studies that can be 
conducted to shed more light on the disease mechanisms underlying CSC.
The role of CFH in CSC
The genetic association of the CFH gene with CSC has been proven in multiple 
candidate gene studies and one genome-wide association study, 2-5 indicating that 
CFH is involved in the development of CSC, albeit via a still unknown mechanism. The 
CFH gene encodes the factor H (FH) protein, which is an inhibitor of the complement 
system, but FH also has been implicated in adrenomedullin (AM) binding. Here, we 
briefly discuss the potential role of FH in the CSC disease mechanism. 
The complement system
The FH protein is most widely known for its function in preventing over activation 
of the complement system by blocking the formation of C3-converstases.12 Together 
with the cofactor factor I, another complement inhibitor, it regulates the feedback 
loop of the alternative pathway of the complement system.12 FH consists of a stretch 
20 complement control protein (CCP) domains, which are also referred to as short 
consensus repeats (SCRs). The N-terminal part of FH (CCP1-5) is thought be involved 
in complement regulation, whereas the C-terminal domains mainly regulate cell 
surface binding (CCP19-20).28 
In the GWAS study on CSC, the genome-wide signal in CFH was driven by 20 SNPs 
that are in high linkage disequilibrium.5 Most of these SNPs are located in introns 
9-15, and one synonymous SNP is located in exon 10 (rs2274700), suggesting that 
they may have a regulatory effect on gene expression, or they may be co-inherited 
with other (yet unidentified) protein-altering variants on the same haplotype. The 
specific function of the protein domains (CCP10-15) around which the 20 variants 
cluster is still obscure, but because eQTL data in the same study predicts that CFH 
and surrounding genes are differentially expressed in multiple tissues, a regulatory 
role of these variants seems likely. 
So far, no rare protein-altering variants in the CFH gene have been associated with 
CSC. However, the common variants and haplotypes associated with CSC have been 
studied before in relation to AMD, which is the most common cause of vision loss 
in the elderly population characterized by lipid accumulations between the Bruch’s 
membrane and RPE.28 Interestingly, their direction of effect appears to be opposite 
between both diseases; variants protective for AMD are risk-conferring for CSC and 
vice versa, suggesting an opposite disease mechanism for both conditions.2,3,5 As 
over-activation of the complement system is thought to underlie AMD development, 
this suggests that the opposite mechanism in CSC would be reduced activity of 
the complement system. Associations of other complement genes besides CFH in 
the CFHR1, CFHR4, C4 and CD46 genes identified in this thesis certainly suggest 
an important role for the complement system in the disease. Currently, studies on 
complement measurements in CSC are limited and have not confirmed this hypothesis 
yet,14 therefore measurements in larger cohorts and of additional complement 
components need to be conducted to test the role of the complement system in CSC. 
Adrenomedullin 
Besides its function in the complement system, the first hypothesis that FH might 
have a function in the CSC disease mechanism was suggested based on its ability 
to bind to adrenomedullin (AM).1 This regulatory peptide is expressed by many cells, 
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including the RPE, is sensitive to corticosteroid stimulation, and is an important factor 
in blood pressure homeostasis and vasodilation, making it a very interesting molecule 
in light of the pathogenesis of CSC.1,29 
The CCP 15-20 domains of the FH protein are thought to be involved in binding 
of AM, which stabilizes AM and prevents it from degradation by metalloprotease 2, 
while also increasing the C3b-conversion ability of FH itself.29 Studies in rats indicate 
that administration of AM leads to reduced pro-inflammatory signals, accelerated 
wound healing and improved gut barrier function after ischemia.29 Although the role 
of AM in the CSC disease mechanisms was speculated already in 2003,1 no research, 
besides the CFH associations, has been published so far linking the ADM gene or AM 
protein to CSC, therefore it remains to be determined if this molecule via binding of 
FH has an influence on the development of CSC. 
Rare variants in CFH
Rare protein-altering variants in CFH have been associated to a range of diseases 
namely C3 glomerulopathy (C3G), characterized by kidney failure due to accumulation 
of C3 in the glomeruli; atypical hemolytic syndrome (aHUS), characterized by acute 
renal failure, microangiopathic hemolytic anemia and thrombocytopenia, and AMD.28 
Rare protein-altering variants identified in AMD tend to cluster at the N-terminal 
part of the protein in CCP3/5/7, indicating an effect on complement interactions, 
whereas aHUS/C3G mutations were more frequent in the SCR19/20 domain at the 
C-terminus, suggesting loss of binding interactions with cells.28 
In our exome sequencing study (Chapter 3.2), we did not observe a genome-wide 
significant association with a rare variant in CFH for cCSC (data not shown). The gene-
burden analysis of the CFH gene also did not show significant associations with the 
gene, but showed nominally significant associations with the neighboring KCNT2 
and CFRH5 genes. The absence of an association for CFH might be explained by the 
limited sample size of the exome sequencing study and the accompanied limited 
power to find associations, especially with rare variants. Besides the power issues, 
we can hypothesize that the association of CFH with cCSC might be driven by the 
common variants and their effect on gene-expression levels of CFH and neighboring 
genes. Another option is that the rare variants associated with cCSC are not located 
in CFH itself, but that the associated CFH haplotypes actually tag alterations of the 
neighboring CFHR genes, which are poorly covered in the exome sequencing study due 
to their repetitive nature. Deep sequencing of the region with for example molecular 
inversion probes and next-generation sequencing might shed light on potential rare 
variants in these genes, but first steps should focus on increasing sample size.  
Data acquisition and analysis of whole exome sequencing data comes with a set of 
challenges. When adding additional samples to the exome sequencing study various 
bioinformatics steps need to be taken into account. The GATK pipeline used to 
process the data in our studies includes an n+1 option for data, meaning that new 
samples can easily be joined to the dataset. However, one must take note to try to 
minimize the differences between different batches of sequencing data. Read depth, 
enrichment kit version, sequencing site and machinery all have to be as similar as 
possible, otherwise the possibility of false positives greatly increases. After merging 
the datasets it is still necessary to perform extended quality control on for example 
population substructure or kinship to achieve homogeneity between the different 
batches, before association analyses can be performed. Even then, confirmation 
of variants with Sanger sequencing is recommended, especially for insertions and 
deletions, which are in general more difficult to call. 
Steroid hormones in cCSC
The most described risk-factors for CSC are the male sex, the use of steroids and 
the presence of stress (Table 1 in Chapter 1). Both the stress- and sex-hormones 
are members of the steroid hormone system. Conversion of cholesterol by various 
enzymes produces hormones of three main pathways, namely, aldosterone involved 
in water homeostasis, the stress-hormones cortisol and cortisone, and finally the 
various sex-hormones with their androgenic, estrogenic and progestinic effects.30 
In Chapter 5, the only chapter of this thesis focusing on non-genetic risk factors, we 
investigated the steroid hormone status in cCSC patients. To date, a limited number 
of studies have looked at steroid hormone levels in individuals affected with cCSC, 
and the results are not very consistent between studies (Table 3).31-43 All previous 
studies focused on one or at maximum four steroids simultaneously, whereas we 
chose to measure 17 steroid hormones at the same time. Measuring multiple steroid 
in the same sample simultaneously allows for the assessment of interactions between 
steroids, is more cost efficient than measuring hormones separately and gives an 
overview of the complete hormone system balance with only one test. We observed 
elevated levels of androsterone, androstenedione, estrone and etiocholanolone, in 
patients with an active episode of cCSC. These hormones are all members of the 
sex-hormone section of the steroid hormone cascade, and have not been associated 
with cCSC before. Although it is still remains to be elucidated what the role of 
these hormones is in the occurrence of CSC, these results shed the first light on the 
involvement of sex-hormones in the etiology of cCSC.
It is perhaps surprising that no association with cortisol or aldosterone was observed 
in our steroid study, as these hormones are thought to be involved in the occurrence 
of CSC.44,45 Absence of association with cortisol might be explained by the current 
study set-up. For this study we used a single time point measurement, and as cortisol 
is known to fluctuate during the day, multiple measurements of the same individual 
at different time points might shed more light on the levels of this hormone in active 
cCSC. For aldosterone, although the levels itself were not altered in cCSC patients, 
we did observe an altered correlation of aldosterone with several other hormones in 
the system. Therefore, we hypothesize that there might be a disruption in the balance 
of the entire system, which might have an effect that leads to the cCSC phenotype, 
via a still unknown mechanism. It is however necessary to replicate these results in a 
larger sample of cCSC patients.
Unanswered questions and future studies
Because the number of studies focused on the genetics of CSC is still limited, many 
questions still remain unanswered. In this section, we briefly address some of the 
remaining questions and suggest possible studies in which they might be answered.
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Immune system-hormone system interactions
Within this thesis we have found multiple lines of evidence that the complement 
system, an important part of our innate immune system, is associated with cCSC, 
and that the system might be downregulated in cCSC patients. Additional lines of 
evidence of involvement of the immunes system in CSC come from the association 
of CSC with stress and the use of steroids.44 Prolonged or repeated stress stimuli, and 
use of exogenous glucocorticoids are known to suppress the immune system and 
inflammatory responses.46 Thus, multiple associations suggest that a downregulation 
of the immune system might underlie the biological mechanism of CSC. 
A significant lowering of the immune system activity would however result in a 
decreased resistance to pathogens as well. Although CSC patients are generally 
healthy besides their visual complaints, the increased frequency of Helicobacter pylori 
infection in CSC patients might suggest that this lowered immune system activation 
makes patients more susceptible to infections.47-51 However, instead of a significant 
downregulation giving rise to increased infection rates, it is more likely that the 
changes in the immune system are more subtle or maybe even only locally affecting 
the eye. Because the retina has a high metabolic turnover and energy demand, 
subtle changes in the biological mechanisms underlying these processes can lead to 
detrimental changes, as might also be the case for CSC. As studies on the immune 
system activity in CSC patients have not been performed on large scale yet, the exact 
status of the immune system in CSC patients still remains to be elucidated. Studies of 
aqueous humor or subretinal fluid, rather than systemic measurements in the blood, 
might be instrumental in discovering local effects present in the eye specifically. 
It is hypothesized that the interaction between stress and the immune system is 
partly mediated by the levels of glucocorticoids in the blood stream. Low levels of 
glucocorticoids (acute stress) will primarily occupy the MR, which has the highest 
binding affinity for GCs, whereas higher levels of GCs (chronic stress) will also promote 
binding to the GR when the MR is saturated, initiating downstream immunosuppressive 
processes mediated by the GR.46 However, the exact mechanism of these interactions 
and if they might be tissue-specific is not yet known.46 Interestingly, overactivation 
of the MR by glucocorticoids has been indicated as one of the underlying causes 
of CSC and currently clinical trials are performed to investigated the efficacy of 
eplerenone, a MR antagonist, as treatment for CSC.52,53 In our analysis of steroids 
in Chapter 5, however, we did not observe significant elevation of glucocorticoids 
or mineralocorticoids in patients with active cCSC, but did observe alterations in 
correlations with aldosterone and other steroid hormones in the system. 
Phenotypic differences in CSC
Currently, there is not a clear consensus of what defines the different CSC phenotypes, 
where some studies use an arbitrary threshold of 3-6 months to distinguish acute 
from chronic CSC, others use the amount of RPE alterations as differentiating 
factor.44 In Chapter 2.1, we proposed new phenotypic definitions for groups of 
patients with chronic CSC. We observed that genetic differences could be identified 
between the most typical form of cCSC and a group of patients that showed signs 
of other retinal diseases together with CSC. This study underscores the necessity of 
accurate phenotyping for cCSC. Therefore, for future studies, it is important that a 
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consensus is reached about the different phenotypes observed in the CSC spectrum, 
and that these separate phenotypes are taken into account when conducting genetic 
association analyses. 
It is still unclear why some people are affected with acute CSC and others are 
immediately affected with the more severe chronic CSC phenotype or why some 
people progress from acute to chronic CSC. In Chapter 2.4 we performed, to our 
knowledge, the first genetic analysis on acute CSC patients specifically. In this study 
we did not observe a genetic difference between acute and chronic CSC for the 
currently identified genetic risk variants. Although risk effects for acute CSC seemed 
higher than compared to chronic CSC patients, these results were not significantly 
different between both groups. This suggests that, based on the currently identified 
genetic variants, the biological mechanism of both forms of the disease might be 
similar. 
However, we cannot exclude that not yet identified genetic factors specific for acute 
or for chronic CSC might exist. When identified, these genetic variants might be used 
to distinguish the two forms of the disease, which might have clinical implications for 
treatment options for patients. One can hypothesize that multiple genetic variants 
combined could make a person more likely to develop chronic CSC instead of acute 
CSC and that for acute CSC, an environmental trigger might be more important for 
disease onset. Therefore, it might be interesting to investigate how the genetic burden 
of an individual interacts with potential environmental triggers, and might make some 
individuals more susceptible for one form of CSC compared to the other. 
The male-female difference
To date, genetic studies have not shed light on the difference in incidence of CSC 
in males (9.9:100,000) compared to females (1.7:100,000).54 For the studied CDH5 
variants, it was reported that the association was mainly driven by the male CSC 
patients. However, due to the low number of females included in the study (n=109),6 
it is likely that there was not enough power to conclusively determine absence of 
association in the female cohort and the results need to be validated. In the single 
GWAS performed on cCSC in Chapter 3.1, the X-chromosome was included in the 
analysis, however no associations were found on this chromosome and no sex-
specific associations were reported.5 In our exome sequencing study in Chapter 
3.2, we  observed a genome-wide significant association in female cCSC patients 
specifically. This suggests that cCSC might be more genetically heterogeneous in male 
cCSC patients and larger samples sizes are required to find significant associations in 
this group. 
It has been reported that sex differences occur in many organs, including the eye, but 
there is still much uncertainty about the role of gonadal hormones on these tissues. 
One recent review has summarized current literature about sex-differences in the 
eye and indicates a neuro-protective role for estrogens.55 As certain physiological 
processes in the eye appear to be different in males and females, we need to take into 
account that the observed sex-differences in CSC could occur due to an interaction 
between intrinsic sex-differences due to hormones, environmental exposures, and 
genetic susceptibility. 
In our analysis of steroid hormones in Chapter 5 we observed a significant association 
of four hormones of the sex-hormone system in males. Confirmation of these 
associations in female CSC patients would be very interesting to ascertain whether 
the hormone system is similarly altered in this group. Additionally, it would be 
very interesting to compare measurements of the same individual during an active 
phase of disease and an inactive phase, either after spontaneous resolution of the 
symptoms or after treatment. In this way the balance of the hormone system might 
be used as a predictive marker for disease status or treatment response. Also new 
treatment modalities might be developed in order to resolve the CSC episode by 
directly targeting the hormone system imbalance. 
The genetic component of CSC
After the completion of this thesis, the inheritance pattern of CSC still remains partly 
obscure. On one hand family pedigree data suggests a Mendelian inheritance pattern, 
while on the other hand the predominantly sporadic occurrence of CSC along with 
the connection with stress or steroid use hints at a complex disease. In our exome 
sequencing study on familial CSC in Chapter 4.2 we could not confirm nor exclude the 
proposed Mendelian inheritance pattern for CSC. We did not observe one variant or 
gene that clearly segregated with the disease, rather in each family multiple variants 
were found to segregate with the disease. This suggests that a complex inheritance 
pattern might indeed be more likely for CSC. However, it must be noted that included 
families were small and data of multiple generations were often not available. 
Therefore, including more and extended pedigrees in the analysis of familial CSC 
might be beneficial to obtain a more clear picture of variants and genes that might 
segregate in multiple families, and thus could contribute to familial CSC. 
Additionally, at the moment, all genetic studies have been conducted on individuals 
of Asian and European descent, and studies on other ethnicities are still lacking. It 
still remains unclear if incidences for CSC differ between ethnicities, and if there 
might be a genetic component contributing to these differences. Some studies have 
reported a higher incidence of CSC in Hispanic, Caucasian and Asian populations, 
compared to African-Americans, but others could not confirm these differences.44 
Also, it has been suggested that severity of CSC differs between populations, with 
a more severe phenotype in African-American and Asian populations. Therefore, 
in addition to replication of current findings in other ethnical groups, to determine 
population specific genetic associations and disease mechanisms, studies on African 
and Hispanic CSC patients will be a valuable addition to the field. 
Future studies for CSC as a complex disease
Conducting genetic association studies to identify rare variants associated with 
complex diseases has its challenges. First of all, the sample sizes required for finding 
single variant associations with rare genetic variants need to be very large due to 
the very low frequency of the variants involved, and significant costs are associated 
with the generation of such large datasets. Additionally, once conducted, stringent 
multiple-testing correction needs to be applied to the results. The latter issue can 
be partially solved with the use of gene-based analyses in which single variants are 
clustered into genes, thereby reducing the number of performed tests. However, 
for the studies included in this thesis, we mainly ran into the first issue, namely the 
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problem of sample size. Collaborations with the Leiden University Medical Center and 
the University Hospital of Cologne increased the number of cCSC patients included 
in the studies, but we did not have sufficient power to identify associations with 
single rare variants in our exome sequencing study in Chapter 4.1. In the future, 
collaborations with additional research institutes and possibly the initiation of a CSC 
consortium would be beneficial for all studies into the genetics of CSC. 
Besides including more samples in the analysis for both sporadic and familial CSC, 
studies on the interaction between genetic and environmental factors are necessary. 
In other complex diseases, such as AMD, it has already been observed that rare 
variants in families do not completely segregate with the phenotype.16 This is likely 
due to the presence of additional genetic variants and environmental triggers in 
affected individuals, and an absence of these variants and triggers in unaffected 
family members. Detailed questionnaires on lifestyle events, psychological stress, 
diet and other habits might be used to obtain information on potential environmental 
triggers that together with the genetic background of an individual increases risk for 
cCSC. Combining both genetic and environmental factors might help to generate a 
prediction model for the occurrence of CSC, which would allow for taking appropriate 
preventive steps in patients at risk for developing CSC and would aid in designing 
personalized treatment.  
One could even take this a step further by combining steroid or complement 
measurements in serum or plasma of individuals with CSC with genetic information, 
or environmental interactions. However, even more interesting would be measuring 
these factors in the target tissue, the eye. So far, one study has measured subretinal 
fluid composition during an episode of CSC.56 One male patient, with consistent 
complaints of CSC was treated with eplerenone, however due to a fibrous clot the 
subretinal fluid did not completely disappear and the patient was operated to remove 
the clot. During the operation subretinal fluid was collected, subsequent protein and 
metabolome analysis was performed on this sample and the measurements were 
compared to fluid from two patients with retinal detachment. 
Interestingly, multiple components of the complement system were altered in the 
CSC-subretinal fluid compared to fluid of the retinal detachments. This included 
downregulation of complement component 4B levels, whereas FH and FHR1 
levels were upregulated, which is consistent with our genetic associations of the 
corresponding genes. These results give the first hints of which processes are 
biologically altered in the eyes of CSC patients and might be causative for the 
accumulation of subretinal fluid. Although these results seem very promising and 
confirm our genetic associations, we do have to take into account that the patient 
included in this study was not treatment naïve, and that the administration of 
eplerenone might have already had impact on proteins and metabolites residing in 
the subretinal fluid pocket. 
Occasions for obtaining serous fluid from patients that at the same time have an 
episode of CSC and have complications that warrant eye surgery will be very rare. An 
intermediate solution could be to perform anterior chamber taps on CSC patients, 
although withdrawal of fluid from the anterior chamber has some associated risks 
and there are ethical considerations since this procedure is not routinely indicated 
for CSC.  
Finally, besides replication of current associations and investigating environmental 
interactions, genetic studies might investigate the relationships between genetic 
variants and treatment response to MR antagonists, micropulse laser or photodynamic 
therapy. Also, in light of the described copy number alterations for the C4B gene, 
genome-wide copy number alterations might be explored in CSC. 
Naturally, the identified genetic associations need to be translated into underlying 
biological mechanisms present in the RPE cells or choriocapillaris. Functional studies 
should be conducted in which the associated genetic variants are introduced into 
cultured RPE cells and choroidal endothelial cells, or such cells could be generated 
from induced pluripotent stem cells of CSC patients. The effect of different steroid 
hormones or complement factors on these cells can then be studied, in light of the 
CSC phenotype. For these models, possible read-outs might be RPE pump function, 
transmembrane resistance, choroidal neovascularization and morphology. Models 
combining multiple cell layers in transwell cultures, or organ-on-a-chip systems have 
the potential to uncover molecular interactions between RPE cells and the choroidal 
endothelium that are relevant for cCSC. 
In this thesis, we aimed to shed light on the genetic background of CSC. To do this, 
we performed candidate gene studies, unbiased genome-wide studies and measured 
hormone levels in patients with cCSC. We have identified new associations with 
CSC and have proposed studies in this general discussion that might be conducted 
in the future. Additional research on the disease will help us to better understand the 
processes behind the occurrence of CSC, and might help to improve treatment for 
patients affected by this curious disease.
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English summary
Central serous chorioretinopathy (CSC) is a chorioretinal disease characterized 
by fluid accumulation between the photoreceptor cells and the retinal pigment 
epithelium (RPE). Two different forms of CSC can be distinguished: acute CSC and 
chronic CSC. Acute CSC usually spontaneously resolves within three months with 
minimum RPE alterations and visual acuity loss. In chronic CSC (cCSC) the subretinal 
fluid persists and more wide-spread RPE atrophy and permanent vision loss occurs. 
The biological mechanisms behind the occurrence of CSC are unknown. The current 
hypothesis about the etiology suggests that an increased pressure from the underlying 
vasculature, the choroid, alone or in combination with a dysfunctional pump-function 
of the RPE leads to the subretinal fluid accumulation.
CSC is more frequent in males and primarily affects men of 45-55 years of age, whom 
are still in their active working years. Complaints of CSC include metamorphopsia and 
blurred vision, which has a significant influence on daily life. Besides the male gender, 
risk factors for CSC include the use of steroids, stress, hypertension, Helicobacter 
pylori infection and pregnancy. Currently, treatment options for CSC are limited, have 
variable success rates and their biological mechanisms are not clear. 
In this thesis we aimed to investigate the genetic components contributing to CSC. 
We used both candidate gene approaches and unbiased genome-wide approaches 
and focused mainly on the chronic form of the disease because of its more prominent 
effect on visual acuity loss. Studying the genetic architecture of CSC might provide 
us with new insights on the biological mechanisms underlying the disease and could 
uncover potential targets for new treatment options in the future. 
Clinical overlap exists between age-related macular degeneration (AMD) and CSC, 
and a previous study of a Japanese group suggested a genetic overlap as well. 
Therefore, in Chapter 2.1 genetic variants that were already known to be associated 
with AMD were investigated in a large cohort of cCSC patients. The cCSC patients 
were extensively phenotyped for this study and divided into three phenotypic groups. 
Group 1 was characterized by bilateral fluid accumulation and RPE alterations, group 
2 showed only unilateral abnormalities, whereas group 3 included individuals with 
retinal abnormalities indicative of other macular diseases. DNA was extracted for 292 
cCSC patients, 1311 healthy controls and 1147 AMD patients and was genotyped 
for 19 single nucleotide polymorphisms (SNPs) in AMD-associated genes and 6 SNPs 
in complement factor H (CFH). A significant association with cCSC was observed for 3 
SNPs (rs800292, rs1329428 and rs1065489) in the CFH gene, 1 SNP (rs10490924) 
at the Age-Related Macular Susceptibility 2 (ARMS2) locus and the CFH-H3 haplotype. 
Interestingly, the variants that were risk-conferring for AMD were protective for cCSC, 
and vice versa. Additionally, a significant difference between phenotype group 1 and 
group 3 was observed for two of the CFH SNPs and the ARMS2 variant, underscoring 
the importance of extensive phenotyping. 
In Chapter 2.2 the role of copy numbers of the complement component 4 (C4) gene 
was investigated in cCSC. The C4 gene, which has two forms (C4A and C4B), is located 
on a region of the genome which is prone to recombination, which has led to the 
occurrence of a variable amount of copies of C4 in different individuals. C4 encodes 
the C4 molecule which plays an important role in the classical and lectin pathway of 
the complement system. We identified a significant association between cCSC and 
the C4B gene in 197 cCSC patients of phenotype group 1 and 303 healthy controls. 
The absence of C4B increased the risk for cCSC, whereas carrying 4 copies of the 
gene was protective. These findings further support that the complement system 
might play a role in cCSC.
Chapter 2.3 focuses on genetic variants in the genes for the glucocorticoid (NR3C1, 
GR) and mineralocorticoid (NR3C2, MR) receptors. The associations of cCSC with 
stress, the use of steroids and other hormonal influences such as pregnancy have 
been extensively described in literature. Also, animal models have suggested a role 
for the mineralocorticoid aldosterone in the disease mechanisms. We selected 3 
functional variants in the GR and 2 in the MR to investigate their potential role in 
the cCSC disease mechanism in 336 cCSC patients of phenotype group 1 and 1314 
unaffected controls. We observed an association with cCSC for the rs2070951 SNP 
in the NR3C2 gene, and haplotypes in the same gene. The associated haplotypes have 
previously been associated to perceived stress, bridging the clinical risk factors for 
cCSC to an underlying genetic association. 
In Chapter 2.4 we tested the variants in CFH, ARMS2, NR3C2 and the copy numbers of 
C4B which were previously associated to cCSC in a cohort of 135 patients with acute 
CSC (aCSC). We also compared the minor allele frequencies of these variants with 
272 cCSC patients and 1385 controls whom were genotyped previously. Three SNPs 
(rs800292, rs1329428 and rs1061170) in the CFH gene and copy number variations 
of C4B were observed to be associated with aCSC. Although odds ratios appeared to 
be higher in aCSC compared to cCSC, no significant differences were observed for 
these variants between aCSC and cCSC. This suggests that, despite the difference 
in clinical presentation, the diseases appear to have a similar genetic predisposition. 
In Chapter 3.1 the first genome-wide association (GWAS) on cCSC was performed 
using a large cohort of 521 cCSC patients collected in three different university 
hospitals and 3577 European population controls. Single variant association analysis 
corrected for sex and ancestry background identified a genome-wide significant 
association with 20 SNPs located at the CFH locus on chromosome 1. Additionally, 
six suggestive association signals were observed that require replication. Haplotype 
analysis with 10 variants in the CFH gene identified an association with the risk-
conferring CFH-H2, CFH-H4, CFH-H5 haplotypes, which all carried the minor allele 
of the GWAS lead-variant, and the protective CFH-H1 and CFH-H3 haplotypes 
containing the major allele of the GWAS lead-variant. Pathway analysis with VEGAS2 
and MAGMA identified a significant association with the complement cascade. Finally, 
the GWAS genotyping data was combined with information of the GTEx database, 
which contains expression quantitative trait loci (eQTL). These eQTLs allowed us 
to predict the expression levels of genes in cCSC patients and controls using the 
PrediXcan program. A significantly different predicted expression in cCSC patients 
was observed for genes at the CFH locus including CFH, CFHR1, CFHR4 and KCNT2. 
Additionally, the complement inhibitor gene CD46 and the TNFRSF10A gene were 
also predicted to be differentially expressed in cCSC patients. This study underlines 
the importance of the complement system in the molecular disease mechanisms of 
cCSC and provides further leads for functional and genetic studies on cCSC. 
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Chapter 3.2 focuses on exome sequencing on a cohort of 269 cCSC patients and 
1586 population controls. Data was jointly processed and stringent quality control 
was performed on the dataset. This retained 263 patients and 1352 controls on 
which gene-burden analyses were performed using the Burden, SKAT and SKAT-O 
tests. The gene-based tests were performed including protein-altering variants or all 
exonic variants combined. Stratification of the data by sex identified a genome-wide 
significant association in female cCSC patients for the PIGZ and DUOX1 genes when 
protein-altering variants were used. Analysis including all exonic variants resulted in 
the associations of two additional genes, RSAD1 and LAMB3, in females specifically. 
Various suggestive associations were found in the male cohort and in the entire 
cohort corrected for sex, however none of these associations reached genome-wide 
significance. The number of carriers of rare variants in the individual PIGZ, DUOX1, 
LAMB3 and RSAD1 genes was significantly higher in female cCSC patients compared 
to female controls. In total for the 4 genes combined, 45.5% of the female cCSC 
patients carried at least one rare variant in either of the 4 genes, compared to 18.5% 
carriers in the female controls. This sex-specific associations observed in this study 
suggest that the contribution of rare genetic variants to cCSC might be different 
between the sexes and that the disease mechanisms might differ between males and 
females. 
In Chapter 4.1 we investigated the phenotype of 103 individuals of 23 different families 
in which cCSC was present in at least two individuals. Extensive multimodal imaging 
was performed on cCSC patients and their family members to assess the phenotypic 
profile of familial cCSC. In 45 individuals (44%) subretinal fluid accumulation or 
leakage was observed indicative of cCSC. In the family members of these patients, 
27 individuals showed findings suggestive of cCSC characterized by a wide spectrum 
of RPE alterations resembling cCSC but without subretinal fluid accumulation. The 
remaining individuals were unaffected. Additionally, this study included 24 individuals 
that had been phenotyped in 1995-1996, and for whom long-term follow-up was 
investigated in this study. In total, 24% of these individuals showed more severe 
phenotypes than observed in the previous study, such as subretinal fluid accumulation 
or RPE alterations not present before. With this study we have shown that CSC 
clusters in families, and that although many individuals remain asymptomatic they 
might be at risk for developing lesions predisposing to CSC. 
Chapter 4.2 investigates the genetics of familial CSC using most of the families 
that were included in Chapter 4.1. Whole exome sequencing was performed on 
72 individuals of 18 different families, including 33 cCSC patients, 18 individuals 
with suggestive cCSC and 18 unaffected family members. Segregation analysis was 
performed for each family for rare genetic variants with a frequency <1% in the 
population, selecting those variants only present in affected individuals and not in 
unaffected family members. Combining the segregating variants in the families 
identified 12 different variants present in 2 families. One of these variants in the 
PTPRB gene was also associated with CSC in our case-control cohort (Chapter 3.2) 
and has potential as a cCSC candidate gene because of its biological function. In total, 
in 28 genes multiples different segregating variants were observed in the families. 
For these genes RareIBD familial burden analysis was performed and the results were 
compared with our gene-burden analyses on the case-control cohort. However, no 
overlap was observed between the analyses. Although a Mendelian inheritance was 
suggested for CSC based on pedigree data, in this study we did not observe a clear 
inheritance with a single rare variant nor with different rare variants within a single 
gene for cCSC. This underlines the notion that CSC is a complex disease for which 
both genetic and environmental factors should be taken into account. 
In Chapter 5 we investigated the steroid hormone status of male cCSC patients by 
simultaneously measuring 17 different steroid hormones in a cohort of 46 patients 
with active cCSC and 46 age- and sex-matched unaffected controls. Levels of 
androsterone, androstenedione, estrone and etiocholanolone were elevated in 
patients compared to controls. Additionally, correlations between the different 
hormone measurements were assessed and compared between cCSC patients and 
controls. Correlations between aldosterone and androsterone, estrone, DHEA, 
DHEAS and 11-deoxycortisol were different compared to controls as well as 
androsterone with estrone and DHT with 17-OHP. These differences indicate an 
altered hormone system balance in patients with active cCSC. This study is the first to 
show associations of cCSC with increased levels of androsterone, androstenedione, 
estrone and etiocholanolone and the first to suggest that evidence for an altered 
hormone system balance in these patients by screening multiple components of the 
steroid hormone system simultaneously.
In the last chapter of this thesis, Chapter 6, all studies on the genetics of CSC to date 
have been summarized and are discussed in the context of literature. Genetic studies 
on pachychoroid, one of the CSC endophenotypes, are also discussed and the role 
of the complement system in the disease is further elaborated. Finally, future studies 
are proposed that might help to unravel the disease mechanisms underlying cCSC. 
277
7
Nederlandse Samenvatting
Centrale sereuze chorioretinopathie (CSC oftewel serosa) is een chorioretinale 
aandoening die wordt gekenmerkt door een vochtophoping, ook wel subretinaal 
vocht genoemd, tussen de het netvlies en het retinaal pigmentepitheel (RPE) in het 
oog. We onderscheiden twee verschillende vormen van serosa namelijk acute en 
chronische serosa. Acute serosa verdwijnt gewoonlijk spontaan binnen drie maanden 
na het ontstaan van de eerste klachten met minimale aantasting van het RPE en weinig 
verlies van het gezichtsvermogen. Bij chronische serosa blijft de subretinale vloeistof 
aanwezig, treden er meer en grotere RPE veranderingen op en is er permanent verlies 
van het gezichtsvermogen. De biologische mechanismen die ten grondslag liggen aan 
het optreden van serosa zijn nog onbekend. De huidige hypothese over het ontstaan 
van de aandoening is dat een verhoogde druk van het onderliggende vaatstelsel, 
het vaatvlies of choroidea genoemd, alleen of in combinatie met een verminderde 
pompfunctie van het RPE leidt tot de subretinale vochtophoping.
Serosa komt het meest voor bij mannen tussen de 45-55 jaar oud, die nog professioneel 
actief zijn. De klachten die gepaard gaan met het hebben van serosa zijn onder andere 
metamorfopsie (vervorming van rechte lijnen) en wazig zicht, wat een aanzienlijke 
invloed heeft op het dagelijks leven van de patiënt. Naast het mannelijke geslacht 
zijn er verschillende andere risicofactoren voor serosa beschreven zoals het gebruik 
van steroïden, het hebben van stress, hypertensie, Helicobacter pylori infectie en 
zwangerschap. Op dit moment zijn de behandelingsopties voor serosa beperkt en 
hebben ze variabele slagingspercentages. Daarnaast zijn de biologische mechanismen 
die ten grondslag liggen aan de behandelingen nog niet geheel duidelijk. Om de 
behandelingsopties voor de patiënt te verbeteren is het belangrijk meer te weten te 
komen de oorzaken van serosa.
In dit proefschrift hebben we de genetische componenten die bijdragen aan het 
ontstaan van serosa onderzocht. Hiervoor hebben we kandidaatgen studies en 
genoomwijde studies uitgevoerd en concentreerden we ons voornamelijk op de 
chronische vorm van serosa, omdat deze vorm van de aandoening een grotere invloed 
heeft het gezichtsvermogen en de kwaliteit van leven van de patiënt. Het bestuderen 
van de genetische achtergrond van serosa kan ons nieuwe inzichten geven over welke 
biologische mechanismen ten grondslag liggen aan de ziekte en welke mechanismen 
in de toekomst potentiële aangrijpingspunten zouden kunnen zijn voor nieuwe 
behandelingsmogelijkheden.
Er bestaat klinische overlap tussen leeftijdsgebonden maculadegeneratie (LMD) een 
andere netvlies aandoening die vooral bij mensen boven de 60 jaar voorkomt, en serosa. 
Het onderzoek van een Japanse groep suggereerde ook een genetische overlap tussen 
de twee aandoeningen. Daarom hebben we in Hoofdstuk 2.1, in een groot cohort 
van chronische serosa patiënten, genetische varianten onderzocht waarvan al bekend 
was dat ze geassocieerd waren met LMD. Voor deze studie hebben we de klinische 
karakteristieken van de chronische serosa patiënten uitgebreid bekeken en hebben 
we de patiënten in drie groepen opgedeeld (fenotypering). Groep 1 werd gekenmerkt 
door vochtophoping en RPE veranderingen in beide ogen, groep 2 vertoonde slechts 
afwijkingen in één oog, terwijl groep 3 bestond uit personen met retinale afwijkingen 
die aanwijzingen gaven voor andere aandoeningen van de macula in combinatie met 
serosa. Voor deze studie hebben we DNA verzameld van in totaal 292 chronische 
serosa patiënten, 1311 gezonde controles en 1147 patiënten met LMD. Daarna 
zijn er 19 nucleotide veranderingen, oftewel single nucleotide polymorfismen 
(SNPs), getest in deze groepen. De varianten lagen in LMD geassocieerde genen, en 
daarnaast werden zes varianten in het complement factor H (CFH) gen getest in deze 
individuen. Een significante associatie met chronische serosa werd waargenomen 
voor drie varianten in het CFH gen (rs800292, rs1329428 en rs1065489) en één 
variant in het Age-Related Macular Susceptibility 2 (rs10490924, ARMS2) locus. Toen 
we naar de combinatie van de verschillende varianten (haplotype) in het CFH gen 
keken, vonden we ook een associatie met het CFH-H3 haplotype. Verassend genoeg 
zagen we dat de varianten die risicodragend waren voor LMD juist beschermend 
waren voor chronische serosa en vice versa. Bovendien werd een significant verschil 
tussen fenotypegroep 1 en groep 3 waargenomen voor twee van de CFH varianten en 
de ARMS2 variant, hetgeen het belang van uitgebreide fenotypering aangeeft.
In Hoofdstuk 2.2 werd de rol van het aantal kopieën van het complement component 4 
(C4) gen onderzocht in chronische serosa. Het C4 gen, dat twee vormen heeft (C4A en 
C4B), ligt op een gebied van het genoom dat gevoelig is voor recombinatie. Dit heeft 
er toe geleid dat er een variabel aantal kopieën van C4 in verschillende individuen 
aanwezig kan zijn. Het C4 gen codeert voor het C4 eiwit dat een belangrijke rol speelt 
in de klassieke en lectine routes van het complementsysteem, een onderdeel van 
ons afweersysteem. In deze studie vonden we een significante associatie tussen 
chronische serosa en het C4B gen bij 197 chronische serosa-patiënten van fenotype 
groep 1 en 303 gezonde controles. De afwezigheid van C4B verhoogde het risico op 
chronische serosa, terwijl het dragen van vier kopieën van het gen beschermend was. 
Aangezien C4 een rol speelt in het complement systeem ondersteunt deze studie dat 
het complementsysteem een rol zou kunnen spelen in chronische serosa.
De associaties van chronische serosa met stress, het gebruik van steroïden en 
andere hormonale veranderingen zoals zwangerschap zijn uitgebreid beschreven 
in de literatuur. Daarnaast hebben diermodellen ook een rol gesuggereerd voor 
het mineralocorticoïde hormoon aldosteron in het ziektemechanisme van serosa. 
De verschillende hormonen in het lichaam binden aan receptoren om hun functie 
uit te voeren en veranderingen in deze receptoren kunnen invloed hebben op het 
effect van het hormoon. Daarom richt Hoofdstuk 2.3 zich op genetische varianten 
in de genen voor de glucocorticoïd (NR3C1, GR) en mineralocorticoïd (NR3C2, MR) 
receptoren. We selecteerden 3 functionele varianten in de GR en 2 in de MR om 
hun mogelijke rol in het ziektemechanisme van chronische serosa te onderzoeken. 
De aanwezigheid van deze varianten werd bepaald in 336 patiënten met chronische 
serosa van fenotypegroep 1 en 1314 gezonde controles. We zagen dat er een variant 
in het NR3C2 (rs2070951) gen en haplotypen in hetzelfde gen vaker voorkwam in 
de patiënten met chronische serosa. Deze haplotypen waarvoor we een associatie 
zagen, werden eerder ook gevonden in mensen die een groter gevoel van stress 
hadden, waardoor er een brug geslagen wordt tussen de klinische risicofactoren voor 
chronische serosa en de onderliggende genetische associatie.
In Hoofdstuk 2.4 hebben we de varianten die eerder beschreven zijn voor chronische 
serosa in een groep van 135 patiënten met acute serosa getest. Deze varianten waren 
aanwezig in de CFH, ARMS2, NR3C2 genen en het aantal kopieën van C4B werd 
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ook onderzocht. De aanwezigheid van de varianten in de acute serosa groep werd 
vergeleken met 272 chronische serosa-patiënten en 1385 controles die eerder waren 
getest. Drie genetische varianten in het CFH gen (rs800292, rs1329428 en rs1061170) 
en het aantal kopieën van het C4B gen bleken ook geassocieerd te zijn met acute 
serosa. Hoewel de effecten van deze varianten hoger leken te zijn voor acute serosa, 
werden er geen significante verschillen waargenomen voor de frequentie van deze 
varianten tussen acute serosa en chronische serosa. Dit suggereert dat, ondanks het 
verschil in klinische presentatie, de ziekten een vergelijkbare genetische achtergrond 
lijken te hebben.
In Hoofdstuk 3.1 werd de eerste genoomwijde associatie analyse (GWAS) voor 
chronische serosa uitgevoerd met behulp van een groot cohort van 521 chronische 
serosa patiënten uit drie verschillende universitaire ziekenhuizen en 3577 Europese 
populatiecontroles. De analyse gecorrigeerd voor geslacht- en genetische etniciteit 
identificeerde een genoomwijde associatie met 20 varianten in het CFH locus op 
chromosoom 1. Daarnaast werden zes suggestieve associaties waargenomen die nog 
moeten worden gerepliceerd. Haplotype analyse met 10 varianten in het CFH gen 
identificeerde een associatie met de risico-verhogende CFH-H2, CFH-H4, CFH-H5-
haplotypen, welke allemaal het secundaire allel van de GWAS-topvariant droegen. De 
beschermende CFH-H1 en CFH-H3-haplotypen droegen daarentegen het wildtype 
allel van de GWAS-topvariant. De VEGAS2 en MAGMA programma’s werden gebruikt 
om de informatie van meerdere genen te combineren om een gemeenschappelijk 
biologisch mechanisme te identificeren. Deze analyse toonde een significante 
associatie met de complementcascade aan. Tenslotte werden de GWAS gegevens 
gecombineerd met informatie van de GTEx-database. Deze database bevat informatie 
over de invloed van een genetische variant op de expressie van een gen in de vorm 
van eQTLs. Met deze eQTLs konden we de expressieniveaus van genen in chronische 
serosa patiënten en controles met behulp van het PrediXcan programma voorspellen, 
zonder deze te hoeven meten. Het programma voorspelde een verschillende expressie 
voor de genen in het CFH locus (CFH, CFHR1, CFHR4 en KCNT2) in chronische 
serosa patiënten. Bovendien werd er ook voorspeld dat het CD46 gen, dat codeert 
voor een complement remmer, en het TNFRSF10A gen een afwijkende expressie 
hebben in chronische serosa patiënten. Deze studie onderstreept het belang van het 
complementsysteem in het moleculaire ziektemechanismen van chronische serosa 
en biedt verdere aanknopingspunten voor functionele en genetische studies naar de 
aandoening.
Hoofdstuk 3.2 richt zich op het exoom sequencen van een groep van 269 chronische 
serosa patiënten en 1586 populatiecontroles. Bij exoom sequencing wordt er gekeken 
naar alle regio’s in het genoom die coderen voor een eiwit, namelijk de exonen van 
een gen. De genetische informatie van alle individuen werd samen verwerkt en er 
werd een strenge kwaliteitscontrole op de dataset uitgevoerd. Daardoor bleven er 
totaal 263 patiënten en 1352 controles over waarop de analyses konden worden 
uitgevoerd. Voor deze studie hebben we gen-testen gebruikt (Burden, SKAT en 
SKAT-O) deze testen gebruiken meerdere varianten in het zelfde gen als input en 
combineren de statistiek van al deze varianten tot één associatie signaal voor elk 
gen. We hebben de gen-testen eerst uitgevoerd met alleen varianten die het eiwit 
van een gen direct veranderden en daarna ook met alle varianten die in de exonen 
aanwezig waren. Door de dataset op te delen in mannen en vrouwen vonden we een 
genoom-wijde associatie in de vrouwelijke chronische serosa patiënten voor de PIGZ 
en DUOX1 genen wanneer we alleen de eiwit-veranderende varianten includeerden 
in de analyse. De analyse waarbij alle varianten in de exonen werden gebruikt 
resulteerde in de associaties van twee andere genen, RSAD1 en LAMB3, in de vrouwen. 
Verschillende suggestieve associaties werden gevonden in het mannelijke cohort en 
in het volledige cohort gecorrigeerd voor geslacht, maar geen van deze associaties 
bereikte de genoom-wijde significantie drempel. Het aantal dragers van zeldzame 
varianten in de PIGZ, DUOX1, LAMB3 en RSAD1 genen was significant hoger in de 
vrouwen met chronische serosa vergeleken met gezonde vrouwen. In totaal droeg 
45,5% van de vrouwen met chronische serosa ten minste één zeldzame variant in 
één van de 4 genen, vergeleken met 18,5% van de controles. De geslachtsgebonden 
associaties die we in deze studie hebben gevonden, suggereren dat de bijdrage van 
zeldzame genetische varianten in chronische serosa mogelijk verschillend is en dat 
het ziektemechanisme kan verschillen tussen mannen en vrouwen.
In Hoofdstuk 4.1 onderzochten we de fenotypes van 103 individuen van 23 
verschillende families waarin chronische serosa aanwezig was in tenminste twee 
familieleden. Uitgebreide beeldvorming werd uitgevoerd op de patiënten en hun 
familieleden om het fenotypische profiel van familiaire chronische serosa te bepalen. 
Bij 45 personen (44%) werd een subretinale vochtophoping of lekkage waargenomen 
die kan wijzen op chronische serosa. In de familieleden van deze patiënten vertoonden 
27 personen bevindingen die wijzen op chronische serosa, gekenmerkt door een 
breed spectrum van RPE-veranderingen die op chronische serosa lijken maar zonder 
subretinale vochtophoping. De overige personen vertoonden geen oogafwijkingen 
die konden duiden op serosa. Daarnaast bevatte deze studie ook 24 individuen 
die in 1995-1996 al waren onderzocht, en waarvoor we nu lange termijn follow-
up gegevens konden verzamelen. In totaal vertoonde 24% van deze personen een 
ernstiger fenotype dan werd waargenomen in de vorige studie, zoals een subretinale 
vochtophoping of RPE-verandering die eerder niet aanwezig was. Met deze studie 
hebben we aangetoond dat serosa voorkomt in families, en dat hoewel veel individuen 
asymptomatisch blijven, ze mogelijk een risico lopen op het ontwikkelen van laesies 
die lijken op serosa.
In Hoofdstuk 4.2 hebben we de genetica van familiale serosa onderzocht in de 
meeste families die zijn opgenomen in Hoofdstuk 4.1. Exoom sequencing werd 
uitgevoerd op 72 individuen van 18 verschillende families, waaronder 33 chronische 
serosa patiënten, 18 individuen met suggestieve chronische serosa en 18 gezonde 
familieleden. Segregatie-analyse werd in elke familie uitgevoerd voor zeldzame 
genetische varianten met een frequentie <1% in de populatie, waarbij die varianten 
werden geselecteerd die alleen aanwezig waren in individuen met serosa en niet in 
gezonde familieleden. Toen we alle segregerende varianten die aanwezig waren in de 
families combineerden, vonden we 12 verschillende varianten die aanwezig waren 
in 2 families. Een van deze varianten in het PTPRB gen was ook geassocieerd in ons 
case-control cohort (Hoofdstuk 3.2) en is een mogelijk kandidaatgen voor serosa 
vanwege zijn biologische functie. In totaal werden er in 28 genen verschillende 
segregerende varianten waargenomen in de families. Voor deze genen werd een 
familiare gen-analyse uitgevoerd met behulp van het programma RareIBD. Deze 
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resultaten werden vergeleken met onze analyse van de gen-testen in het case-control 
cohort. Er werd echter geen overlap waargenomen tussen de analyses. Hoewel een 
dominante overerving werd voorgesteld voor serosa op basis van stamboomgegevens, 
observeerden we in deze studie geen duidelijke overerving met een enkele zeldzame 
variant noch met meerdere zeldzame varianten in hetzelfde gen voor chronische 
serosa. Dit onderstreept het idee dat serosa een complexe ziekte is waarbij rekening 
moet worden gehouden met zowel genetische factoren als omgevingsfactoren.
In Hoofdstuk 5 hebben we de steroïde hormoonstatus van chronische serosa 
patiënten onderzocht door gelijktijdig 17 verschillende steroïde hormonen te meten 
in een groep van 46 mannelijke patiënten met actieve chronische serosa en 46 
gezonde mannelijke controles van dezelfde leeftijd. De niveaus van androsteron, 
androstenedione, oestron en etiocholanolone in het bloed waren verhoogd bij 
patiënten in vergelijking met controles. We vergeleken ook de correlaties tussen de 
verschillende hormoonmetingen in de patiënten en controles. De correlaties tussen 
aldosteron en androsteron, oestron, DHEA, DHEAS en 11-deoxycortisol waren 
verschillend in de patiënten met serosa in vergelijking met de controles, evenals 
de correlaties van androsteron met oestron en DHT met 17-OHP. Deze verschillen 
duiden op een verandering in de hormoonhuishouding bij patiënten met actieve 
chronische serosa. Dit is de eerste studie die verhoogde spiegels van androsterone, 
androstenedione, oestron en etiocholanolone laat zien in patiënten met actieve 
chronische serosa. Bovendien is het de eerste keer dat een verandering in de 
balans van het hormoonsysteem is aangetoond bij deze patiënten door meerdere 
componenten van het steroïde hormoon systeem tegelijkertijd te meten.
In het laatste hoofdstuk van dit proefschrift, Hoofdstuk 6, zijn alle studies over 
de genetica van serosa tot op heden samengevat en worden ze besproken in de 
context van de literatuur. Genetische studies over pachychoroid, een van de serosa 
endofenotypen, worden ook besproken en de rol van het complementsysteem bij de 
ziekte wordt verder uitgewerkt. Tenslotte worden toekomstige studies voorgesteld 
die kunnen helpen om het ziektemechanisme dat ten grondslag ligt aan chronische 
serosa verder te ontrafelen.
Dankwoord
Het is zover, na 4 jaar is de reis voorbij, en zit ik in een café in Nijmegen het laatste 
gedeelte van mijn proefschrift te schrijven. Het dankwoord wordt ook wel het meest 
gelezen stuk van een proefschrift genoemd en het schrijfproces voelt een beetje als 
een artikel waar je al lang op zit te broeden. Door de jaren heen maak je veel dingen 
mee, collega’s worden langzaamaan vrienden waarmee je lief en leed deelt, mensen 
om je heen gaan weg, of er komen nieuwe mensen bij, daarom is het dan ook lastig 
om de ervaringen en de dankbaarheid van meerdere jaren samen te vatten in een stel 
bladzijden. Wellicht is dit hoofdstuk wel het lastigste van mijn proefschrift te noemen, 
gelukkig ben ik dit keer zelf de editor. ;)
Zonder mijn gezellige en leuke collega’s bij oogheelkunde en genetica was mijn 
promotie een hele andere ervaring geweest, maar velen van jullie ken ik al langer 
dan 4 jaar door mijn stages bij beide afdelingen. So first of all, Anna I would like to 
thank you for guiding me during my first internship, for teaching me to distinguish 
male from female fruitflies (a skill that still comes in handy during summer) but also 
for all the great memories we made (cinco vino blanco!), I still have to make that 
paella again! Bjorn, bedankt voor al je hulp tijdens mijn stage en tijdens mijn PhD 
periode, je wist altijd een oplossing te vinden als er in het lab of bij de serosadagen 
een probleem was (hopelijk gaat die printer een keer de deur uit!)! Ellen en Jaap, 
bedankt voor al jullie antwoorden op mijn vragen in het lab, zonder jullie had mijn PhD 
een stuk langer geduurd denk ik! En ook bedankt voor alle gezelligheid als ik weer 
eens een grote hoeveelheid 384-platen moest pipetteren! Saskia, bedankt voor de 
goede samenwerking wat betreft het verzamelen van nieuwe DNA samples voor mijn 
onderzoek, en het delen van je celkweek expertise. Simone en Wendy, mijn korte 
tijd bij diagnostiek was erg gezellig en leerzaam door jullie inzet! Galuh, is it an opil 
or an ingus? I still forget which one is which, thank you for all the fun times! Julio and 
Riccardo, thank you so much for the good times we had! Riccardo remember: “Don’t 
be lazy switch like crazy!” Julio, being a paranimf with you was great, good luck in 
London! Silvia, thanks for the great time at Graspop, and all the other concerts! Frans, 
Ronald, Hannie, Erwin en Rob bedankt voor jullie waardevolle input op mijn project 
tijdens de sensory disease meetings. Christian en Dimitra bedankt voor jullie hulp 
met het exoom sequencing project en het delen van jullie expertise op dit gebied! 
Remco bedankt voor het helpen met al mijn computer vragen en mijn redder in nood 
zijn als ik weer eens een programma wou hebben dat het Radboud niet toestaat. Alle 
andere collega’s van genetica, heel erg bedankt voor alle ervaringen in het lab, de 
koffiekamer, alle afdelingsuitjes, feestjes en afterparty’s in de Malle Babbe, gelukkig 
hebben we de foto’s nog!
Tijdens mijn PhD heb ik de gelukkige mogelijkheid gekregen heel wat tripjes te maken 
voor cursussen en conferenties. Janita en Marieke bedankt voor de gezellige tijd 
in Berlijn! Die zonnebank en speciale stapavond heeft een blijvende indruk achter 
gelaten. Ralph, onze roadtrip naar Californië was echt super! Selfie-koning! Bedankt 
voor de gezelligheid en je altijd goede humeur! (sorry dat ik zo vaak in slaap viel als 
je aan het rijden was!) Lot, Margot, Stefan, Laurens, Christian, Sinje en Ilja het delen 
van het appartement in Orlando (more bacon!), het gezellig samen uit eten gaan (met 
Han), het bizarre extravagante feestje en als afsluiting Universal studios was super! 
Laurens speciaal bedankt dat ik met je mee mocht naar het “Give kids the world” dorp, 
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dat was een hele speciale ervaring. Dear Suus, Mubeen and Alex, our trip in Hawaii 
was amazing. Thank you so much for this experience, the sea, sun and Aloha spirit was 
so much better with you guys there! I will think about you every time I see a sea turtle! 
What can I say except : “You’re welcome!!”
Dear ophthalmology (ex-)roommates of the real PhD kamer 1, my PhD would have 
been so much more boring without you. Clasien bedankt dat we altijd je chocolade 
mochten opeten, je enthousiasme en interesse in ons onderzoek, het windsurfen en 
natuurlijk het passen op mijn monster Pico. Bart, bedankt voor het helpen met Epic, en 
andere computer gerelateerde vragen. Sarah thanks for the coffee breaks, your great 
ability to tell funny anecdotes and ranting sessions :p. Susette, ik zal nog steeds niet 
naar de kneu luisteren. Erkin thank you for your sense of humor, and nerdiness, and 
remember lunch breaks are important! Elja, ons geadopteerde kamergenootje, wat 
heb jij een doorzettingsvermogen! Bedankt voor de gezelligheid en de welverdiende 
biertjes in de Aesculaaf!
Alle (ex-)PhDs van de andere kamer(s), Nathalie, Michel, Freekje, Freerk, Nicole, 
Ramon, Yara,  Shazia, Sanne, Vivian, Bart, Tom, Esmee, Birgit, Anita en Patty bedankt 
voor jullie input in mijn project tijdens de research meeting. Daarnaast zal ik de 
gezelligheid bij een van onze spelletjesavonden, filmmarathons, DOPS en andere 
feestjes niet gauw vergeten. En denk ik met veel plezier terug op het maken van al die 
mooie PhD filmpjes. Stanley in het specifiek bedankt voor al je audio-magie, ik kan 
toch best wel zingen! Constantin great work with all the movies, and a lot of luck with 
your photography career! Dyon, wanneer gaan we weer eens gamen en pizza eten? 
Thanks G voor de gezelligheid!
Dear Arjen, Jordi, Marc and Erkin thank you for all the bioinformatic support, and for 
helping me to find the love for computer science. I can only hope to accomplish your 
skill levels in the near future! Also, let’s keep killing monsters together Marc and Jordi! 
Fight the gloom!
Maaike en Lisa het was super om jullie als studenten te hebben. Ik heb erg veel van 
jullie geleerd, en jullie hopelijk ook wat van mij ;)! Heel veel succes met jullie eigen 
PhD projecten!
Berna en Francis en de andere dames van het secretariaat, heel erg bedankt voor 
het regelen van al die posters, het beantwoorden van allerlei vragen en alle gezellige 
praatjes bij het koffiezetapparaat.
Alle mensen op de poli heel erg bedankt voor het helpen met de serosadagen en 
Lonneke speciaal bedankt voor het bloedprikken van al mijn patiënten!
Lieve Asha, zonder jouw tomeloze inzet waren er nooit zoveel serosa patiënten 
opgenomen in mijn onderzoek. Het enthousiasme waarmee je je inzet voor het serosa 
onderzoek en waarmee je beneden op de poli rondloopt is bewonderenswaardig, 
heel erg bedankt dat je me wegwijs heb gemaakt in de wereld van de patiënt. Ook 
bedankt voor al het gezellige kletsen, het samen rennen van de Dam-tot-damloop en 
je positieve blik op het leven! You’re the best! 
Lieve Eveline, samen DOPS organiseren en het zijn van Maartje’s paranimf was een 
super ervaring, fijn dat we zo goed op een lijn zaten! Bedankt voor alle gezellige 
momenten tijdens en buiten het werk, jij gaat het ver schoppen als oogarts! 
Dear Alex, the last years it has been great being both your friend and colleague! I 
admire your love for science and your dedication to strive for the best. Let’s keep 
cycling our race bikes through life together with Erwin, when is the next tour? ;)
Camiel, Elon en Danial bedankt voor de fijne samenwerking op het Leids-Nijmeegse-
serosa project. Fijn dat jullie het onderzoek blijven voorzetten, heel veel succes 
daarmee, dat gaat helemaal goed komen!
Heel erg bedankt Anneke voor je goede begeleiding tijdens mijn project. Je wist mijn 
artikelen altijd net even dat beetje extra te geven en naar een hoger niveau te tillen. 
Fijn dat ik altijd bij je binnen kon lopen voor vragen!
Eiko, ik heb het al vaker tegen je gezegd en ik blijf het herhalen: “Zonder jou zou dit 
proefschrift er niet geweest zijn”. Bedankt voor je goede begeleiding de afgelopen 
jaren, je tomeloze inzet voor mijn project, je vaardigheid om me enthousiast te 
houden en je gevoel voor humor. Ik kon altijd m’n ei bij je kwijt, daarvoor ben ik je erg 
dankbaar. Ik ben benieuwd wat de toekomst je brengt! Let’s keep in touch!
Lieve Aafke en Tamara, we zijn al zo lang vriendinnen dat het niet meer uitmaakt dat 
je elkaar een paar maanden niet ziet. Bedankt dat jullie er allebei altijd waren voor 
de nodige gezelligheid, spelletjes, etentjes en afleiding in een behoorlijke drukke en 
stressvolle tijd waarin mijn hoofd nog wel eens vergat om wat af te spreken ;). 
Lieve Myrte, wat was het een fijne ervaring om eerst met jou samen te werken 
en daarna samen ons huis te delen! Ik heb heel veel van je geleerd op persoonlijk 
en professioneel vlak, en heb veel bewondering voor je altijd aanwezig energie en 
niet-miepen-maar-doen-mentaliteit. Ik wens je heel erg veel plezier en succes in de 
toekomst en zal met veel plezier terugdenken aan ons gezamenlijke huis!
Wat zullen we vieren? Bata-vieren!! Alle kano-maatjes heel erg bedankt voor 
alle gezellige trainingen, toernooien, spelletjesavonden, borrels, zaal- en 
zwembadtrainingen. Ineke ons weekendje Lissabon was super! Snel nog maar een 
keer overdoen, dit keer met de mannen? Eva, Elke, Hein, Lein, Abel, Maartje en Bram 
bedankt voor alle gezellige spelletjesavonden!
Fietsend de PhD door, letterlijk en figuurlijk. Bedankt Jules voor alle ongein op de 
weg en het eindeloos kletsen over capibara’s en lievelingskleuren. Fokko en Kenneth 
ook bedankt voor het wind-tegenhouden, ik ga jullie nog missen in Nieuw Zeeland ;). 
Het is bijna onmogelijk om de intriges in de tijden van King Arthur of de tweede 
wereldoorlog, de avonturen op Skye, de ervaringen met het runnen van restaurants, 
energiemaatschappijen, boerderijen en onze vaardigheden als koeienhandelaars, 
wereldveroveraars en treinmachinisten samen te vatten in zo’n klein stukje tekst. 
Lieve Rob, Annemarie, Esther, Maarten, Linsey, Joost, Laurent en Rosalie heel erg 
bedankt voor alle leuke middagen, avonden en weekenden vol met avontuur, veel bier 
en lekker eten! Langzaamaan is de spelletjesgroep uitgegroeid tot wat hij nu is, en ik 
hoop dat ondanks dat we zo allemaal onze aparte wegen gaan, we nog steeds zo door 
kunnen blijven spelen! 
Annemarie en Esther, samen zijn we ooit begonnen met studeren en binnenkort 
285
7
breekt echt de tijd aan dat we na 9 jaar niet meer bij elkaar in de buurt wonen. Esther, 
laten we vooral doorgaan met onze carnavalstraditie, dan wordt het misschien nog 
wat met mijn Limburgs, roetewisser!! Annie, ik ben heel benieuwd wanneer ik je voor 
het eerst op tv zie bij de Nationale wetenschapskwis, waar je ook terecht komt, volg 
je hart!
Dear Maartje en Laura, dear paranimfas, I am so happy that we did our PhD together 
and to have you both next to me today. I cannot imagine what it would have been 
without you! Maartje bedankt voor alle gezellige koffie-wijn-escaperoom-spelletjes-
pokémon-kano-dates, laten we daar vooral mee doorgaan! Guapa, thank you so much 
for everything, all our moments together including Dollars and meeting all your great 
friends. Maybe one day we should still open our beachbar! I cannot express how 
much I love you both! <3
Marjo en Heleen ineens heb ik er twee moeders bij, bedankt dat ik me vanaf dag 1 
welkom bij jullie voel, het voelt als thuiskomen in een warm nest.
Lieve Abel, wat is het fijn dat jij er bent. Bij jou kan ik mezelf zijn, lekker nerdy en 
prettig-gestoord, slechts enkele woorden nodig en je begrijpt me, (toch die kloon-
eigenschappen hé) en ik mag nog eens een keer magic van je winnen ook ;). Ik ben 
benieuwd wat de toekomst ons gaat brengen, laten we het gezellig maken. Suki desu!
Lieve familie, bedankt voor de continue steun en interesse in mijn onderzoek de 
afgelopen jaren. En fijn dat jullie soms genoegen namen met mijn redelijk korte 
antwoorden als ik er even niet over wou praten. ;) 
Janine wat kan ik een zeurpiet zijn als het om opmaak gaat, sorry daarvoor! Bedankt 
dat je het met me hebt uitgehouden, het resultaat is geweldig! Je kan er heel erg trots 
op zijn! Super bedankt voor het maken van mijn opmaak en al de moeite die je erin 
hebt gestoken! 
Lieve Yvonne en Gerda, Lieve oma’s, wat heb ik ongelofelijk veel respect en liefde 
voor jullie beide, ik vind het erg fijn dat jullie er beide zijn om dit moment mee te 
maken. Met trots draag ik dan ook dit boekwerk aan jullie en aan Henk en Ed, de 
opa’s, op. 
Lieve Maarten, kleine broertjes worden groot en wat is het speciaal dat je vandaag 
naast me staat. Waar we vroeger vaak ruzie hadden, zijn we nu steeds dichter naar 
elkaar toe gegroeid. Blijf vooral jezelf, kijk af en toe “met het mes op tafel” zonder 
geluid, en er ligt een gouden toekomst voor je. Ik ben trots op je!
Papa en mama, bedankt dat jullie er altijd voor me zijn en me steunen in alles wat ik 
doe. Het is niet altijd makkelijk geweest de afgelopen jaren, maar er was altijd een 
solide thuisbasis waar ik op terug kon vallen. Onze reis naar Santiago was er een om 
nooit te vergeten wat ben blij dat we deze met z’n allen gemaakt hebben. Ik hou heel 
veel van jullie!
List of Publications
RL Schellevis, L Altay, A Kalisingh, V Sitnilska, CB. Hoyng, CJF Boon, JMM Groenewoud, 
AI den Hollander, EK de Jong. “Elevated steroid hormone levels in active chronic 
central serous chorioretinopathy” Submitted to JAMA Ophthalmology
A Castells-Nobau; I Eidhof; M Fenckova; DB Brenman-Suttner; JM Scheffer-de 
Gooyert; S Christine; RL Schellevis; K van der Laan; C Quentin; L van Ninhuijs; F 
Hofmann; R Ejsmont; SE Fisher; JM Kramer; SJ Sigrist; AF Simon; A Schenck. 
“Conserved regulation of neurodevelopmental processes and behavior by FoxP in 
Drosophila”. Accepted for publication in PLOS ONE
RL Schellevis*, EHC van Dijk*, MB Breukink, JE Keunen, GWE Santen, CB Hoyng, 
AI den Hollander, CJF Boon, EK de Jong. “Exome sequencing in familial chronic 
central serous chorioretinopathy” Accepted for publication in Molecular Genetics & 
Genomics Medicine
RL Schellevis, MB Breukink, C Gilissen, CJF Boon, CB Hoyng, AI den Hollander* 
& EK de Jong*. “Exome sequencing identifies PIGZ, DUOX1, LAMB3 and RSAD1 
as susceptibility genes for chronic central serous chorioretinopathy in females” 
Submitted to Scientific Reports
D Mohabati*, RL Schellevis*, EHC van Dijk, L Altay, S Fauser, CB. Hoyng, EK. de Jong, 
CJF Boon#, S Yzer# “Genetic risk factors in acute central serous chorioretinopathy” 
Retina, In Press 
Schellevis RL, van Dijk EHC, Breukink MB, Altay L, Bakker B, Koeleman BPC, 
Kiemeney LA, Swinkels DW, Keunen JEE, Fauser S, Hoyng CB, den Hollander AI, 
Boon CJF, de Jong EK. “Role of the Complement System in Chronic Central Serous 
Chorioretinopathy: A Genome-Wide Association Study.” JAMA Ophthalmol. 2018 Aug 
2. doi: 10.1001/jamaophthalmol.2018.3190.
Kersten E, Paun CC, Schellevis RL, Hoyng CB, Delcourt C, Lengyel I, Peto T, Ueffing 
M, Klaver CCW, Dammeier S, den Hollander AI, de Jong EK. “Systemic and ocular 
fluid compounds as potential biomarkers in age-related macular degeneration.” Surv 
Ophthalmol. 2018 Jan - Feb;63(1):9-39. doi: 10.1016/j.survophthal.2017.05.003. 
van Dijk EHC*, Schellevis RL*, Breukink MB, Mohabati D, Dijkman G, Keunen JEE, 
Yzer S, den Hollander AI, Hoyng CB, de Jong EK, Boon CJF. “Familial Central Serous 
Chorioretinopathy.” Retina. 2017 Nov 28. doi: 10.1097/IAE.0000000000001966. 
van Dijk EHC*, Schellevis RL*, van Bergen MGJM, Breukink MB, Altay L, Scholz P, 
Fauser S, Meijer OC, Hoyng CB, den Hollander AI, Boon CJF, de Jong EK. “Association 
of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, 
With Chronic Central Serous Chorioretinopathy.” JAMA Ophthalmol. 2017 May 
1;135(5):446-451. doi: 10.1001/jamaophthalmol.2017.0245.
Breukink MB*, Schellevis RL*, Boon CJ, Fauser S, Hoyng CB, den Hollander AI, de Jong 
EK. “Genomic Copy Number Variations of the Complement Component C4B Gene 
Are Associated With Chronic Central Serous Chorioretinopathy.” Invest Ophthalmol 
Vis Sci. 2015 Aug;56(9):5608-13. doi: 10.1167/iovs.15-17343.
287
7
de Jong EK, Breukink MB, Schellevis RL, Bakker B, Mohr JK, Fauser S, Keunen JE, 
Hoyng CB, den Hollander AI, Boon CJ. “Chronic central serous chorioretinopathy is 
associated with genetic variants implicated in age-related macular degeneration.” 
Ophthalmology. 2015 Mar;122(3):562-70. doi: 10.1016/j.ophtha.2014.09.026. 
Curriculum Vitae
Rosa (Roos) Louise Schellevis was born on the 
15th of October, 1991 in Doetinchem, the 
Netherlands. In 2009, she graduated from 
the Rietveld Lyceum in Doetinchem with a 
secondary school diploma focused on Nature 
and Technical sciences and started her bachelor 
on Molecular Life Sciences at the Radboud 
University Nijmegen, The Netherlands. During 
her Bachelor degree she spent a semester 
abroad at the Washington & Jefferson College in 
Washington, Pennsylvania in the United States 
of America. Her Bachelor was completed in 
2012 with an internship at the department of 
Pathology of the Radboud university medical 
center (Radboudumc) under supervision of 
Patricia Groenen. For this internship she studied 
the integration of the Epstein Barr virus in the 
genome using fluorescent in situ hybridization.
During her Master on Molecular Life Sciences she followed courses in Medical Biology 
and Neurobiology. She conducted her first internship at the department of Human 
Genetics of the Radboudumc under supervision of Annette Schenck and Ana Castells 
Nobau, studying the role of the FOXP gene in communication using Drosophila as a 
model organism. Her second Master internship was performed at the department of 
Ophthalmology of the Radboudumc where she worked on the genetics of chronic 
central serous chorioretinopathy (cCSC) under supervision of Eiko de Jong and 
Anneke den Hollander. 
In 2014, after finishing her Masters with the honor “cum laude”, she continued 
her work on the genetics of cCSC to obtain her PhD degree. During her PhD she 
generated and analyzed large datasets of genetic information of cCSC patients and 
controls in order to unravel the mechanisms of the disease. Her interests lie in using 
computational science and the latest bio-informatics tools to answer biologically 
relevant questions regarding disease mechanisms. She was co-organizer of the Dutch 
Ophthalmology PhD Students (DOPS) congress in 2016, was awarded the Bayer 
Ophthalmology Research Award (BORA) in 2018 and obtained a travel grant from 
the Association for Research in Vision and Ophthalmology (ARVO) in the same year. 
Her four years of doctoral research are presented in this thesis entitled “The Genetics 
of Central Serous Chorioretinopathy”. She plans to defend the work of her doctoral 
thesis on the genetics of cCSC in the beginning of 2019. 
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Department of 
Ophthalmology
Donders Institute for 
Brain, Cognition and 
Behaviour
Radboud university 
medical center
Phd Period:
Promotor:
Co-promotor:
01-10-2014 to 01-10-2018
Prof. A.I. den Hollander
Dr. Eiko K. de Jong
Training activities Year (s) ECTS
I. Courses & Workshops
Graduate school introduction RIMLS 2015 2
Introduction day Radboudumc 2014 0.5
Statistics introduction 2014 0.2
Genetic Epidemiology Course (MED-5E005) 2014 5.7
Scientific Integrity for PhD Students 2015 0.6
Complex Trait Analysis of Next Generation Sequencing 
Data
2015 1.75
Intermediate & Advanced workshop UCSC 2015 0.4
eBROK Academy 2016 1.3
Linux Course 2016 0.8
BBMRI-omics: Introduction 2017 0.8
MBSR: Mindfulness Based Stress Reduction for PhD 
Students
2017 2
GTEx Resources: eQTLs and Gene Expression work-
shop
2017 0.1
II. Seminars & Lectures
Radboud Research Rounds (9x) 2014-2018 0.9
RIMLS Technical Forum (4x) 2014-2016 0.4
RIMLS PhD Retreat* (2x) 2015-2016 1.5
Sensory Disease Meeting (weekly; 12 presentations#) 2014-2018 4
Theme Discussion Human Genetics (weekly, 3 presen-
tations#)
2014-2018 3
Research Meeting Oogheelkunde (weekly; 12 presen-
tations#)
2014-2018 4
Radboud Science Day: Sensory Disorders* 2015 0.5
PhD Portfolio
Lecture Prof. Evan E. Eicler 2015 0.1
Seminar Jorge Cham 2016 0.1
Donders Sessions (1x) 2016 0.1
Introductory seminar about long-read sequencing and 
the Sequel
2017 0.1
Transitioning from academia to industry seminar 2017 0.1
III. Symposia & congresses
RIMLS New Frontiers Symposium (2x) 2014-2015 2
Refereeravonden Oogheelkunde (2x) 2014-2015 2
Science Day: Maastricht-Nijmegen 2015 0.25
EUGENDA Retreat & AMD-day## (4x) 2014-2017 1.5
National PhD Day 2016 0.25
Perception Day 2016 0.5
Donders Discussions* 2016 0.75
ASHG 2017 conference * 2017 1.25
Nederlands Oogheelkunde Gezelschap (NOG) 2017# 2017 0.5
Dutch Ophthalmology PhD Students conference 
(DOPS)*# # (n=4)
2015-2018 2.75
Annual ARVO conference*# (2x) 2016+
2018
3
IV. Teaching activities and other
Treasurer DOPS 2016 2016 2
Supervision Master Student Maaike van Bergen 2014-2015 3
Supervision Master Student Lisa Schiffelers 2016-2017 2
Total 52.7
* Poster presentation; # Oral presentation
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Type of Data Subject to 
privacy (yes/
no)
Way of 
anonymization
Storage
DNA of patients 
used in this 
thesis
Yes A DNA number is 
assigned to each 
individual by the 
cell culture facility 
of the Department 
of Human 
Genetics. 
The key is stored in the MCCD database and 
is only accessible by clinicians and members of 
the cell culture facility. DNA samples are stored 
at the Department of Human Genetics. Contact 
person for the DNA samples is Saskia van 
der Velde-Visser, saskia.vandervelde-visser@
radboudumc.nl
Genotype data 
of individual 
SNPs
No Samples in the 
dataset are already 
anonymized
Genotype information is stored in an SPSS file 
in the following folder on the Human Genetics 
H-drive:
I:\GR Theme groups\06 PI Group Anneke 
den Hollander\01 Personal folders\Schellevis, 
Roos\02_KASPAR\01_Statistiek Masterfile\ 
Serosa_genetica_FINAL.sav
Results per SNP can be found on the 
Ophthalmology R-drive:
R:\KASPAR\
GWAS 
genotyping data
No Samples in the 
dataset are already 
anonymized
All files regarding the GWAS study can be found 
in the following folder on the Ophthalmology 
R-drive:
R:\GWASData
Exome 
sequencing data
No Samples in the 
dataset are already 
anonymized
All files regarding the exome sequencing study 
can be found in the following folder on the 
Ophthalmology R-drive:
R:\ExomeData
Clinical characte-
ristics of familial 
CSC patients and 
family members
Yes Samples are coded 
according to their 
position in the 
pedigree and the 
key is locked with 
a password
An excel file for conversion can be found on the 
Ophthalmology H-drive: H:\Onderzoek\Roos 
Schellevis
Additional clinical information can be found 
here:
H:\Onderzoek\Roos Schellevis\ Beeldvorming 
families extra.7z
Both files are encrypted with a password which 
is stewarded by Prof. Anneke den Hollander, 
Anneke.denhollander@radboudumc.nl
Data Management Page
Contact details 
of patients and 
family members 
participating 
in the family 
studies
Yes Files are zipped 
and protected with 
a password
The zipped files is stored on the Ophthalmology 
H-drive:
H:\Onderzoek\Roos Schellevis\Serosadag\
Bellen info.7z
The file is encrypted with a password which 
is stewarded by Prof. Anneke den Hollander, 
Anneke.denhollander@radboudumc.nl
Contact 
information of all 
patients included 
in the study until 
2015
Yes Files are zipped 
and protected with 
a password
The zipped file is stored on the Ophthalmology 
H-drive:
H:\Onderzoek\Roos Schellevis\ Adressen.7z
The file is encrypted with a password which 
is stewarded by Prof. Anneke den Hollander, 
Anneke.denhollander@radboudumc.nl
Export of Castor 
database at 
the end of this 
thesis containing 
all CSC for 
which DNA was 
collected and 
whom have been 
included in the 
studies in this 
thesis
Yes Patients are 
anonymized and 
are coded with a 
database number
The Castor database is set offline and prof. 
Anneke den Hollander is still able to login at: 
https://data.castoredc.com/login
The final export can be found on the H-drive of 
Ophthalmology:
H:\Onderzoek\Roos Schellevis\SEROSA_
DATABASE\
The key for conversion to DNA and Radboud 
number is stored in the following file:
H:\Onderzoek\Roos Schellevis\SEROSA_
DATABASE\ CASTOR_sleutel_serosa_database.
xlsx
The file is encrypted with a password which 
is stewarded by Prof. Anneke den Hollander, 
Anneke.denhollander@radboudumc.nl
Informed 
Consents of all 
patients included 
in the studies
Yes Pdf files of all 
patients are zipped 
in a password 
protected file
The zipped file can be found on the H-drive of 
Ophthalmology: H:\Onderzoek\Roos Schellevis\
IC\ICs.7z
The file is encrypted with a password which 
is stewarded by Prof. Anneke den Hollander, 
Anneke.denhollander@radboudumc.nl
Clinical files for 
grading of all 
patients
Yes PowerPoint files 
of all patients 
are zipped in 
a password 
protected file
The zipped file can be found on the H-drive of 
Ophthalmology: H:\Onderzoek\Roos Schellevis\ 
graden.7z
The file is encrypted with a password which 
is stewarded by Prof. Anneke den Hollander, 
Anneke.denhollander@radboudumc.nl
Information of 
steroid use for 
patients included 
in the study
Yes Patient data is 
stored in an excel 
file protected with 
a password
The excel file van be found on the H-drive of 
Ophthalmology:
H:\Onderzoek\Roos Schellevis\ steroid check.
xlsx
The file is encrypted with a password which 
is stewarded by Prof. Anneke den Hollander, 
Anneke.denhollander@radboudumc.nl
Type of Data Subject to 
privacy (yes/
no)
Way of 
anonymization
Storage
293
7
Type of Data Subject to 
privacy (yes/
no)
Way of 
anonymization
Storage
Serum and 
plasma samples 
of patients
Yes Anonymized with 
a number and 
clinical information 
is stored in 
a password 
protected excel file
Stored in the -80C freezers at the Department 
of Ophthalmology and in the Radboudumc 
Biobank.
Contact person where to find the samples is 
Bjorn Bakker; bjorn.bakker@radboudumc.nl
Clinical information of the samples can be 
found on the H-drive of Ophthalmology: H:\
Trialcentrum\Studies\promovendi\Serosa\ 
Serum samples serosa patienten.xlsx
The file is encrypted with a password which 
is stewarded by Prof. Anneke den Hollander, 
Anneke.denhollander@radboudumc.nl
All files for the 
publications 
presented in this 
thesis
No NA All files can be found on the H-drive of Human 
Genetics:
I:\GR Theme groups\06 PI Group Anneke 
den Hollander\01 Personal folders\Schellevis, 
Roos\09_Publications
Donders Graduate School for Cognitive Neuroscience
For a successful research Institute, it is vital to train the next generation of young 
scientists. To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour 
established the Donders Graduate School for Cognitive Neuroscience (DGCN), which 
was officially recognised as a national graduate school in 2009. The Graduate School 
covers training at both Master’s and PhD level and provides an excellent educational 
context fully aligned with the research programme of the Donders Institute. 
The school successfully attracts highly talented national and international students 
in biology, physics, psycholinguistics, psychology, behavioral science, medicine 
and related disciplines. Selective admission and assessment centers guarantee the 
enrolment of the best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alumni 
show a continuation in academia with postdoc positions at top institutes worldwide, 
e.g. Stanford University, University of Oxford, University of Cambridge, UCL London, 
MPI Leipzig, Hanyang University in South Korea, NTNU Norway, University of Illinois, 
North Western University, Northeastern University in Boston, ETH Zürich, University 
of Vienna etc.
Positions outside academia spread among the following sectors: 
- specialists in a medical environment, mainly in genetics, geriatrics, psychiatry and 
neurology,
- specialists in a psychological environment, e.g. as specialist in neuropsychology, 
psychological diagnostics or therapy, 
- higher education as coordinators or lecturers. 
A smaller percentage enters business as research consultants, analysts or head of 
research and development. Fewer graduates stay in a research environment as lab 
coordinators, technical support or policy advisors. Upcoming possibilities are positions 
in the IT sector and management position in pharmaceutical industry. In general, the 
PhDs graduates almost invariably continue with high-quality positions that play an 
important role in our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please 
visit:
http://www.ru.nl/donders/graduate-school/phd/
295
7
The Genetics of Central Serous 
Chorioretinopathy
Rosa Louise Schellevis
373
T
H
E
 G
E
N
E
T
IC
S
 O
F
 C
N
E
T
R
A
L
 S
E
R
O
U
S
 C
H
O
R
IO
R
E
T
IN
O
P
A
T
H
Y
 
Rosa Louise Schellevis
